KOL | Roger F Butterworth∗Department of Medicine, University of Montreal, 45143 Cabot Trail, Englishtown, NS B0C 1H0 Canada | Department of Medicine, University of Montreal, Montreal, Canada | ... |
CV Kol pour Roger F Butterworth∗
| Year | |
|---|---|
| 2021 | Department of Medicine, University of Montreal, 45143 Cabot Trail, Englishtown, NS B0C 1H0 Canada |
| 2020 | Department of Medicine, University of Montreal, Montreal, Canada |
| 2019 | Department of Medicine, University of Montreal, 45143 Cabot Trail, B0C 1H0, Englishtown, NS, Canada University of Montreal (St-Luc Hospital), Montreal, QC |
| 2018 | CHUM St-Luc Hospital and Department of Medicine, University of Montreal, Canada. University of Montreal (St-Luc Hospital), Montreal, Québec, Canada |
| 2015 | Department of Medicine, University of Montreal, Montreal, Quebec, Canada |
| 2014 | Neuroscience Research Unit, Hopital St-Luc (CHUM) and Department of Medicine, University of Montreal, Montreal, QC H2W 3J4, Canada |
| 2013 | Neuroscience Research Unit, Hôpital St-Luc (CHUM), 1058 Rue St-Denis, H2X 3J4, Montreal, QC, Canada |
| 2012 | Neuroscience Research Unit, Saint-Luc Hospital (CHUM), University of Montreal, Montreal, Quebec, Canada |
| 2011 | Department of Medicine, University of Montreal, Neuroscience Research Unit, Montreal, Quebec, Canada |
| 2010 | Neuroscience Research Unit, Hôpital Saint-Luc (CHUM), University of Montreal, 1058 St. Denis Street, Montreal, Quebec, Canada |
| 2009 | Neuroscience Research Unit, Hôpital Saint‐Luc, CHUM, Montreal, QC, Canada |
| 2008 | Neuroscience Research Unit, Université de Montréal, Montreal, QC, Canada |
| 2007 | Neuroscience Research Unit, CHUM (Campus Saint-Luc), University of Montreal, 1058, Saint-Denis Street, H2X 3J4, Montreal, Quebec, Canada |
| 2006 | Neuroscience Research Unit, University of Montreal (CHUM), Hôpital Saint-Luc, 1058 St-Denis Street, Montreal, Que., Canada H2X 3J4 |
| 2005 | Neuroscience Research Unit, Hôpital Saint-Luc (CHUM), Montréal, Quebec, Canada |
| 2004 | Neuroscience Research Unit, Montreal, Quebec, Canada |
Roger F Butterworth∗: Statistiques d'influence
Rapport d'exécution
| Concept | World rank |
|---|---|
| hepatic encephalopathy activation | #1 |
| humans wernickes encephalopathy | #1 |
| coa levels brain | #1 |
| pons gaba content | #1 |
| glyt1 mrna | #1 |
| alf rats | #1 |
| cirrhotic patients benzodiazepines | #1 |
| chronic thiamine deprivation | #1 |
| routine neurological evaluation | #1 |
| 3hnisoxetine sites | #1 |
| capacity cerebral cortex | #1 |
| ptbribp frontal cortex | #1 |
| rats insulin hypoglycaemia | #1 |
| ammonialowering agents | #1 |
| result toxins | #1 |
| lola prevention | #1 |
| abnormal pyruvate oxidation | #1 |
| muscarinic m1 sites | #1 |
| early astrocytic response | #1 |
| ammonia exposure brain | #1 |
| nacl taurine | #1 |
| portacaval shunting activities | #1 |
| gaba 11 | #1 |
| cerebellar amino acids | #1 |
| alcoholthiamine interactions | #1 |
| 3865 258 nm | #1 |
| cell increased synthesis | #1 |
| compounds pyrithiamine | #1 |
| brain edema rats | #1 |
| receptor cirrhotic patients | #1 |
| hyperglycemic focal | #1 |
| experimental pse | #1 |
| leigh disease forms | #1 |
| 213caspartate | #1 |
| protective pathogenesis | #1 |
| therapy ornithine transcarbamylase | #1 |
| specific l3hnoarg binding | #1 |
| encephalopathy histamine humans | #1 |
| brain glutamine | #1 |
| glast protein day | #1 |
| encephalopathy cerebral edema | #1 |
| increased densities | #1 |
| kgdh decreased | #1 |
| predictive model investigator | #1 |
| pbgd mrna expression | #1 |
| serotonin transporter deficit | #1 |
| rats pca | #1 |
| restricted transfer glutamine | #1 |
| neuroinflammation liver failure | #1 |
| csf concentrations ammonia | #1 |
| concentrations serotonin precursor | #1 |
| atp free coenzyme | #1 |
| mutant spf | #1 |
| clf alf | #1 |
| acquired hyperammonemia | #1 |
| acute male muscle | #1 |
| pregnenolone brain tissue | #1 |
| abstract5fluoromethylornithine | #1 |
| cirrhosis nature | #1 |
| ammonia toxins | #1 |
| dawley ammonia | #1 |
| brain distribution rats | #1 |
| pca rats patients | #1 |
| haloperidol humans haloperiodol | #1 |
| onset hypoglycaemic convulsions | #1 |
| clinicallydefined entities | #1 |
| alf messenger | #1 |
| edema acute | #1 |
| ldeprenyl thiamine deficiency | #1 |
| ammonia mrna | #1 |
| 15–1788 | #1 |
| matkowskyj | #1 |
| ammonia acute | #1 |
| disorders ammonia metabolism | #1 |
| spine neurochemical | #1 |
| liver spf mice | #1 |
| densities 3hpk11195 sites | #1 |
| cerebral cortex pca | #1 |
| pca loss | #1 |
| indwelling cisterna | #1 |
| term fluorescence phenomenon | #1 |
| thalamus cirrhotic patients | #1 |
| circulating neurotoxins | #1 |
| encephalopathy central | #1 |
| hyperammonemic syndromes | #1 |
| findings manganese | #1 |
| edema glutamine | #1 |
| primary energy failure | #1 |
| portacavalshunted rats protective | #1 |
| increased brain | #1 |
| mild hypothermia prevention | #1 |
| thiamine deficiency brains | #1 |
| decreased detoxification ammonia | #1 |
| antagonist pyrithiamine | #1 |
| disproportionately levels | #1 |
| surgical probenecid rats | #1 |
| loss nmda | #1 |
| dehydrogenase complex friedreichs | #1 |
| lola reductions | #1 |
| 15–1788 pharmacokinetics cirrhosis | #1 |
| csf lactate accumulation | #1 |
| age time interval | #1 |
| brain gaba uptake | #1 |
| deficiency densities | #1 |
| freechoice drinking paradigm | #1 |
| atp free coa | #1 |
| lipoamide dehydrogenase lad | #1 |
| chronic hyperammonemic syndromes | #1 |
| friedreich gilbert | #1 |
| 3hpk cultured astrocytes | #1 |
| pss dopamine hepatic | #1 |
| maoa activities cerebellum | #1 |
| pfco frontal cortex | #1 |
| stress encephalopathy | #1 |
| ligase hepatic | #1 |
| alf neuroinflammation | #1 |
| hypoglycaemic convulsions | #1 |
| alf rats precoma | #1 |
| kgdh activities | #1 |
| cerebellar concentration aspartate | #1 |
| akinesia rats | #1 |
| dawley amino | #1 |
| alf increases | #1 |
| cns wernickekorsakoff | #1 |
| mg2dependentatpase | #1 |
| expression ptbrs | #1 |
| cns relation | #1 |
| pbz binding site | #1 |
| selective alterations | #1 |
| ammonia mechanisms | #1 |
| viral hepatitis alf | #1 |
| igg extravasation reduction | #1 |
| cirrhosis psychometric testing | #1 |
| stages igg immunohistochemistry | #1 |
| normal cd1 | #1 |
| pyrithiamine quinuclidinyl | #1 |
| testis densities | #1 |
| pathogenesis wernickekorsakoff syndrome | #1 |
| ” benzodiazepine | #1 |
| alterations brain dopamine | #1 |
| findings ammonia | #1 |
| rate thiamine turnover | #1 |
| encephalopathy cirrhosis | #1 |
| animal pyridinium | #1 |
| proinflammatory mechanisms | #1 |
| malnutrition hepatic failure | #1 |
| bbb animal hepatic | #1 |
| ligand3hpirenzepine | #1 |
| thiamine deficiency alcoholics | #1 |
| ldopa octopamine | #1 |
| regionselective reductions | #1 |
| metabolic scavengers | #1 |
| etanercept decreased plasma | #1 |
| congenital otc deficiencies | #1 |
| ptbr ligand 3hpk11195 | #1 |
| alzheimertype astrocytosis | #1 |
| peripheral inflammation etanercept | #1 |
| brain ammonia pca | #1 |
| cerebrospinal fluid ammonia | #1 |
| monoaminergic synaptic function | #1 |
| poor nutrition vitamin | #1 |
| normal conditions gut | #1 |
| thiamine deficiency appearance | #1 |
| increase brain extracts | #1 |
| alf amino | #1 |
| binding sites cerebellum | #1 |
| shunting hyperammonemia | #1 |
| catecholaminelike trace amines | #1 |
| free neurological | #1 |
| pathogenesis hyperammonemic syndromes | #1 |
| rats hepatic devascularization | #1 |
| alcoholic peripheral neuropathy | #1 |
| nimesulide thiamine deficiency | #1 |
| measured homogenates | #1 |
| pca operation | #1 |
| sgc cerebral cortex | #1 |
| nh4 neurons | #1 |
| dawley thiamine | #1 |
| alterations pse | #1 |
| nmda receptor alf | #1 |
| brain edema increases | #1 |
| 3htryptamine receptors | #1 |
| liver failure increases | #1 |
| betaep brain | #1 |
| brain human experimental | #1 |
| ammonia central | #1 |
| astrocytic glycine transporter | #1 |
| experimental thiamine | #1 |
| encephalopathy neuropsychiatric | #1 |
| thiamine phosphatases | #1 |
| glutamate originating | #1 |
| encephalopathy alanine | #1 |
| presence brain extracts | #1 |
| ω3 receptor 3hpk11195 | #1 |
| 15–1788 pharmacokinetics | #1 |
| seasonal ataxia | #1 |
| pca portacaval anastomosis | #1 |
| hereditary familial hyperbilirubinemia | #1 |
| tnfα delayed progression | #1 |
| pcs rats protective | #1 |
| degree pss | #1 |
| portacaval shunting hyperammonemia | #1 |
| continues rely | #1 |
| induced stereotyped behavior | #1 |
| dissected brain tissue | #1 |
| alf37 | #1 |
| loss 3hnisoxetine sites | #1 |
| hyperammonemia accounts | #1 |
| neuronal thalamus | #1 |
| 3hmuscimol binding studies | #1 |
| alf rats expression | #1 |
| cerebral cortex hypokinesia | #1 |
| polyclonal antibody glt1 | #1 |
| spectrum neuropsychiatric abnormalities | #1 |
| pathogenesis clinic | #1 |
| glucose loading decreases | #1 |
| alf precise role | #1 |
| hypothermia ammonia | #1 |
| nacl mm nacl | #1 |
| ldopa trace amines | #1 |
| encephalopathy alf rats | #1 |
| agents metabolic potential | #1 |
| caudate putamen sum | #1 |
| aspartate pons | #1 |
| medium kcl | #1 |
| serum lad patients | #1 |
| rats metallic | #1 |
| ptbr complex | #1 |
| 202 55 nm | #1 |
| ptbr sites | #1 |
| cirrhosis ammonia hepatic | #1 |
| encephalopathy alcoholic | #1 |
| mbr astrocytes | #1 |
| aom mice | #1 |
| sparsefur spf mice | #1 |
| molecular standpoint | #1 |
| portacaval anastomosis brain | #1 |
| modulatory sites | #1 |
| pyrithiaminetreated rats | #1 |
| encephalopathy adult | #1 |
| blood manganese etiology | #1 |
| cirrhotic patients densities | #1 |
| ptbr nnos | #1 |
| genes brain edema | #1 |
| experimental alf increases | #1 |
| hepatic encephalopathy cirrhosis | #1 |
| decarboxylase hepatic | #1 |
| psychometric testing risk | #1 |
| alterations brain glutamate | #1 |
| aqp4 proinflammatory mediators | #1 |
| regionselective increases | #1 |
| alcoholrelated brain dysfunction | #1 |
| pse increased densities | #1 |
| novo lactate synthesis | #1 |
| 3acetyl pyridine rats | #1 |
| ethanol preference ratio | #1 |
| nh4oac administration | #1 |
| liver failure ucds | #1 |
| azoxymethane toxicity | #1 |
| coma stages | #1 |
| ptbr mrna | #1 |
| neuropathologic damage | #1 |
| ammonia pca | #1 |
| flunitrazepam modulation | #1 |
| regionselective alterations | #1 |
| hypermmonemia | #1 |
| nonvulnerable frontal cortex | #1 |
| reduction brain ammonia | #1 |
| nacetylcysteine cerebral complications | #1 |
| chat loss | #1 |
| cerebellar concentration | #1 |
| hyperammonemic spf | #1 |
| hepatic microcirculation addition | #1 |
| ammoniaprecipitated coma | #1 |
| capacity ammonia removal | #1 |
| mild hypothermia reduction | #1 |
| effects ammonia | #1 |
| alf therapeutic | #1 |
| brain altered expression | #1 |
| receptor ptbr | #1 |
| dansyl chloride microassay | #1 |
| glucose loading precipitates | #1 |
| findings reported increase | #1 |
| csf ammonia control | #1 |
| congenitally hyperammonemic | #1 |
| thiaminedeficient medium 7 | #1 |
| omega 3 receptor | #1 |
| response alf | #1 |
| thiamine deficiency humans | #1 |
| improvements hepatic microcirculation | #1 |
| inflammation thiamine deficiency | #1 |
| type astrocytosis | #1 |
| perivascular endothelial cells | #1 |
| ro15 10 microm | #1 |
| phenols fig 1structure | #1 |
| deficiency wernicke | #1 |
| region selective alterations | #1 |
| electroencephalogram tracings | #1 |
| albumin dialysis systems | #1 |
| portacavalshunting | #1 |
| portacaval | #1 |
| portocaval shunting activities | #1 |
| isoquinolinebinding moiety | #1 |
| 7 thiaminedeficient medium | #1 |
| 3hpk11195 ligands | #1 |
| rtpcr experiments betaactin | #1 |
| frontal cortex exp | #1 |
| liver dysfunction findings | #1 |
| alterations increased expression | #1 |
| pse complication | #1 |
| acute hyperammonemic syndromes | #1 |
| pca rats phosphate | #1 |
| alf animal hypothermia | #1 |
| daily pyrithiamine treatment | #1 |
| hyperammonemic spf mice | #1 |
| selectively decreased | #1 |
| material equal | #1 |
| 6hydroxydopamine anterolateral hypothalamus | #1 |
| cloned rat ptbr | #1 |
| lactate medial thalamus | #1 |
| 3hpk11195 human brain | #1 |
| relation energy metabolism | #1 |
| spf mice activities | #1 |
| cirrhotic brain tissue | #1 |
| proinflammatory mechanisms pathogenesis | #1 |
| maob encephalopathy humans | #1 |
| endogenous opioid brain | #1 |
| prevents brain | #1 |
| reversible symptoms | #1 |
| tdwt mice | #1 |
| normal conditions kidney | #1 |
| neurosteroid modulatory | #1 |
| decreased pdhc | #1 |
| findings neuroinflammatory response | #1 |
| hepatic glt1 | #1 |
| rats coma | #1 |
| inhibitory ammonium ions | #1 |
| rats antisense elements | #1 |
| hepatic encephalopathy integrity | #1 |
| densities 3hpk11195 | #1 |
| brain pregnant rats | #1 |
| assessment locomotor activities | #1 |
| brain portacaval anastomosis | #1 |
| evidence thiamine deprivation | #1 |
| edema energy | #1 |
| prevention brain edema | #1 |
| humans gabaa steroids | #1 |
| local brain production | #1 |
| neurological disorders selection | #1 |
| pse csf lactate | #1 |
| neuropsychiatric disorder evidence | #1 |
| free coa atp | #1 |
| thiamine deficiency activities | #1 |
| glutamine resonance | #1 |
| expression hyperglycemic | #1 |
| prior detoxification liver | #1 |
| wellestablished actions | #1 |
| doses lcarnitine | #1 |
| encephalopathy humans opioid | #1 |
| pbg pbgd | #1 |
| ohe prevention prophylaxis | #1 |
| cerebellum sustained hyperammonemia | #1 |
| astrocyte undergoes | #1 |
| l‐3harginine | #1 |
| 100 microm manganese | #1 |
| transketolase tk activities | #1 |
| astrocyte morphology alterations | #1 |
| ammonia liver failure | #1 |
| manganese deposition | #1 |
| mhe clinical practice | #1 |
| ohe cirrhosis | #1 |
| pca astrocytic | #1 |
| igg extravasation expression | #1 |
| monoamines hplc | #1 |
| rat sustained hyperammonemia | #1 |
| animal hepatectomy hepatitis | #1 |
| muscle portacaval shunting | #1 |
| neuroinflammatory response alf | #1 |
| encephalopathy il1beta | #1 |
| glial filament network | #1 |
| pss rats | #1 |
| enzyme activities loss | #1 |
| liver pca rats | #1 |
| coma edema stages | #1 |
| neurosteroids hepatic encephalopathy | #1 |
| nacl calcium | #1 |
| alterations expression result | #1 |
| pathophysiology hepatic | #1 |
| fco cau | #1 |
| encephalopathy expression | #1 |
| surgical rna | #1 |
| astrocytic integrity | #1 |
| acquired hyperammonemic | #1 |
| increased expression ptbribp | #1 |
| hepatic microcirculation patients | #1 |
| acute chronic hyperammonemia | #1 |
| encephalopathy humans pallidus | #1 |
| dying hepatic | #1 |
| lactate brain regions | #1 |
| gut ammonia | #1 |
| s‐3h5‐fluorowillardiine | #1 |
| focal lactic | #1 |
| transketolase enzyme activities | #1 |
| protective findings | #1 |
| selectively increased | #1 |
| nh4ac rats | #1 |
| protein coma stages | #1 |
| central thiamine antagonist | #1 |
| reduction mild hypothermia | #1 |
| αkgdh onset | #1 |
| peripheral‐type benzodiazepine receptors | #1 |
| accumulate brain | #1 |
| 3hkainate sites | #1 |
| alcohol‐thiamine interactions | #1 |
| maob cerebellum | #1 |
| ammonia central nervous | #1 |
| pathogenetic defect | #1 |
| plasma alf rats | #1 |
| pathogenesis reversible symptoms | #1 |
| thiaminedeficient encephalopathy | #1 |
| etanercepttreated alf mice | #1 |
| combined metabolic stresses | #1 |
| cerebral energy deficit | #1 |
| maximal binding absence | #1 |
| progression thiamine deficiency | #1 |
| affinity ptbr | #1 |
| genetic xlinked deficiency | #1 |
| portacavalshunted pcs rats | #1 |
| neuronal crosstalk | #1 |
| key astroglial proteins | #1 |
| dopamine thiamine deficiency | #1 |
| pca cns | #1 |
| 2 7fold increases | #1 |
| spf mice | #1 |
| pathogenesis wernicke encephalopathy | #1 |
| action acute hyperammonemia | #1 |
| hypothermia delay | #1 |
| 15–1788 plasma levels | #1 |
| alanine cerebral cortex | #1 |
| pfco fco | #1 |
| l‐deprenyl treatment | #1 |
| encephalopathy zidovudine | #1 |
| brain pse | #1 |
| pathogenesis brain | #1 |
| additional thiamine | #1 |
| isomorphic model predictions | #1 |
| surgical rats rats | #1 |
| exclusion brain diseases | #1 |
| diabetes ataxia humans | #1 |
| previous exposure benzodiazepines | #1 |
| hyperammonaemia brain function | #1 |
| increased synthesis cell | #1 |
| cox2 tle | #1 |
| investigator predictions | #1 |
| brain ptbr | #1 |
| autopsy cirrhotic | #1 |
| manganese distribution brain | #1 |
| wernicke′s encephalopathy | #1 |
| portalsystemic encephalopathy | #1 |
| alcoholic peripheral | #1 |
| raphe serotonin serotonin | #1 |
| deficiency encephalopathy | #1 |
| elucidation neurotransmitter | #1 |
| brain cirrhotic patients | #1 |
| lola mental state | #1 |
| pca beta endorphin | #1 |
| peripheral steroidal sources | #1 |
| encephalopathy animals | #1 |
| disorder isomorphic model | #1 |
| cerebral disorder | #1 |
| benzoate spf | #1 |
| mild hypothermia alf | #1 |
| 3hpk11195 | #1 |
| aom nac | #1 |
| veratramines action | #1 |
| opca messenger receptors | #1 |
| acute male pregnenolone | #1 |
| csf concentrations bzrls | #1 |
| action ro15 | #1 |
| surgical probenecid | #1 |
| brain ammonia concentrations | #1 |
| thalamus thiaminedeficient rats | #1 |
| bilirubin ataxics | #1 |
| preference pca | #1 |
| pca increased densities | #1 |
| neurological complications alf | #1 |
| glt1 transporter proteins | #1 |
| coma pathophysiologic basis | #1 |
| 062 009 liter | #1 |
| experimental portal | #1 |
| bbb permeability alf | #1 |
| alf brain edema | #1 |
| acute neurons mechanisms | #1 |
| occludin medial thalamus | #1 |
| major role mechanisms | #1 |
| oatreated rats alf | #1 |
| increased extracellular brain | #1 |
| brain levels dheas | #1 |
| thiamine deficiency result | #1 |
| alf nmda receptor | #1 |
| portacaval anastomosis | #1 |
| protective portacavalshunted rats | #1 |
| spraguedawley statistics immunohistochemistry | #1 |
| spf mutant | #1 |
| l3hnoarg binding | #1 |
| veratramines action parachlorophenylalanine | #1 |
| alpha1 isoform ec50 | #1 |
| glast spraguedawley statistics | #1 |
| ligand3h | #1 |
| removal bloodborne ammonia | #1 |
| increased activities tdpase | #1 |
| gabaa ammonia animals | #1 |
| ptbr ligand | #1 |
| pse probenecid | #1 |
| concomitantly increased | #1 |
| alcoholic manganese | #1 |
| hepatic coma patients | #1 |
| rtpcr experiments messenger | #1 |
| tdpase activities | #1 |
| 70 tk | #1 |
| perivenous hepatocytes brain | #1 |
| selective loss | #1 |
| pbgd rat model | #1 |
| reflex pdhc activities | #1 |
| propanolamines putamen | #1 |
| precise role glutamine | #1 |
| pugh score iii | #1 |
| disorder portalsystemic encephalopathy | #1 |
| fco cirrhotic patients | #1 |
| portacaval‐shunted rat | #1 |
| wistar receptors pca | #1 |
| rats surgical probenecid | #1 |
| methylspiperone pet | #1 |
| sodium benzoate atp | #1 |
| glt1 encephalopathy humans | #1 |
| pallidal binding sites | #1 |
| increased binding sites | #1 |
| astrocytic proteins | #1 |
| focal lactic acidosis | #1 |
| older cirrhotic patients | #1 |
| azoxymethane mouse | #1 |
| thiamine deficiency expression | #1 |
| alterations 3h8ohdpat | #1 |
| increased brain concentrations | #1 |
| thiamine deficiency bckdh | #1 |
| antiparkinson drugs hypokinesia | #1 |
| etanercept il6 levels | #1 |
| hypoglycaemia cerebral cortex | #1 |
| encephalopathy sham | #1 |
| ” benzodiazepine receptors | #1 |
| 071−084 | #1 |
| key astrocytic proteins | #1 |
| pathogenesis brain edema | #1 |
| thiaminedeficient ataxic gait | #1 |
| ammoniainduced decrease | #1 |
| friedreichs ataxia thiaminedeficient | #1 |
| pharmaceutical benzodiazepine | #1 |
| thalamus thiamine deficiency | #1 |
| deficiency prior | #1 |
| thiaminedeficient encephalopathy implications | #1 |
| animals thiamine deficiency | #1 |
| receptors thiamine | #1 |
| lola efficacy | #1 |
| thiamine monophosphatetmp | #1 |
| cns complications alf | #1 |
| inhibition bloodbrain transfer | #1 |
| brain liver failure | #1 |
| caveolin1 pathway | #1 |
| ptbr brain | #1 |
| progressive volume increase | #1 |
| genes astrocytic proteins | #1 |
| immunohistochemistry cox2 immunoreactivity | #1 |
| content pallidum | #1 |
| ammonia intoxication rats | #1 |
| mechanisms wemickes encephalopathy | #1 |
| dose dependent swelling | #1 |
| hyperammonemic sparse | #1 |
| pdhc step | #1 |
| nac normalization | #1 |
| 3hpk11195 rats | #1 |
| increased glutamine synthesis | #1 |
| modulation nitric oxide | #1 |
| failure hepatic | #1 |
| hypokinesia stereotaxic microinjection | #1 |
| etanercept biological plausibility | #1 |
| neuromodulatory site | #1 |
| thiamine‐deficient rats | #1 |
| astrocytic accumulation glutamine | #1 |
| pss degree | #1 |
| failure thiamine | #1 |
| normal limits findings | #1 |
| decreased expression glt1 | #1 |
| 15–1788 kinetics | #1 |
| platelet taurine uptake | #1 |
| glutamine synthetase capacity | #1 |
| edema formation mnsod | #1 |
| thiamine deficiency decreases | #1 |
| hepatic encephalopathy neurobiology | #1 |
| ptbr alterations | #1 |
| alf mild hypothermia | #1 |
| pca rat | #1 |
| brain edema complications | #1 |
| rats fpc | #1 |
| reduced thiamine intake | #1 |
| rats probenecid treatment | #1 |
| glast medial thalamus | #1 |
| alf mice deletion | #1 |
| rats portacaval | #1 |
| reactive gliosis contrast | #1 |
| liver pathology increases | #1 |
| portacaval anastomosis tips | #1 |
| fluid taurine | #1 |
| cirrhosis brain dysfunction | #1 |
| direct evidence rats | #1 |
| alf alterations | #1 |
| thiaminedeficient medium | #1 |
| azoxymethane bloodbrain barrier | #1 |
| manganese extrapyramidal symptoms | #1 |
| amines hepatic | #1 |
| brain portacaval | #1 |
| maternal thiamine deficiency | #1 |
| benzodiazepine site contrast | #1 |
| loss gfap expression | #1 |
| ammonia glutamate uptake | #1 |
| serum lad friedreich | #1 |
| effective urea cycle | #1 |
| initial reports pathogenesis | #1 |
| decreased detoxification | #1 |
| modulators hepatic | #1 |
| alzheimer type astrocytosis | #1 |
| deficiency tritium | #1 |
| portacaval pcs rats | #1 |
| cau lobe hepatic | #1 |
| vulnerable medial thalamus | #1 |
| thalamus vulnerable region | #1 |
| pca ethanol | #1 |
| 3hpk11195 binding sites | #1 |
| ptbr expression pathogenesis | #1 |
| 57 caudate putamen | #1 |
| onset neurological symptoms | #1 |
| tissue distribution neuropathology | #1 |
| cuznsod cox2 | #1 |
| evidence otc deficiency | #1 |
| edema complications | #1 |
| pfco cirrhotic patients | #1 |
| model human disorder | #1 |
| ouabain pyrimethamine rats | #1 |
| acute male microglia | #1 |
| key astrocytic | #1 |
| overt encephalopathy alterations | #1 |
| ammonia removal brain | #1 |
| glutamate exposure ammonia | #1 |
| thalamus wernicke encephalopathy | #1 |
| dehydrogenase αkgdh | #1 |
| tmpase tdpase | #1 |
| lumbar gray matter | #1 |
| therapeutic efficacy prevention | #1 |
| otc deficiency activities | #1 |
| cell swelling major | #1 |
| activities alpha kgdh | #1 |
| cox2 cuznsod mrna | #1 |
| congenital otc | #1 |
| precise nature | #1 |
| pse altered expression | #1 |
| lipopolysaccharide precipitates | #1 |
| mild hypothermia onset | #1 |
| atp acetyl coa | #1 |
| synthesis intercellular transport | #1 |
| findings therapeutic efficacy | #1 |
| astrocytic accumulation | #1 |
| therapeutic efficacy lcarnitine | #1 |
| metabolism ammonia | #1 |
| neurotransmitter function | #1 |
| shunted rats presence | #1 |
| encephalopathy male | #1 |
| additional bloodborne ammonia | #1 |
| 11 thiamine deficiency | #1 |
| components brain glutamate | #1 |
| liver normal cd1 | #1 |
| dipeptides hepatic | #1 |
| autopsied frontal cortex | #1 |
| gabaaassociated receptors | #1 |
| disorder thiamine deficiency | #1 |
| increased gabaergic | #1 |
| friedreichs ataxia dehydrogenase | #1 |
| increased gabaergic tone | #1 |
| dha administration mnsod | #1 |
| blood ammonia md | #1 |
| increased activities maoa | #1 |
| onset brain edema | #1 |
| primary astrocytopathy | #1 |
| pfco cau | #1 |
| blood ammonia improvement | #1 |
| reduction cognitive dysfunction | #1 |
| severe liver atrophy | #1 |
| tdpase encephalopathy humans | #1 |
| manganese pathogenesis | #1 |
| superoxide dismutase rat | #1 |
| widespread alterations | #1 |
| administration novo synthesis | #1 |
| brain astrocytes alterations | #1 |
| brain levels tmp | #1 |
| congenital acquired hyperammonemia | #1 |
| reduced astrocytic uptake | #1 |
| congenital hyperammonemia lcarnitine | #1 |
| alf glucose | #1 |
| 90 fmol protein | #1 |
| locomotor activities difference | #1 |
| severe pse | #1 |
| pathogenesis cerebral complications | #1 |
| hypothermia prevents | #1 |
| rats ouabain pyrimethamine | #1 |
| liver failure modulation | #1 |
| neurosteroids pregnenolone allopregnanolone | #1 |
| thalamus symptomatic | #1 |
| liver failure neuroinflammation | #1 |
| nakatpase activity thalamus | #1 |
| encephalopathy pse | #1 |
| ammoniainduced reduction | #1 |
| serotonin precursor metabolite | #1 |
| activities thalamus | #1 |
| mbr decreased expression | #1 |
| previous portacaval anastomoses | #1 |
| unchanged brain | #1 |
| death wernicke | #1 |
| ptbribp | #1 |
| ptbrs binding | #1 |
| sites thiamine | #1 |
| alf hypothermia | #1 |
| loss tdpase activities | #1 |
| brain ammonia reduction | #1 |
| sites ptbr | #1 |
| ptbrs portacaval anastomosis | #1 |
| pallidal signal hyperintensity | #1 |
| ammonium acetate administration | #1 |
| taurine medium | #1 |
| ω3 receptor | #1 |
| pathogenesis hepatic | #1 |
| nh4cl glutamates hippocampus | #1 |
| alf35 | #1 |
| mrnas ampa receptor | #1 |
| medial thalamus day | #1 |
| relationship blood manganese | #1 |
| ammoniainduced inhibition | #1 |
| pyrithiamine pyruvate | #1 |
| tdpase tdpase activities | #1 |
| binding sites 3hpk11195 | #1 |
| borne ammonia | #1 |
| nac animal hepatic | #1 |
| animal model encephalopathy | #1 |
| encephalopathy nitrogen | #1 |
| thiamine deficiency neurons | #1 |
| densities ptbr sites | #1 |
| oxotremorine particle size | #1 |
| p005 5mm nh4cl | #1 |
| hippocampal sclerosis induction | #1 |
| encephalopathy new | #1 |
| integrity gabaa receptors | #1 |
| 3hpk binding | #1 |
| histamine receptor sites | #1 |
| stroke forms | #1 |
| ptbr | #1 |
| ohe mhe patients | #1 |
| ampa sites | #1 |
| interferongamma brains | #1 |
| brain edema encephalopathy | #1 |
| fasting intravenous injection | #1 |
| normothermic alf rats | #1 |
| liver diseases range | #1 |
| alf include | #1 |
| in3hpk11195 binding sites | #1 |
| mhe life | #1 |
| neurological symptoms encephalopathy | #1 |
| pathogenesis hepatic encephalopathy | #1 |
| rats alf | #1 |
| psychometric testing falls | #1 |
| exposure proinflammatory | #1 |
| loss righting reflexes | #1 |
| cyclase content | #1 |
| astrocytic glycine | #1 |
| fastigial interpositus | #1 |
| ammonia cns function | #1 |
| pglycoprotein mild hypothermia | #1 |
| csf lactate pse | #1 |
| glutaminecycle | #1 |
| brain ammonia measurement | #1 |
| severity akinesia | #1 |
| patient olivopontocerebellar atrophy | #1 |
| pregnanolone brain chemistry | #1 |
| daily injections thiamine | #1 |
| anastomosis pca | #1 |
| role endogenous benzodiazepines | #1 |
| hepatic encephalopathy | #1 |
| absence wernickes encephalopathy | #1 |
| caudate putamen 57 | #1 |
| brain major | #1 |
| hereferences | #1 |
| nac neurological complications | #1 |
| loss 3hcitalopram sites | #1 |
| hepatic coma bbb | #1 |
| pharmaceutical benzodiazepines | #1 |
| hepatic encephalopathy activities | #1 |
| update hepatic encephalopathy | #1 |
| astrocyticneuronal cross | #1 |
| excess bloodborne ammonia | #1 |
| chronic hyperammonemia syndromes | #1 |
| ammonia normal conditions | #1 |
| xlinked inherited defect | #1 |
| bioaccumulation neuropathology | #1 |
| encephalopathy alf | #1 |
| thiamine deficiency encephalopathy | #1 |
| daily injections ldeprenyl | #1 |
| ouabain pyrimethamine | #1 |
| lornithine laspartate lola | #1 |
| osmotic disturbance | #1 |
| glur3 subunits opca | #1 |
| control alf37 | #1 |
| pse lornithinelaspartate | #1 |
| ptbr mrna thalamus | #1 |
| minocyclinetreated alf rats | #1 |
| immunohistochemistry spraguedawley statistics | #1 |
| ammonialowering strategies | #1 |
| acute hyperammonemia activation | #1 |
| l‐3hnitroarginine | #1 |
| nh4 forms neurons | #1 |
| thalamus thiamine | #1 |
| pyrithiamine | #1 |
| activities thiamine | #1 |
| alf37 degrees | #1 |
| brain dysfunction pse | #1 |
| tdpase activities loss | #1 |
| shunted dogs | #1 |
| bloodborne ammonia | #1 |
| vivo cerebral microdialysis | #1 |
| glutamine astrocyte | #1 |
| subclass sites | #1 |
| animal liver failure | #1 |
| neuroinflammation alf | #1 |
| flunitrazepam hepatic | #1 |
| encephalopathy thiamine | #1 |
| copper pallidum | #1 |
| liver failure alterations | #1 |
| treatment lola | #1 |
| etanercept treatment reduction | #1 |
| vulnerable medial | #1 |
| thiamine deficiency 23 | #1 |
| vicious cycle sarcopenia | #1 |
| alf effects | #1 |
| novo synthesis gaba | #1 |
| pyrithiamine rats | #1 |
| congenital otc deficiency | #1 |
| kidney portacaval anastomosis | #1 |
| alf hepatic | #1 |
| aom mice nac | #1 |
| pse surgical probenecid | #1 |
| propanolamines putamen rats | #1 |
| wernickes encephalopathy aids | #1 |
| metabolites term fluorescence | #1 |
| result manganese deposition | #1 |
| alf animals expression | #1 |
| symptoms wernicke | #1 |
| experimental thiamine deficiency | #1 |
| precoma | #1 |
| neurological symptoms normalisation | #1 |
| taurine electrolyte balance | #1 |
| pathogenesis wernicke | #1 |
| alf37 alf37 degrees | #1 |
| oatreated rats | #1 |
| 3h 11195 | #1 |
| heneuropathology | #1 |
| nh4cl glutamate release | #1 |
| r071–084 | #1 |
| ngnitrol3harginine | #1 |
| brain osmolytes | #1 |
| ammonium acetate challenge | #1 |
| cau cirrhotic patients | #1 |
| brains spf mice | #1 |
| muscle ammonia removal | #1 |
| ouabain doses | #1 |
| encephalopathy selective loss | #1 |
| cerebral hepatic levels | #1 |
| grc integrity | #1 |
| ligand 3hpk11195 | #1 |
| treatment mild encephalopathy | #1 |
| caudate putamen concentrations | #1 |
| bzrls cirrhotic patients | #1 |
| hypokinesia et495 | #1 |
| reversal antiparkinson drugs | #1 |
| brain congenital | #1 |
| ammonia increased expression | #1 |
| mental state grade | #1 |
| pca portacaval | #1 |
| ethanol nutritional deficit | #1 |
| 3hpk11195 binding | #1 |
| betaactin housekeeping gene | #1 |
| ammonia brain | #1 |
| aom animal hypothermia | #1 |
| novo synthesis aspartate | #1 |
| nnos expression result | #1 |
| “peripheraltype | #1 |
| h1 receptor density | #1 |
| neuroinflammation cns complications | #1 |
| thiaminedeficient brain | #1 |
| cultured cells mrna | #1 |
| loss thiamine | #1 |
| precipitation severe stages | #1 |
| selective reversible decreases | #1 |
| bzrls | #1 |
| manganese etiology | #1 |
| encephalopathy increased | #1 |
| magna catheter | #1 |
| efficacy lola | #1 |
| cox2 cuznsod | #1 |
| deficiency selective | #1 |
| electroencephalogram tracings patients | #1 |
| glut1 alf | #1 |
| deterioration neurological status | #1 |
| disease outcome prevention | #1 |
| pharmacological manipulation ptbr | #1 |
| 3hcitalopram sites | #1 |
| 44433a | #1 |
| brain regions pyrithiamine | #1 |
| deficiency binding | #1 |
| weeks portacaval | #1 |
| human hepatic encephalopathy | #1 |
| investigator neurological disorders | #1 |
| microglia evidence | #1 |
| hyperammonemia aaas | #1 |
| distribution 3htryptamine | #1 |
| radioenzymatic assays activities | #1 |
| sgc activation brain | #1 |
| pca rats | #1 |
| thiamine deficiency implications | #1 |
| surgical portacaval anastomosis | #1 |
| liver spleen ratios | #1 |
| alf proinflammatory | #1 |
| mild hypothermia delay | #1 |
| precoma coma stages | #1 |
| frontal cortex fco | #1 |
| 5mm nh4cl | #1 |
| liver failure muscle | #1 |
| acids aaas | #1 |
| osmotic actions | #1 |
| taurines role | #1 |
| human brain ammonia | #1 |
| cell damage mechanisms | #1 |
| thalamus pyrithiamine treatment | #1 |
| 5mm nh4cl p0001 | #1 |
| brains increased concentrations | #1 |
| familial hyperbilirubinemia | #1 |
| autopsied brain tissue | #1 |
| brain glutamine severity | #1 |
| 3hcitalopram sites rats | #1 |
| hepatic encephalopathy relationship | #1 |
| progression prevention | #1 |
| alf restricted transfer | #1 |
| finding loss | #1 |
| neuronastrocytic trafficking | #1 |
| thdoc brain tissue | #1 |
| dehydrogenase complex transketolase | #1 |
| activation ptbr | #1 |
| died hepatic | #1 |
| prevention ohe | #1 |
| development nutritional recommendations | #1 |
| thiamine daily administration | #1 |
| stages encephalopathy | #1 |
| fumazenil | #1 |
| lola nash | #1 |
| cirrhotic patients cau | #1 |
| pglycoprotein willebrand factor | #1 |
| hyperammonemic disorders | #1 |
| jadad cochrane ohe | #1 |
| lcarnitine energy metabolites | #1 |
| pathogenesis neuronal loss | #1 |
| measurement aqp4 levels | #1 |
| 25mm nh4cl p005 | #1 |
| failure ammonia | #1 |
| inhibitory nh4cl | #1 |
| activities neuronal | #1 |
| tissues spf mice | #1 |
| ammonia increased | #1 |
| brain pca rats | #1 |
| hypothermia brain | #1 |
| degree shunting hyperammonemia | #1 |
| regional variation bckdh | #1 |
| pse neurotransmitter agents | #1 |
| deficiency transketolase | #1 |
| rat wernickes encephalopathy | #1 |
| muscarinic thiamine | #1 |
| exp assessment | #1 |
| experimental portacaval shunt | #1 |
| enos gene deletion | #1 |
| glutamateper | #1 |
| etanercept aom | #1 |
| alterations neurological alterations | #1 |
| regions pyrithiamine | #1 |
| autopsy brain choline | #1 |
| reflex selective decreases | #1 |
| manifest altered expression | #1 |
| portacaval shunted | #1 |
| inherited ataxias characteristics | #1 |
| encephalopathy prevention | #1 |
| brain prominent neurotoxin | #1 |
| hepatic devascularization | #1 |
| pse findings | #1 |
| effective approach prevention | #1 |
| ammonia proinflammatory | #1 |
| inhibitors acute hyperammonemia | #1 |
| pfco brain tissue | #1 |
| regional lactate levels | #1 |
| lcarnitinetreated | #1 |
| astrocytes ammonia levels | #1 |
| mechanisms brain edema | #1 |
| mm nacl nacl | #1 |
| alf relation | #1 |
| region‐selective | #1 |
| congenital hyperammonemia nakatpase | #1 |
| αkgdh | #1 |
| glut1 expression alf | #1 |
| brain hepatic | #1 |
| expression astrocytic | #1 |
| taurine hepatic encephalopathy | #1 |
| cirrhosis extrapyramidal symptoms | #1 |
| mitochondrial enzyme αkgdh | #1 |
| selective ptbr ligand | #1 |
| brain glutamate synthesis | #1 |
| microsomes medium | #1 |
| encephalopathy cau | #1 |
| offspring animal pyruvate | #1 |
| neuroinflammatory mechanisms pathogenesis | #1 |
| nac aom | #1 |
| cerebral aminoacids | #1 |
| enzyme perivenous hepatocytes | #1 |
| alf azoxymethane | #1 |
| astrocytic cox2 | #1 |
| relation deterioration | #1 |
| alf studies | #1 |
| acute symptomatic animals | #1 |
| portalsystemic encephalopathy pse | #1 |
| devascularized rat | #1 |
| experimental wernicke | #1 |
| surgical rna messenger | #1 |
| thiaminedeficient rats | #1 |
| postshunt myelopathy | #1 |
| brains alf rats | #1 |
| sparsefur spf mouse | #1 |
| increased brain ammonia | #1 |
| ammonia metabolism disorders | #1 |
| rats varying degrees | #1 |
| fig dansyl | #1 |
| nonsclerotic tle patients | #1 |
| homogenates cirrhotic patients | #1 |
| altered thiamine neurochemistry | #1 |
| varying degrees pss | #1 |
| wernickekorsakoff syndrome disturbances | #1 |
| congenital ornithine | #1 |
| thalamus symptomatic rats | #1 |
| pdhc activities | #1 |
| sustained hyperammonemia pca | #1 |
| lornithine laspartate ammonia | #1 |
| spf mouse | #1 |
| hepatocerebral disorders | #1 |
| aom treatment alf | #1 |
| thiaminedeficient animals | #1 |
| coma stages encephalopathy | #1 |
| encephalopathy brain edema | #1 |
| akgdh | #1 |
| pathophysiology cirrhosis | #1 |
| induction astrocytic cox2 | #1 |
| pca rats pca | #1 |
| nonvulnerable fpc | #1 |
| increased levels allopregnanolone | #1 |
| activities maob | #1 |
| liver pca | #1 |
| male pyrithiamine | #1 |
| encephalopathy activities | #1 |
| cirrhosis vicious cycle | #1 |
| thiamine neurochemistry | #1 |
| wernickes encephalopathy humans | #1 |
| transverese friedreich ataxia | #1 |
| reduction bbb breakdown | #1 |
| cerebral γ‐aminobutyric acid | #1 |
| taurine microsomes | #1 |
| maternal thiamine | #1 |
| proinflammatory cytokines strategies | #1 |
| seesection | #1 |
| mmt manganese phosphate | #1 |
| l3hnoarg | #1 |
| progression encephalopathy | #1 |
| thiaminedependent enzymes establishment | #1 |
| specific energy metabolism | #1 |
| shunting hyperammonemia rats | #1 |
| circulating ammonia | #1 |
| ptbr mrna levels | #1 |
| lad platelets | #1 |
| hypoglycaemia onset | #1 |
| reduction circulating neurotoxins | #1 |
| nakatpase activities striatum | #1 |
| ammonia major roles | #1 |
| brain ammonia removal | #1 |
| receptors pca | #1 |
| 1 lola | #1 |
| decreased tdp concentrations | #1 |
| rats acute | #1 |
| tissue cirrhotic | #1 |
| expression ptbr | #1 |
| activation brain ptbr | #1 |
| induction epileptic patients | #1 |
| ligand3hpk11195 | #1 |
| plasma clearance halflife | #1 |
| symptomatic pyrithiamine | #1 |
| pbz receptor densities | #1 |
| csf benzodiazepine | #1 |
| ptbrs | #1 |
| thiamine deficiency synthesis | #1 |
| parkinsonism cirrhosis | #1 |
| 2 mm ammonia | #1 |
| increased csf lactate | #1 |
| fur spf | #1 |
| iii flumazenil | #1 |
| severity brain edema | #1 |
| symptomatic stages encephalopathy | #1 |
| glutamine synthetase activities | #1 |
| severe encephalopathy coma | #1 |
| encephalopathy hypothermia | #1 |
| pca encephalopathy humans | #1 |
| central thiamine | #1 |
| glutamine synthetase protein | #1 |
| diencephalic cerebellar | #1 |
| thiamine deficiency | #1 |
| thiaminedeficient mothers | #1 |
| experimental model metabolic | #1 |
| liver failure upregulation | #1 |
| encephalopathy | #1 |
| ptbr increased expression | #1 |
| encephalopathy vivo | #1 |
| azoxymethane mouse model | #1 |
| stress alf | #1 |
| pca activities | #1 |
| 24 hours pca | #1 |
| selective increases | #1 |
| atrophy brain glutamate | #1 |
| isoquinoline benzodiazepine ligands | #1 |
| brain herniation alf | #1 |
| cytokines mild | #1 |
| lcarnitine doses | #1 |
| increased blood manganese | #1 |
| alterations receptor sites | #1 |
| hepatic encephalopathies | #1 |
| pca increased | #1 |
| lola treatment | #1 |
| lola effective | #1 |
| that11cpk11195 | #1 |
| concentrations olfactory bulb | #1 |
| anastomosis ammonia | #1 |
| mice encephalopathy | #1 |
| brain consequent increases | #1 |
| hippocampus cirrhotic patients | #1 |
| azoxymethane brain | #1 |
| rats thiamine deficiency | #1 |
| restricted transfer cell | #1 |
| hypothesis hepatic encephalopathy | #1 |
| olivopontocerebellar atrophy expression | #1 |
| pca portacaval shunt | #1 |
| spontaneous release glutamate | #1 |
| appearance neurological symptoms | #1 |
| coding key | #1 |
| failure brain | #1 |
| 10 microm flumazenil | #1 |
| 25mm nh4cl | #1 |
| neurotransmitter alterations prevention | #1 |
| neuroinflammationinflammation | #1 |
| hepatic devascularized rats | #1 |
| relation sustained hyperammonemia | #1 |
| pathogenesis portalsystemic encephalopathy | #1 |
| region‐selective alterations | #1 |
| prevention ammoniaprecipitated coma | #1 |
| lornithinelaspartate therapeutic efficacy | #1 |
| increases glutamine | #1 |
| comatose rats | #1 |
| lornithinelaspartate prevention | #1 |
| csf portacaval anastomosis | #1 |
| oxygenase1 hepatic | #1 |
| pfco | #1 |
| effective approach onset | #1 |
| complications alf | #1 |
| pse portalsystemic shunting | #1 |
| encephalopathy brain | #1 |
| direct hepatoprotective effects | #1 |
| therapy refractive tle | #1 |
| exposure azoxymethane | #1 |
| 32°c–35°c | #1 |
| flumazenil cirrhotic patients | #1 |
| thiamine interactions | #1 |
| failure amino | #1 |
| neurological syndrome nature | #1 |
| hepatic encephalopathy authors | #1 |
| pons thiamine treatment | #1 |
| pyrithiamine treatment | #1 |
| histamine caudate putamen | #1 |
| rats direct evidence | #1 |
| microglia neuroinflammatory response | #1 |
| prophylaxis reductions | #1 |
| “ peripheral | #1 |
| selective damage pdhc | #1 |
| ucds liver failure | #1 |
| failure alanine | #1 |
| etanercept hepatic | #1 |
| neuroinhibitory steroid | #1 |
| brains pcs rats | #1 |
| wks spraguedawley receptors | #1 |
| thiamine‐deficient | #1 |
| cox2 ca1 subfield | #1 |
| 3htryptamine receptor | #1 |
| pathogenesis pse | #1 |
| increased brain content | #1 |
| expression glyt1 transporter | #1 |
| brain thiamine metabolism | #1 |
| manganese phosphate mmt | #1 |
| edema encephalopathy | #1 |
| microglial activation protective | #1 |
| opioid encephalopathy humans | #1 |
| thiamine‐dependent enzymes | #1 |
| predilection neuropathologic damage | #1 |
| pca penicillamine | #1 |
| ptbr expression | #1 |
| region selective | #1 |
| shunted rat | #1 |
| rendered ataxic | #1 |
| neuroprotection onset | #1 |
| increased activity katpase | #1 |
| dismutase hyperglycemic | #1 |
| establishment adult activities | #1 |
| ptbr densities | #1 |
| iotal6 | #1 |
| cns pca | #1 |
| downregulation glutamate transporter | #1 |
| subjects transport defect | #1 |
| pca brainstem | #1 |
| noradrenaline transporter sites | #1 |
| autopsied brain samples | #1 |
| cox2 il1beta mrna | #1 |
| tk activity onset | #1 |
| blood ammonia concentrations | #1 |
| encephalopathy binding | #1 |
| distribution l3hnoarg | #1 |
| reversal neurological symptoms | #1 |
| alf evidence | #1 |
| cerebellum 22 | #1 |
| cerebral levels glutamine | #1 |
| alf aom | #1 |
| prevention brain | #1 |
| αkgdh activities | #1 |
| neurobiology hepatic encephalopathy | #1 |
| hepatic abnormality characteristics | #1 |
| hyperammonemic pathologies | #1 |
| loss transporter sites | #1 |
| edema cytokines | #1 |
| 8 cirrhotic patients | #1 |
| 001 cerebral | #1 |
| ammonia increased production | #1 |
| caudate nucleus cau | #1 |
| gabaa neurosteroids | #1 |
| sgc activation lymphocytes | #1 |
| nuclei fastigial interpositus | #1 |
| 3h8ohdpat frontal cortex | #1 |
| normalisation enzyme activities | #1 |
| markedly impaired | #1 |
| increase coma | #2 |
| alf drug | #2 |
| cortical astrocytes ammonia | #2 |
| aqp4 cerebral cortex | #2 |
| lower levels arginine | #2 |
| 2 flumazenil | #2 |
| wernickes encephalopathy | #2 |
| liver cirrhosis activation | #2 |
| thiamine‐dependent | #2 |
| wks decreased activities | #2 |
| deficiency include | #2 |
| brains 36 patients | #2 |
| nitric oxide brain | #2 |
| bckdh bckdh activity | #2 |
| cuznsod mrna cuznsod | #2 |
| treatment asparagine | #2 |
| thiamine turnover | #2 |
| modulation brain | #2 |
| modulation sgc | #2 |
| induced liver failure | #2 |
| densities bmax | #2 |
| hyperammonemia increased | #2 |
| edema hepatic | #2 |
| gaba ammonia | #2 |
| ataxia animals | #2 |
| plasma proinflammatory cytokines | #2 |
| increasing dheas currents | #2 |
| alpha1 sites | #2 |
| male portacaval shunt | #2 |
| symptoms thiamine | #2 |
| wks enzyme activities | #2 |
| gammagba nalphaacetylarginine nalphaaa | #2 |
| allopregnanolone fold | #2 |
| gabaa receptor indomethacin | #2 |
| increased activities | #2 |
| gabaa encephalopathy humans | #2 |
| defect membrane transport | #2 |
| encephalopathy portacaval | #2 |
| pallidum cirrhotic patients | #2 |
| 3acetyl pyridine | #2 |
| haloperiodol | #2 |
| astrocytic benzodiazepine | #2 |
| lornithinelaspartate | #2 |
| mice alf | #2 |
| autopsy delay intervals | #2 |
| encephalopathy aids | #2 |
| 3beta5alphathp | #2 |
| 67 coma stages | #2 |
| rats cortex male | #2 |
| coma stages p001 | #2 |
| swelling cortical astrocytes | #2 |
| impaired gaba function | #2 |
| systemic encephalopathy | #2 |
| cirrhotic patients modulation | #2 |
| lactate coma stages | #2 |
| portacaval anastomosis pca | #2 |
| cisterna magna catheters | #2 |
| computed wernicke encephalopathy | #2 |
| alcoholics absence | #2 |
| 4week portacaval | #2 |
| indomethacin locomotor deficit | #2 |
| early precoma stages | #2 |
| enzyme deficits | #2 |
| experimental alf | #2 |
| sgc brain | #2 |
| mrna expression gfap | #2 |
| neurosteroid pregnenolone fold | #2 |
| neuroinhibitory steroids | #2 |
| thp metabolites fatigue | #2 |
| dheas bdl rats | #2 |
| brain organic myoinositol | #2 |
| cns consequences | #2 |
| taurine platelets | #2 |
| disorder mystery | #2 |
| congenital hyperammonemias | #2 |
| shunted | #2 |
| shunted pcs | #2 |
| brain glutamine synthesis | #2 |
| hepatic encephalopathy gabaa | #2 |
| liver failure gfap | #2 |
| tyrosine tyr levels | #2 |
| 3alpha5alphathp 3alpha5betathp | #2 |
| body fatigue rats | #2 |
| mouse astrocytes effects | #2 |
| rats portacaval anastomosis | #2 |
| l‐ornithine‐l‐aspartate | #2 |
| improvement mental state | #2 |
| brain lactate synthesis | #2 |
| precoma coma | #2 |
| alpha kgdh | #2 |
| activities maoa | #2 |
| neuronal loss alterations | #2 |
| loss eaat2 protein | #2 |
| thiamine phosphorylation | #2 |
| ligand 3hpk | #2 |
| thiaminedeficiency | #2 |
| 3hpk11195 brain regions | #2 |
| 3alpha5betathp patients | #2 |
| glutamate syndrome | #2 |
| alf control | #2 |
| novo synthesis lactate | #2 |
| increased levels pregnenolone | #2 |
| animals hepatic | #2 |
| ammonia central role | #2 |
| 970±079 | #2 |
| ammonia animal hepatic | #2 |
| brain dehydroepiandrosterone dhea | #2 |
| electrified grid | #2 |
| hyperammonemia synaptosomes | #2 |
| intracranial hypertension alf | #2 |
| moderate grade iii | #2 |
| glt1 increased | #2 |
| hydrolases aged | #2 |
| brain samples alcoholics | #2 |
| alf mrna expression | #2 |
| pallidal manganese | #2 |
| edematous cerebral cortex | #2 |
| iggimmunoreactivity | #2 |
| mice acetaminophen toxicity | #2 |
| fold allopregnanolone | #2 |
| ammonia octanoic acid | #2 |
| restricted transfer | #2 |
| cerebral edema loss | #2 |
| central neuroinflammatory | #2 |
| activities choline acetyltransferase | #2 |
| encephalopathy glutamine concentrations | #2 |
| ornithine aminotransferase administration | #2 |
| portacaval shunting | #2 |
| liver spf | #2 |
| pyrithiamine rats rats | #2 |
| brain edema concentrations | #2 |
| gfap immunoreactivity degree | #2 |
| human brain contrast | #2 |
| concentrations gammaguanidinobutyric acid | #2 |
| mri neurological evaluation | #2 |
| immunohistochemistry liver failure | #2 |
| reflex stage | #2 |
| inbred strains glutamine | #2 |
| pathogenesis portal | #2 |
| decreased reuptake | #2 |
| pca rats allopregnanolone | #2 |
| brain lactate increase | #2 |
| thiaminedeficient mice | #2 |
| implicated pathogenesis | #2 |
| extracellular brain | #2 |
| dheas reduced | #2 |
| encephalopathy onset | #2 |
| thirtytwo cirrhotic patients | #2 |
| csf ammonia | #2 |
| osmotic effects glutamine | #2 |
| development ethanol preference | #2 |
| increase coma stages | #2 |
| glutamate glur2 | #2 |
| membranes tomography | #2 |
| hepatic encephalopathy controls | #2 |
| thdoc fold | #2 |
| thiamine bloodbrain barrier | #2 |
| dheas body fatigue | #2 |
| brain taurine concentrations | #2 |
| concentrations ammonium chloride | #2 |
| hepatic cerebral | #2 |
| 26 153 | #2 |
| ammoniainduced neurotoxicity | #2 |
| reduced brain levels | #2 |
| cerebral complications alf | #2 |
| ohe encephalopathy humans | #2 |
| ammonia detoxification glutamine | #2 |
| symptomatic rats | #2 |
| brain portacaval shunting | #2 |
| hyperammonemic brain | #2 |
| encephalopathy acute | #2 |
| increased novo synthesis | #2 |
| 150 dose increase | #2 |
| 3000 microg m3 | #2 |
| neurons nmr | #2 |
| cholinergic neuronal loss | #2 |
| deficient encephalopathy | #2 |
| animal hepatic encephalopathy | #2 |
| edema alf | #2 |
| glutamine hepatic | #2 |
| chronic thiamine | #2 |
| densities binding sites | #2 |
| 2 brain samples | #2 |
| neurons glutamine synthesis | #2 |
| binding 3hpk11195 | #2 |
| mice congenital | #2 |
| cirrhotic patients pathology | #2 |
| tdp dependent enzymes | #2 |
| encephalopathy major | #2 |
| thiamine deficiency patients | #2 |
| failure alf | #2 |
| loss eaat2 expression | #2 |
| activities muscle | #2 |
| neuropathic pain etanercept | #2 |
| serum lad | #2 |
| densities binding | #2 |
| vulnerable brain structures | #2 |
| computerized autotrack | #2 |
| thiamine‐dependent enzyme | #2 |
| responsible neurological | #2 |
| degree gfap immunoreactivity | #2 |
| reduced concentrations dheas | #2 |
| nash addition | #2 |
| 5ht turnover brain | #2 |
| carboxamide binding | #2 |
| thiamine dependent | #2 |
| neuropsychiatric complication | #2 |
| isomorphic models | #2 |
| cisterna magna catheter | #2 |
| ataxic animals | #2 |
| encephalopathy wernicke | #2 |
| rats thiamine | #2 |
| thiamine deficiency wks | #2 |
| kinetics taurine | #2 |
| sustained deficiency arginine | #2 |
| nmda receptor pca | #2 |
| millimolar concentrations brain | #2 |
| pyrithiamine induced | #2 |
| spf mutant mice | #2 |
| hepatic encephalopathy ohe | #2 |
| wernickes encephalopathy patients | #2 |
| disorder loss | #2 |
| diseases manganese | #2 |
| reduction dopamine turnover | #2 |
| increased brain turnover | #2 |
| alanine frontal cortex | #2 |
| kidney ammonia | #2 |
| cerebellum output | #2 |
| pathophysiologic mechanisms | #2 |
| pathogenesis friedreichs ataxia | #2 |
| sustained hyperammonemia | #2 |
| gammagba | #2 |
| rat brain relation | #2 |
| fold thdoc | #2 |
| decreased gfap immunoreactivity | #2 |
| model wernicke | #2 |
| aged muscimol | #2 |
| reduced brain dheas | #2 |
| death thiamine | #2 |
| ouabain upregulation | #2 |
| increased manganese | #2 |
| cerebellum cirrhotic patients | #2 |
| selective increase | #2 |
| hepatic encephalopathy complication | #2 |
| hypokinesia produced | #2 |
| precoma stages p001 | #2 |
| pyrithiamine treated | #2 |
| hyperammonaemia hepatic encephalopathy | #2 |
| liver failure studies | #2 |
| isomorphic model | #2 |
| dheas hepatic | #2 |
| protein levels glast | #2 |
| form ataxia | #2 |
| pdh activity platelets | #2 |
| failure altered | #2 |
| concentrations dheas | #2 |
| ammonia metabolism astrocytes | #2 |
| thiamine deprivation loss | #2 |
| sites increased | #2 |
| vesicular dysfunction | #2 |
| glutamine intracranial | #2 |
| encephalopathy histamine | #2 |
| bergmann glial pathology | #2 |
| methyhistamine | #2 |
| plasma levels 3alpha5alphathp | #2 |
| progression ohe | #2 |
| thiaminedependent enzymes | #2 |
| ammoniainduced alterations | #2 |
| phosphate sulfate mixture | #2 |
| brain levels neurosteroids | #2 |
| bath concentration ammonia | #2 |
| thiamine deprivation | #2 |
| controls 3alpha5alphathp | #2 |
| treatment cns complications | #2 |
| brain shunted rats | #2 |
| pca brain regions | #2 |
| precoma stages increase | #2 |
| liver thiamine | #2 |
| mental state trials | #2 |
| ammonia gabaergic neurotransmission | #2 |
| congenital hyperammonemia | #3 |
| testis preparations | #3 |
| ammonia‐induced brain edema | #3 |
| lobe hepatic | #3 |
| ammonia swelling | #3 |
| pcs rat brain | #3 |
| endogenous agonists role | #3 |
| brain densities | #3 |
| concentrations αmt | #3 |
| cogent explanation | #3 |
| carnitine ammonia | #3 |
| transporter snat5 | #3 |
| portacaval anastomosis rats | #3 |
| hepatic neurological | #3 |
| administration ammonium | #3 |
| repetitive removal | #3 |
| akinesia βendorphin | #3 |
| rats pyrithiamine | #3 |
| il6 levels brain | #3 |
| transketolase activities | #3 |
| prevents cerebral | #3 |
| ganglia structures | #3 |
| predictions disorder | #3 |
| effects ldeprenyl | #3 |
| corneal reflex apomorphine | #3 |
| strains thiamine | #3 |
| decreased densities | #3 |
| rats pse | #3 |
| addition astrocyte morphology | #3 |
| total brain glutamine | #3 |
| acids relation | #3 |
| pallidal signals | #3 |
| ammonia hepatic | #3 |
| brain concentrations rats | #3 |
| cerebellum activities | #3 |
| glutamine brain edema | #3 |
| activities brains | #3 |
| brain edema alf | #3 |
| deficiency acidosis | #3 |
| tetrahydrodesoxycorticosterone | #3 |
| homogenates frontal cortex | #3 |
| astrocytic cell swelling | #3 |
| kornetsky | #3 |
| encephalopathy aged | #3 |
| 5fmorn | #3 |
| tissue ornithine concentrations | #3 |
| 5fmorn treatment | #3 |
| central cholinergic deficit | #3 |
| rats glutamates hippocampus | #3 |
| αketoglutarate dehydrogenase | #3 |
| potent neuroactive properties | #3 |
| pbgd study | #3 |
| selective down‐regulation | #3 |
| blood transketolase | #3 |
| mhe lola | #3 |
| hyperammonemia acute | #3 |
| amphetamine amphetamine animals | #3 |
| glutamate transporter cells | #3 |
| coma equal | #3 |
| brain portocaval anastomosis | #3 |
| cerebral cortex pons | #3 |
| thiamine deficient | #3 |
| ammoniainduced impairment | #3 |
| controls emax | #3 |
| turnover study rats | #3 |
| 13 consecutive weeks | #3 |
| onset neurological signs | #3 |
| cirrhosis iii | #3 |
| acids cerebrospinal | #3 |
| 3hdaspartate uptake | #3 |
| doubt25 ammonia | #3 |
| encephalopathy inflammation | #3 |
| akinesia corneal reflex | #3 |
| ammonia glutamate | #3 |
| decreased concentrations striatum | #3 |
| selective brain lesions | #3 |
| treatment portalsystemic encephalopathy | #3 |
| hepatic devascularized rat | #3 |
| adequate substrates | #3 |
| acrylamide pyrithiamine | #3 |
| neurotransmission failure | #3 |
| ammonia energy metabolism | #3 |
| lcarnitine atp | #3 |
| electrically stimulated release | #3 |
| bckdh activity rats | #3 |
| deletion delays | #3 |
| portocaval anastomosis pca | #3 |
| odn immunolabeling | #3 |
| late symptomatic stages | #3 |
| ammonia brain edema | #3 |
| animals profiles | #3 |
| brain improvement | #3 |
| male portacaval | #3 |
| hepatobiliary route | #3 |
| coma stage | #3 |
| platelets 10 patients | #3 |
| pca odn immunolabeling | #3 |
| acute ammonia exposure | #3 |
| αmt midbrain | #3 |
| binding sites heart | #3 |
| protein hepatic | #3 |
| neurobiological characterization | #3 |
| pallidus hepatic | #3 |
| protective glutamine | #3 |
| increases il1beta | #3 |
| animals coma | #3 |
| abstract mild hypothermia | #3 |
| cerebellar amino | #3 |
| pdhc acetyl coa | #3 |
| glial cells ammonia | #3 |
| hypothermia brain edema | #3 |
| medium 5 mm | #3 |
| operated controls | #3 |
| glutamates hippocampus rats | #3 |
| genial expression | #3 |
| thiamine deficiency wernicke | #3 |
| reflex serotonin βendorphin | #3 |
| drug situ nickend | #3 |
| regions cns | #3 |
| ishen guidelines | #3 |
| skeletal portacaval shunt | #3 |
| singlesite model | #3 |
| cholestasis‐associated fatigue | #3 |
| statistical significance regions | #3 |
| cirrhosis agents | #3 |
| midbrain turnover study | #3 |
| decreased concentrations αmt | #3 |
| autotrack | #3 |
| hepatic encephalopathy humans | #3 |
| rats pathogenesis | #3 |
| effects ro15 | #3 |
| decreased aspartate | #3 |
| severity reviews see1–4 | #3 |
| basal ganglia βendorphin | #3 |
| neuroglial proteins | #3 |
| synthesis aspartate | #3 |
| thiamine phosphate | #3 |
| major neurotransmitter systems | #3 |
| pathogenesis central | #3 |
| peripheral‐type | #3 |
| portacavalshunted rats | #3 |
| nmda subclass | #3 |
| intraneuronal release | #3 |
| mk‐801‐sensitive nitration | #3 |
| encephalopathy hepatic | #3 |
| liver–brain axis | #3 |
| 320350 degrees | #3 |
| doubt25 | #3 |
| edema intracranial | #3 |
| cholinergic m1 | #3 |
| astrocyte glutamine | #3 |
| precoma stages | #3 |
| homologous models | #3 |
| increased ptbr | #3 |
| βendorphin apomorphine basal | #3 |
| βendorphin akinesia | #3 |
| 38 alcoholic patients | #3 |
| models thiamine | #3 |
| alf animals | #3 |
| humans neurotransmitter | #3 |
| βendorphin decreased concentrations | #3 |
| increase brain lactate | #3 |
| abstract hepatic encephalopathy | #3 |
| vitro binding technique | #3 |
| signs mild personality | #3 |
| ammoniatreated cells | #3 |
| αmt βendorphin | #3 |
| increased uptake capacity | #3 |
| alcoholics wks | #3 |
| gfap mrna gfap | #3 |
| type ” | #3 |
| altered glial | #3 |
| cellspecific pathways | #3 |
| muscle glutamine synthetase | #3 |
| pdh friedreich | #3 |
| activities reduced | #3 |
| deficiency thiamine | #3 |
| globus pallidus putamen | #3 |
| rats αmt | #3 |
| mrna ammonia | #3 |
| condition development | #4 |
| pse increased | #4 |
| ammonia levels blood | #4 |
| mmars increased icp | #4 |
| inflammation mediators icp | #4 |
| effects mild hypothermia | #4 |
| xlinked deficiency | #4 |
| shamoperated controls | #4 |
| anastomosis rat | #4 |
| peripheral‐type benzodiazepine | #4 |
| deoxyglucose endothelium | #4 |
| alf expression | #4 |
| rat brain pca | #4 |
| neurotransmitter dysfunction | #4 |
| brain energy failure | #4 |
| 5 mm nh4cl | #4 |
| brain dopamine receptor | #4 |
| decreased activities | #4 |
| alcoholism thiamine | #4 |
| alf brain | #4 |
| patients wernicke | #4 |
| acute liver failure | #4 |
| severe neuronal dysfunction | #4 |
| brain edema increase | #4 |
| total shunting | #4 |
| tdinduced cell death | #4 |
| histaminergic histamine | #4 |
| brain thiamine | #4 |
| mhe mildest form | #4 |
| increased brain glutamine | #4 |
| inos mnsod | #4 |
| mmars brain water | #4 |
| surgical rna rats | #4 |
| lornithine laspartate | #4 |
| locomotor deficit | #4 |
| cases alcohol abuse | #4 |
| arterial ammonia mmars | #4 |
| thiamine‐deficient rat brain | #4 |
| expression alf | #4 |
| 6 hrs alf | #4 |
| guanylate cyclase patients | #4 |
| treatment hepatic encephalopathy | #4 |
| gaba friedreich | #4 |
| ornithine aspartate | #4 |
| affinities densities | #4 |
| astrocytic metabolic | #4 |
| loss glt1 | #4 |
| wernickekorsakoff syndrome | #4 |
| cerebral cortex kidney | #4 |
| acute ammonia treatment | #4 |
| inbred strains ammonia | #4 |
| activities brain | #4 |
| albumin dialysis alf | #4 |
| benzodiazepines increase | #4 |
| ions synaptic | #4 |
| activities prefrontal cortex | #4 |
| alf | #4 |
| amino acids areas | #4 |
| animals liver failure | #4 |
| ischemic liver failure | #4 |
| activities glutamine synthetase | #4 |
| tdpase | #4 |
| postmortem delay interval | #4 |
| rats asparagine | #4 |
| cbf inflammatory mediators | #4 |
| increased icp alf | #4 |
| cerebral amino acids | #4 |
| locomotor evaluation | #4 |
| otcdeficient mice | #4 |
| subclinical seizure activity | #4 |
| glt1 transcript | #4 |
| plasma clearance groups | #4 |
| early microglial response | #4 |
| rats portacaval shunting | #4 |
| calcium microsomes | #4 |
| newly synthesized glutamine | #4 |
| opioid pca | #4 |
| carnitine energy | #4 |
| thiochrome derivatives | #4 |
| postsynaptic action | #4 |
| tspo sites | #4 |
| liver brain | #4 |
| shunted rats | #4 |
| p001 hypothermia | #4 |
| transketolase wernicke | #4 |
| normal coupling | #4 |
| sham mmars | #4 |
| vitro techniques ketoglutarate | #4 |
| time mmars | #4 |
| izuru matsumoto | #4 |
| protein expression brain | #4 |
| amino acids regions | #4 |
| icp arterial ammonia | #4 |
| synaptic membrane preparations | #4 |
| arterial ammonia alf | #4 |
| elevated ammonia levels | #4 |
| astrocytic genes | #4 |
| thiamine diphosphatase | #4 |
| edema gene | #4 |
| 13 moles | #4 |
| brain pregnenolone content | #4 |
| hepatocytes ascorbate | #4 |
| brain neuroinflammation | #4 |
| increased concentrations prostaglandins | #4 |
| ouabain ec50 | #4 |
| alcohol thiamine deficiency | #4 |
| liver central | #4 |
| thp metabolites | #4 |
| brain 5ht release | #4 |
| thiamine deficiency rats | #4 |
| extrapyramidal symptoms patients | #4 |
| rats βendorphin | #4 |
| brain glutamic | #4 |
| degree alzheimer type | #4 |
| aged pyruvate | #4 |
| thiamine deficient animals | #4 |
| administration central | #4 |
| thiamine antagonist | #4 |
| ouabainlike compounds | #4 |
| encephalopathy coma | #4 |
| thiamine thiamine pyrophosphate | #4 |
| regional amino | #4 |
| brain hepatic encephalopathy | #4 |
| taurine friedreichs ataxia | #4 |
| maoa isoform | #4 |
| onset severe encephalopathy | #4 |
| mmars time | #4 |
| encephalopathy cerebral | #5 |
| tpp cofactor | #5 |
| rats fatigue | #5 |
| acetyl pyridine | #5 |
| manganese astrocytes | #5 |
| laspartate lola | #5 |
| spectroscopy tomography emissioncomputed | #5 |
| congenital urea | #5 |
| exposure cultured astrocytes | #5 |
| neurological status | #5 |
| brain glutamate concentrations | #5 |
| homologous model | #5 |
| pet scan study | #5 |
| activities cerebellum | #5 |
| vulnerable regions | #5 |
| prevention prophylaxis | #5 |
| alf ammonia | #5 |
| adequate experimental models | #5 |
| ammonia lowering | #5 |
| studied brain | #5 |
| result altered | #5 |
| astrocytic | #5 |
| medial thalamus | #5 |
| genetics astrocytes blotting | #5 |
| neurotransmitter pool | #5 |
| acute magnetic | #5 |
| 45 cirrhotic patients | #5 |
| kgdh | #5 |
| chronic exposure manganese | #5 |
| reserpinelike | #5 |
| acute rats rats | #5 |
| sites peripheral | #5 |
| content modulation | #5 |
| monoamines metabolites | #5 |
| thiamine status | #5 |
| vulnerable brain | #5 |
| hepatic encephalopathy gaba | #5 |
| hyperammonemia liver | #5 |
| cytokines ammonia | #5 |
| glutamate symporters | #5 |
| currents concentrations | #5 |
| reduction glutamate | #5 |
| amino acid regions | #5 |
| transporter sites | #5 |
| liver disease rats | #5 |
| complication acute | #5 |
| kinetics pharmacology | #5 |
| ammonia metabolism | #5 |
| gait animals | #5 |
| pregnenolone content | #5 |
| ammonia muscle | #5 |
| mmars | #5 |
| pse encephalopathy humans | #5 |
| hand densities | #5 |
| amino acids pathogenesis | #5 |
| tk activities | #5 |
| alcoholic receptors | #5 |
| activities choline | #5 |
| branchedchain analysis | #5 |
| aspartate lola | #5 |
| patients hepatic | #5 |
| allopregnanolone thdoc | #5 |
| treatment malnutrition | #5 |
| convulsions onset | #5 |
| activities gad | #5 |
| tissue autopsy | #5 |
| cerebral hepatic | #5 |
| ammonia removal | #5 |
| latenight snack | #5 |
| liver assist devices | #5 |
| intracranial hypertension rats | #5 |
| maoa function | #5 |
| maoa activities | #5 |
| rats portacaval shunts | #5 |
| extracellular quin | #5 |
| brain histamine receptors | #5 |
| cns ammonia | #5 |
| brain acute | #5 |
| topic rifaximin | #5 |
| alterations glutamatergic | #5 |
| kstimulated ca2dependent release | #5 |
| glutamine hypothesis | #5 |
| spf mice controls | #5 |
| responsible brain | #5 |
| mild personality | #5 |
| sustained deficiency | #5 |
| saturation binding isotherms | #5 |
| thiaminedeficient diet | #5 |
| onset coma | #5 |
| glur2 glur3 subunits | #5 |
| surgical receptors | #5 |
| age matched subjects | #5 |
| increases ammonia | #5 |
| wernicke | #5 |
| anterolateral hypothalamus | #5 |
| methioninesulfoximine | #5 |
| allopregnanolone gabaa | #5 |
| brain ammonia | #5 |
| hexyl1h | #5 |
| publication animals rats | #5 |
| fmorn | #6 |
| nencki | #6 |
| increased expression aqp4 | #6 |
| glast transporter | #6 |
| glt1 brain | #6 |
| implications pathogenesis | #6 |
| mars alf | #6 |
| 14c taurine | #6 |
| deterioration neurological | #6 |
| dogs hepatic encephalopathy | #6 |
| glt1 glast protein | #6 |
| models alf | #6 |
| fur mice | #6 |
| cerebellum caudate nucleus | #6 |
| increased glut1 expression | #6 |
| concomitant 24fold increase | #6 |
| controls arginine | #6 |
| ammonia glutamine | #6 |
| arginine brain | #6 |
| capacity removal | #6 |
| brain benzodiazepine | #6 |
| dehydrogenase pdhc | #6 |
| alf nac | #6 |
| righting reflexes | #6 |
| enzymes brains | #6 |
| ascorbate protects | #6 |
| nac alf | #6 |
| activities liver | #6 |
| mice nacetylcysteine | #6 |
| thiamine phosphate esters | #6 |
| hypothermia alf | #6 |
| induced thiamine | #6 |
| receptors hepatic | #6 |
| enzymes pyruvate | #6 |
| 3htryptamine binding | #6 |
| thiamine esters | #6 |
| hepatic encephalopathy effects | #6 |
| acetyl lcarnitine | #6 |
| inflammatory mediators groups | #6 |
| platelets 11 patients | #6 |
| astrocyte cell volume | #6 |
| direct neurotoxic | #6 |
| unaltered distribution | #6 |
| perispinal etanercept | #6 |
| hyperammonemic | #6 |
| tmpase | #6 |
| cerebral cortex activities | #6 |
| relationship neurological symptoms | #6 |
| encephalopathy humans | #6 |
| expression astrocytic genes | #6 |
| endstage liver failure | #6 |
| 3htryptamine binding sites | #6 |
| benzodiazepine intake | #6 |
| term fluorescence | #6 |
| blood‐brain barrier integrity | #6 |
| humans hyperammonemia | #6 |
| plasma frontal cortex | #6 |
| basal ganglia structures | #6 |
| gabaergic tone | #6 |
| output cerebellum | #6 |
| dha administration | #6 |
| brain cirrhotic | #6 |
| 3nmol | #6 |
| pca sham | #6 |
| frontal cortex rats | #6 |
| central proinflammatory | #6 |
| disease ammonia | #6 |
| lola improvement | #6 |
| liver failure | #6 |
| cerebral amino | #6 |
| alphaketoglutarate dehydrogenase | #6 |
| hiaa increased | #7 |
| ischemia hyperglycemic | #7 |
| liver hepatic encephalopathy | #7 |
| astrocytic transporters | #7 |
| flumazenil 10 microm | #7 |
| typical friedreichs ataxia | #7 |
| chronic deprivation | #7 |
| wernicke‐korsakoff syndrome | #7 |
| tppdependent enzymes | #7 |
| thiamine absorption | #7 |
| columbia rating scale | #7 |
| failure acute | #7 |
| loss transporter | #7 |
| frontal cortex controls | #7 |
| fatigue severity patients | #7 |
| edema extracellular | #7 |
| encephalopathy findings | #7 |
| kcl medium | #7 |
| neuronal cell loss | #7 |
| increased cerebellum | #7 |
| brain glutamate | #7 |
| alf arterial ammonia | #7 |
| glutamine synthesis ammonia | #7 |
| central neuroinflammation | #7 |
| pregnant rats offspring | #7 |
| 70 mm kcl | #7 |
| uremic coma | #7 |
| igg immunohistochemistry | #7 |
| cyclase hepatic | #7 |
| alcoholic brain damage | #7 |
| tdp ttp | #7 |
| size portacaval | #7 |
| neuropsychiatric abnormalities patients | #7 |
| animal hepatic | #7 |
| notion activation | #7 |
| vpmt | #7 |
| ammonia kidney | #7 |
| edema plasma | #7 |
| transporter deficit | #7 |
| neurological symptoms | #7 |
| hepatic encephalopathy studies | #7 |
| metallic phosphate | #7 |
| central benzodiazepine receptors | #7 |
| acute minocycline | #7 |
| perineuronal astrocytes | #7 |
| icp alf | #7 |
| glutamate acute | #7 |
| alf sham | #7 |
| transketolase animals | #7 |
| neuroinhibitory | #7 |
| chemistry disease | #7 |
| rats ammonium acetate | #7 |
| nutritional management patients | #7 |
| fulminant liver failure | #7 |
| skeletal muscle adapts | #7 |
| swelling astrocytes | #7 |
| concentrations allopregnanolone | #7 |
| l3harginine uptake | #7 |
| gdh activities | #7 |
| severe thiamine deficiency | #7 |
| mediators liver | #7 |
| surgical rats | #7 |
| pca pss | #7 |
| glutamine increased | #7 |
| 3htryptamine | #7 |
| cerebral alterations alf | #7 |
| thiamine dependent enzymes | #7 |
| inhibitor src | #7 |
| flumazenil patients | #7 |
| alterations modulation | #8 |
| probenecid 5 | #8 |
| 3alpha5betathp | #8 |
| active pyruvate dehydrogenase | #8 |
| cerebellum activation | #8 |
| regional alterations | #8 |
| concentrations thdoc | #8 |
| cirrhotic patients | #8 |
| content frontal cortex | #8 |
| tests ataxia | #8 |
| proinflammatory mediators expression | #8 |
| portalsystemic shunting | #8 |
| disease gad | #8 |
| alcohol brain damage | #8 |
| taurine ca2 | #8 |
| ammonium ions | #8 |
| central noradrenergic function | #8 |
| loss congenital | #8 |
| intracranial pressure increase | #8 |
| synthesis lactate | #8 |
| hyperglycemic cerebral | #8 |
| spraguedawley temporal lobe | #8 |
| induced akinesia | #8 |
| sourkes | #8 |
| alf administration | #8 |
| hyperglycemic cerebral ischemia | #8 |
| ammonia metabolites | #8 |
| voluntary ethanol consumption | #8 |
| brain ammonia levels | #8 |
| nmda sites | #8 |
| clive harper | #8 |
| falls cirrhosis | #8 |
| rindi | #8 |
| receptors mitochondrial | #8 |
| synthesis thiamine | #8 |
| strains ornithine | #8 |
| direct toxic actions | #8 |
| assessment bioaccumulation | #8 |
| complications liver disease | #8 |
| expression glyt1 | #8 |
| prefrontal nmda | #8 |
| affinity glutamate uptake | #8 |
| brain increased expression | #8 |
| study binding sites | #8 |
| elfar adalsteinsson | #8 |
| neuropathologic consequences | #8 |
| ultraviolet uv spectrum | #8 |
| measurement cell volume | #8 |
| antisense elements genetics | #8 |
| chronic brain dysfunction | #8 |
| gaba reverse | #8 |
| thalamus cerebellum | #8 |
| portocaval anastomosis | #8 |
| autopsied human | #8 |
| alcohol thiamine | #8 |
| neuroprotective steroids | #8 |
| ammonia hyperammonemia | #8 |
| normal metabolic balance | #8 |
| peter dodd | #8 |
| result decreased | #8 |
| activities glutamine | #8 |
| cells ammonia | #8 |
| tellez | #8 |
| dependent enzymes | #8 |
| izuru | #8 |
| lactate synthesis | #8 |
| arterial ammonia concentrations | #8 |
| neurobehavioral damage | #8 |
| hepatic encephalopathy ammonia | #9 |
| acute hyperammonemia | #9 |
| pcs rats | #9 |
| gabaa tissue distribution | #9 |
| sham alf | #9 |
| manganese dust | #9 |
| disease thiamine | #9 |
| portacaval rat | #9 |
| mechanisms responsible | #9 |
| vulnerable brain regions | #9 |
| hepatocerebral | #9 |
| central gabaa receptor | #9 |
| ammonia binding | #9 |
| glutamate glt1 | #9 |
| protein glut1 | #9 |
| adolf pfefferbaum | #9 |
| nonneuronal elements | #9 |
| transcarbamylase otc | #9 |
| animals acute | #9 |
| arterial ammonia concentration | #9 |
| glucose hypothermia | #9 |
| ammonia key role | #9 |
| observed frontal | #9 |
| glial tca cycle | #9 |
| 37 decrease | #9 |
| activities skeletal muscle | #9 |
| brain postsynaptic | #9 |
| prevention complications | #9 |
| joanne lewohl | #9 |
| mild hypothermia | #9 |
| acute nitric oxide | #9 |
| acute rats | #9 |
| hyperammonemia liver cirrhosis | #9 |
| hepatic coma | #9 |
| neurotoxic substance | #9 |
| pallidal signal | #9 |
| thiamine monophosphatase | #9 |
| ammonia induced | #9 |
| binding sites nmda | #9 |
| 11 cirrhotic patients | #9 |
| sites frontal | #9 |
| male cirrhotic patients | #9 |
| gaba reference | #9 |
| acid hepatic | #9 |
| order address | #9 |
| kinetics distribution | #9 |
| edith sullivan | #9 |
| taurine calcium | #9 |
| rats phosphate | #9 |
| edema rats | #9 |
| cerebral ammonia toxicity | #9 |
| neuroinhibition | #9 |
| perispinal administration | #9 |
| binding sites brain | #9 |
| 5fluoromethylornithine | #9 |
| brain herniation | #9 |
| glyt1 transporter | #9 |
| cerebellum medulla oblongata | #9 |
| glutamate receptor ligands | #9 |
| autopsied brain | #9 |
| rat brain density | #9 |
| portal hypertension result | #9 |
| ammonia neurotoxicity | #9 |
| taurine binding | #9 |
| cord taurine | #10 |
| loss reflex | #10 |
| cerebral consequences | #10 |
| mechanisms free radicals | #10 |
| rats nimesulide | #10 |
| expression superoxide | #10 |
| neuropsychiatric disorder | #10 |
| subsequent gc analysis | #10 |
| encephalopathy cirrhotic | #10 |
| massive brain edema | #10 |
| glutathione levels expression | #10 |
| neuroactive amino acids | #10 |
| 10 mm concentration | #10 |
| complication chronic | #10 |
| encephalopathy grade | #10 |
| activation pathogenesis | #10 |
| glutamine synthesis astrocytes | #10 |
| model alf | #10 |
| deficiency congenital | #10 |
| labeling glutamine | #10 |
| affinities binding sites | #10 |
| flumazenil hepatic | #10 |
| brain edema | #10 |
| rat leads | #10 |
| cerebellum pons | #10 |
| 3omethylglucose animals animals | #10 |
| selective brain regions | #10 |
| 200 appearance | #10 |
| rats stereotyped behavior | #10 |
| thalamic structures | #10 |
| hrqol mhe | #10 |
| thiamine replenishment | #10 |
| mnsod cuznsod | #10 |
| bdl surgery | #10 |
| 3hpk | #10 |
| mechanisms include | #10 |
| fur mouse | #10 |
| 3hketanserin binding sites | #10 |
| nh4ac | #10 |
| urea cycle enzymopathies | #10 |
| mechanisms tnfalpha | #10 |
| rats daily injections | #10 |
| dissected material | #10 |
| nh4 forms | #10 |
| ammonia study | #10 |
| neurological symptomatology | #10 |
| anastomosis hepatic | #10 |
| decreased glutamate | #10 |
| brain pca | #10 |
| thiamine transketolase | #10 |
| identification alterations | #10 |
| stress thiamine | #10 |
| disorders include | #10 |
| swelling ammonia | #10 |
| progression hepatic encephalopathy | #10 |
| rats nh4cl | #11 |
| ammonia pathogenesis | #11 |
| ammonia astrocytes | #11 |
| ammonia amino acids | #11 |
| amino acids rats | #11 |
| brain liver | #11 |
| brain increased | #11 |
| manganese blood | #11 |
| alterations brain | #11 |
| biosynthetic purposes | #11 |
| studies convincing evidence | #11 |
| patients gabaa | #11 |
| 1h‐13c | #11 |
| increased expression brain | #11 |
| deficiency brain | #11 |
| pdh alpha | #11 |
| benzodiazepines neurosteroids | #11 |
| gabaergic tonic currents | #11 |
| isoforms mrna | #11 |
| benzodiazepinelike compounds | #11 |
| glutamate gammaaminobutyric acid | #11 |
| reduced activities | #11 |
| placebo benzodiazepines | #11 |
| benzodiazepine bdz receptors | #11 |
| time icp | #11 |
| cerebral vulnerability | #11 |
| impaired locomotor activity | #11 |
| signal hyperintensity | #11 |
| hyperammonemias | #11 |
| portal systemic | #11 |
| capacity ammonia | #11 |
| experimental design limitations | #11 |
| halflife age | #11 |
| oxidative nitrosative stress | #11 |
| brain h1 | #11 |
| fluoromethylornithine | #11 |
| dawley thalamus | #11 |
| hypothermia liver | #11 |
| cirrhotic patients relationship | #11 |
| dehydrogenase alpha | #11 |
| brain alf | #11 |
| impaired oxidation | #11 |
| pca brain | #11 |
| ammonia animals rats | #11 |
| pca p005 | #11 |
| patients frontal cortex | #12 |
| aqp4 brain edema | #12 |
| perispinal | #12 |
| loss righting | #12 |
| ammonia animals | #12 |
| selective radioligands | #12 |
| cerebellar tissue | #12 |
| clinical hepatic encephalopathy | #12 |
| hyperammonemia liver failure | #12 |
| selective inactivator | #12 |
| selective loss expression | #12 |
| diphosphate form | #12 |
| thalamus cerebral cortex | #12 |
| pairfed control mice | #12 |
| ammonia | #12 |
| ammonia amino | #12 |
| brains rats | #12 |
| neuroactive amino | #12 |
| thiamin triphosphate | #12 |
| deficiency amino | #12 |
| thiamine deficient diet | #12 |
| binding medium | #12 |
| binding sites ligands | #12 |
| brain chronic | #12 |
| contribute pathogenesis | #12 |
| igg extravasation | #12 |
| blood manganese concentrations | #12 |
| acetyltransferase disease | #12 |
| humans hepatic | #12 |
| microglial activation brain | #12 |
| mild hypothermia patients | #12 |
| rats glut1 | #12 |
| shunt surgical | #12 |
| total glutamine | #12 |
| p005 pca | #12 |
| improvement neurological symptoms | #12 |
| brain slices synaptosomes | #12 |
| prevention hepatic encephalopathy | #12 |
| ammonia salts | #12 |
| humans ketoglutarate | #12 |
| mm nh4cl | #12 |
| subclinical encephalopathy | #12 |
| anaplerotic activity | #12 |
| increased ammonia | #12 |
| transcarbamylase deficiency | #13 |
| survival liver injury | #13 |
| hyperglycemic ischemia | #13 |
| endogenous neuropeptide ligands | #13 |
| patients flumazenil | #13 |
| hepatic encephalopathy patients | #13 |
| ampa receptor glur2 | #13 |
| postsynaptic gaba | #13 |
| growing body evidence | #13 |
| regions rat brain | #13 |
| increased copper content | #13 |
| expression ammonia | #13 |
| pallidal dopamine | #13 |
| brain water accumulation | #13 |
| butyrylglycine | #13 |
| thiamine intake | #13 |
| increased brain lactate | #13 |
| veratramine | #13 |
| increased csf concentrations | #13 |
| cytokines hepatic | #13 |
| sites brain | #13 |
| ammonia cytokines | #13 |
| neurosteroids gabaa | #13 |
| loss chat | #13 |
| ishen | #13 |
| peripheral nerve conduction | #13 |
| levels octopamine | #13 |
| evidence central | #13 |
| ammonia manganese | #13 |
| amino acids lactate | #13 |
| acute ammonia | #13 |
| blood csf concentrations | #13 |
| hand activities | #13 |
| body fatigue | #13 |
| development severe encephalopathy | #13 |
| loss gfap | #13 |
| neurosteroids pregnenolone | #13 |
| complex ketone | #13 |
| role selective vulnerability | #13 |
| treatment liver failure | #13 |
| hyperammonemic conditions | #13 |
| presence hippocampal sclerosis | #13 |
| liver toxins | #13 |
| neuroprotection pretreatment | #13 |
| gfap protein | #13 |
| frontal cortex administration | #13 |
| tissuespecific alterations | #13 |
| greatest vulnerability | #13 |
| cerebral edema icp | #13 |
| hyperammonemia ammonia | #13 |
| 8024 | #14 |
| mammillary body atrophy | #14 |
| models hepatic | #14 |
| gfap aqp4 | #14 |
| sparse fur | #14 |
| glutamine concentrations | #14 |
| pathogenesis | #14 |
| striatum concentrations | #14 |
| ataxia neurological signs | #14 |
| manganese distribution | #14 |
| aged biogenic | #14 |
| portacaval rats | #14 |
| cerebellum cerebellar cortex | #14 |
| clinical neurological signs | #14 |
| αmt | #14 |
| antibiotic minocycline | #14 |
| brain energy metabolites | #14 |
| systemic shunting | #14 |
| hypothermia reduction | #14 |
| 3hpk 11195 | #15 |
| cirrhosis systematic review | #15 |
| thiamin metabolism | #15 |
| ataxics | #15 |
| purkinje cell terminals | #15 |
| gabaa reference values | #15 |
| manganese phosphate | #15 |
| apaptreated mice | #15 |
| fulminant liver | #15 |
| acute liver | #15 |
| activity pdhc | #15 |
| portocaval shunts | #15 |
| hyperintensity patients | #15 |
| glur3 subunits | #15 |
| alcoholic brain | #15 |
| moderate drinkers | #15 |
| role thiamine | #15 |
| white matter cbf | #15 |
| vulnerable region | #15 |
| cerebral complications | #15 |
| 3hquisqualate | #15 |
| treatment measurement | #15 |
| microglial activation neuroinflammation | #15 |
| astrocytic volume | #15 |
| failure encephalopathy | #15 |
| proteins implicated | #16 |
| new prospects | #16 |
| addition degree | #16 |
| pcs sham | #16 |
| pathophysiologic cascade | #16 |
| benzodiazepine ligands | #16 |
| encephalopathy chronic | #16 |
| isoform gene | #16 |
| taurine brain | #16 |
| nonvulnerable | #16 |
| socalled type | #16 |
| brain modulation | #16 |
| brain proinflammatory | #16 |
| gabaa receptor complex | #16 |
| encephalopathy liver | #16 |
| endothelial glucose | #16 |
| benzodiazepine gaba | #16 |
| hypothermia 35 | #16 |
| hypothesises | #16 |
| agonal status | #16 |
| encephalopathy loss | #16 |
| wks | #16 |
| distribution tritium | #16 |
| animal modelling | #16 |
| hepatic metabolic pathways | #16 |
| cirrhosis ammonia | #16 |
| new mechanistic basis | #16 |
| glutamine increase | #16 |
| complications malnutrition | #17 |
| onset convulsions | #17 |
| vulnerable structures | #17 |
| acid thiamine | #17 |
| pathogenesis complications | #17 |
| early microglial | #17 |
| patient malnutrition | #17 |
| surgical construction | #17 |
| early glial | #17 |
| upregulation aqp4 | #17 |
| activation sgc | #17 |
| acids ammonia | #17 |
| dependent enzyme | #17 |
| encephalopathy rats | #17 |
| liver disease mice | #17 |
| synthetase activities | #17 |
| cox2 expression immunohistochemistry | #17 |
| glutamate enzyme | #17 |
| platelets dopamine | #17 |
| cortical astrocyte | #17 |
| ammonia induces | #17 |
| endogenous benzodiazepines | #17 |
| 4fold increases | #17 |
| day heavy drinking | #17 |
| antibiotic rifaximin | #17 |
| cerebellum enzyme | #17 |
| reprint | #17 |
| glutamine phenylalanine | #17 |
| absence ammonia | #17 |
| excess ammonia | #17 |
| pregnenolone allopregnanolone | #17 |
| benzoate therapy | #17 |
| loss liver | #17 |
| neuroinflammatory mechanisms | #17 |
| isoquinoline carboxamide | #17 |
| coa levels | #18 |
| concentrations kcl | #18 |
| 11195 binding | #18 |
| autopsied | #18 |
| neuropathological damage | #18 |
| beta endorphin betaep | #18 |
| astrocytes blotting | #18 |
| patients therapeutic options | #18 |
| result molecules | #18 |
| astrocytic glutamine synthetase | #18 |
| activities alpha | #18 |
| brain regions rat | #18 |
| doserelated reduction | #18 |
| wernicke korsakoff syndrome | #18 |
| portocaval shunting | #18 |
| prevention progression | #18 |
| encephalopathy patients | #18 |
| selective neuronal | #18 |
| type benzodiazepine | #18 |
| 13c isotopomer analysis | #18 |
| reversible coma | #18 |
| compared pair | #18 |
| alcoholic cirrhotic patients | #18 |
| bbb igg | #18 |
| active pyruvate | #18 |
| condition evidence | #18 |
| wernicke korsakoff | #18 |
| administration aom | #18 |
| generalized reduction | #18 |
| neuropathologic evaluation | #18 |
| neurological psychiatric | #18 |
| binding sites hippocampus | #18 |
| synthetase protein | #19 |
| csf concentrations 5hiaa | #19 |
| equal age | #19 |
| energy metabolism brain | #19 |
| disease frontal | #19 |
| rats stages | #19 |
| pathophysiology hepatic encephalopathy | #19 |
| severe encephalopathy | #19 |
| agents hepatic | #19 |
| lola patients | #19 |
| acids glutamate | #19 |
| increase brain water | #19 |
| blood manganese | #19 |
| free coa | #19 |
| errors mice | #19 |
| response neurodegeneration | #19 |
| serum ammonia levels | #19 |
| ornithine transcarbamylase | #19 |
| complications acute | #19 |
| 125iiodopindolol | #19 |
| treatment mhe | #19 |
| exposure cultured | #19 |
| expression result | #19 |
| endogenous benzodiazepine | #19 |
| distribution binding | #19 |
| brain peripheral | #19 |
| brain lactate | #19 |
| cholinergic cell loss | #19 |
| astrocytic neuronal | #19 |
| outcome prevention | #19 |
| glutamates glutamine | #19 |
| control groups animals | #19 |
| cirrhotic patients controls | #19 |
| diencephalic | #20 |
| l3harginine | #20 |
| syndrome wks | #20 |
| expression oxidative stress | #20 |
| brain organic osmolytes | #20 |
| brain autopsy samples | #20 |
| benzodiazepine medication | #20 |
| adequate dietary protein | #20 |
| pallidal hyperintensity | #20 |
| glutamate increased | #20 |
| biochemical lesion | #20 |
| effects neurosteroids | #20 |
| volume plasmapheresis | #20 |
| lola | #20 |
| glutamate nmda receptors | #20 |
| alf mars | #20 |
| animal frontal | #20 |
| rats patients | #20 |
| animals tests | #20 |
| bbb alterations | #20 |
| coma brain | #20 |
| aids patients patients | #20 |
| regions rat | #20 |
| acute ammonia toxicity | #20 |
| mhe encephalopathy humans | #21 |
| 3alpha5alphathp | #21 |
| glast protein | #21 |
| tetrahydrodeoxycorticosterone | #21 |
| plasma ammonia concentrations | #21 |
| 5 p0001 | #21 |
| cisterna magna csf | #21 |
| sgc nitric oxide | #21 |
| metabolic trafficking | #21 |
| 8094 | #21 |
| blood–brain barrier permeability | #21 |
| vivo cerebral | #21 |
| failure skeletal | #21 |
| alanine increased | #21 |
| transport ammonia | #21 |
| symptomatic stages | #21 |
| protective hypothermia | #21 |
| hyperammonemia rats | #21 |
| selective loss neurons | #21 |
| deficiency synthesis | #21 |
| direct neurotoxic effects | #21 |
| nakatpase activities | #21 |
| endorphin induced | #21 |
| mild hypothermia survival | #21 |
| inbred strains cns | #22 |
| normal circumstances | #22 |
| sham operation rats | #22 |
| brain alanine | #22 |
| characterized model | #22 |
| sites cerebral | #22 |
| deficiency alterations | #22 |
| stereotyped behavior rats | #22 |
| antiparkinson drugs | #22 |
| 3alpha5beta | #22 |
| zieve | #22 |
| exposed manganese | #22 |
| alf infection | #22 |
| gabaa receptors humans | #22 |
| hepatic carnitine | #22 |
| cerebral cortex brainstem | #22 |
| partial inverse agonists | #22 |
| effects glutamate | #22 |
| temporal cortex cerebellum | #22 |
| brain experimental | #22 |
| concentrations glycine | #22 |
| 3hafdx | #22 |
| gaba regions | #22 |
| acute hepatic encephalopathy | #22 |
| sites measured | #22 |
| distribution amino acids | #22 |
| bckdh activity | #23 |
| glutamine accumulation | #23 |
| marrero | #23 |
| oxidative stress nac | #23 |
| proinflammatory cytokines mice | #23 |
| increased sites | #23 |
| neuropathological evaluation | #23 |
| hippocampus thalamus | #23 |
| glutamine taurine | #23 |
| brain neurosteroid | #23 |
| aspartate alanine | #23 |
| thiamine homeostasis | #23 |
| ammonia liver | #23 |
| deficiency animals | #23 |
| cortex male rats | #23 |
| cerebral gaba | #23 |
| portal systemic encephalopathy | #23 |
| ammonia lactate | #23 |
| diphosphate dependent | #23 |
| mm ammonia | #23 |
| astrocytic protein | #23 |
| impaired absorption | #23 |
| treatment sarcopenia | #23 |
| gabaa steroids | #23 |
| brain cell function | #23 |
| dewhurst | #23 |
| glutamine neurons | #23 |
| amino acids model | #23 |
| ” ligands | #24 |
| neuropathologic studies | #24 |
| serotonin 5ht metabolism | #24 |
| pathophysiological levels | #24 |
| sites ligands | #24 |
| p005 activities | #24 |
| external warming | #24 |
| encephalopathy ammonia | #24 |
| activites | #24 |
| controls cirrhotic | #24 |
| brain coenzyme | #24 |
| cns complication | #25 |
| sites glutamate | #25 |
| ammonia reduction | #25 |
| 11195 | #25 |
| nmdareceptor | #25 |
| glutamine synthesis | #25 |
| synthase activities | #25 |
| glutamine liver | #25 |
| transketolase tk | #25 |
| cytotoxic brain edema | #25 |
| severe muscle damage | #25 |
| chronic hepatic | #25 |
| copper zinc concentrations | #25 |
| human experimental | #25 |
| malnutrition chronic | #25 |
| katpase src | #25 |
| uptake 14c | #25 |
| damage dysfunction | #25 |
| extracellular glutamine | #25 |
| deficiency regulation | #25 |
| mousseau | #25 |
| inhalation exposure rats | #25 |
| 60p | #26 |
| treatment hepatic | #26 |
| isoquinolines ligands | #26 |
| synthesis amino acids | #26 |
| concentrations ammonia | #26 |
| pathophysiological significance | #26 |
| anastomosis rats | #26 |
| flumazenil placebo | #26 |
| oxidative stress processes | #26 |
| aqp4 levels | #26 |
| fluid amino | #26 |
| alanine concentrations | #26 |
| 17 39 | #26 |
| failure increased | #26 |
| arterial ammonia levels | #26 |
| pathogenesis cerebral | #26 |
| adult patterns | #26 |
| ketoglutarate dehydrogenase | #26 |
| treatment cirrhosis | #27 |
| regional densities | #27 |
| fgin1 | #27 |
| accumulation glutamine | #27 |
| binding 3hmuscimol | #27 |
| deficient brain | #27 |
| support potential | #27 |
| ornithine transcarbamylase otc | #27 |
| glucose loading | #27 |
| asparagine glutamine | #27 |
| rifaximin mhe | #27 |
| cerebellum brain | #27 |
| brain serotonin metabolism | #27 |
| liver fasting | #27 |
| beta sites | #27 |
| oxidative stress evidence | #27 |
| binding site densities | #27 |
| increased concentrations | #27 |
| manganese ammonia | #27 |
| noradrenaline transport | #27 |
| onset encephalopathy | #27 |
| alf induced | #27 |
| activities decreased | #28 |
| allosteric modulatory | #28 |
| eaat3 expression | #28 |
| chronic liver failure | #28 |
| baldessarini | #28 |
| astrocytic metabolism | #28 |
| selective neuronal loss | #28 |
| metabolism relation | #28 |
| glutamate transporter activity | #28 |
| effects thiamine | #28 |
| experimental acute | #28 |
| devascularized | #28 |
| wernicke encephalopathy | #28 |
| astrocytes loss | #28 |
| ataxic gait | #28 |
| type hepatic | #28 |
| serotonin turnover | #29 |
| effective adjunct therapy | #29 |
| 3hro5 | #29 |
| isopregnanolone | #29 |
| pairfed controls | #29 |
| increased glutamine | #29 |
| travelled distance | #29 |
| induction mild hypothermia | #29 |
| cerebral energy failure | #29 |
| glutamine content | #29 |
| cerebral cortex thalamus | #29 |
| optimal supply | #29 |
| rats probenecid | #29 |
| cytoplasmic nuclear signal | #29 |
| dopamine metabolism striatum | #29 |
| flumazenil flunitrazepam | #29 |
| superoxide scavenger | #29 |
| re‐evaluation | #29 |
| oxide brain | #29 |
| putamen frontal cortex | #29 |
| subchronic inhalation exposure | #29 |
| diverse etiology | #29 |
| shamoperated control animals | #29 |
| striatum contrast | #29 |
| frontal temporal cortex | #29 |
| dust rats | #29 |
| mediated excitotoxicity | #30 |
| nonabsorbable disaccharides | #30 |
| 3dsrt | #30 |
| inflammatory cascades | #30 |
| glycine glutamine | #30 |
| progression liver injury | #30 |
| hyperglycemic stroke | #30 |
| chat activities | #30 |
| encephalopathy portal | #30 |
| presymptomatic animals | #30 |
| increased nmda | #30 |
| neuronal cell counts | #30 |
| studies experimental | #30 |
| blood ammonia concentration | #30 |
| neurotransmitter amino acids | #30 |
| quantitative receptor | #30 |
| chronic hyperammonemia | #30 |
| flumazenil gaba | #30 |
| glutamate cgmp | #30 |
| gaba receptor complex | #30 |
| frontal cortex samples | #30 |
| glutamate content | #30 |
| aspartate glutamine | #30 |
| west criteria | #30 |
| stroke neurological | #30 |
| peripheral type | #31 |
| leading increased | #31 |
| brain decreased | #31 |
| production microglial | #31 |
| antisense elements | #31 |
| glutamate nmda | #31 |
| shunted animals | #31 |
| neuroinflammation pathogenesis | #31 |
| expression tight junction | #31 |
| clinical prospects | #31 |
| study ammonia | #31 |
| stupor | #31 |
| cerebral glutamate | #31 |
| pannecrosis | #31 |
| brain monoamine oxidase | #31 |
| dogs hepatic | #31 |
| cuznsod protein | #31 |
| cerebral ammonia | #32 |
| astrocytes ammonia | #32 |
| deficiencies vitamins | #32 |
| temporal cortex patients | #32 |
| friedreichs ataxia | #32 |
| indian national association | #32 |
| hepatoprotective properties | #32 |
| increased nitric | #32 |
| detoxification unit | #32 |
| 2 alteration | #32 |
| effects mild | #32 |
| binding gaba | #32 |
| gabaa receptor ligands | #32 |
| acute hyperglycemic | #32 |
| akinesia | #32 |
| telemethylhistamine | #32 |
| binding sites presence | #32 |
| hepatic symptoms | #32 |
| intracellular osmolarity | #32 |
| uptake ammonia | #32 |
| minimal mhe | #32 |
| fixed intervals | #32 |
| neuronal cell survival | #33 |
| ohe patients | #33 |
| species rats | #33 |
| cns concentrations | #33 |
| cns complications | #33 |
| proinflammatory cytokines brain | #33 |
| nash treatment | #33 |
| binding microsomes | #33 |
| hand addition | #33 |
| regions brains | #33 |
| monoamines brain | #33 |
| snat5 | #33 |
| failing liver | #33 |
| brain gaba levels | #33 |
| reversible alterations | #33 |
| clinical laboratory findings | #33 |
| otc deficiency | #33 |
| selective decreases | #33 |
| rats ammonia | #33 |
| et495 | #33 |
| glycine aspartate | #33 |
| gaba aspartate | #33 |
| nh4oac | #34 |
| inadequate dietary intake | #34 |
| stupor coma | #34 |
| ammonium tartrate | #34 |
| nonepileptic controls | #34 |
| 11 agematched controls | #34 |
| hepatic artery ligation | #34 |
| acetylcholinesterase activities | #34 |
| severe neurological symptoms | #34 |
| encephalopathy hippocampus | #34 |
| cytotoxic brain | #34 |
| nac reduction | #34 |
| gad activities | #34 |
| groups cirrhotic patients | #34 |
| severe neurological dysfunction | #34 |
| relation brain | #34 |
| metabolite 5 | #34 |
| fatigue rats | #35 |
| free hepatic | #35 |
| ammonia concentrations | #35 |
| type gaba | #35 |
| chronic hepatic encephalopathy | #35 |
| total thiamine | #35 |
| manganese tricarbonyl | #35 |
| severe compromise | #35 |
| astrocytic glutamate | #35 |
| fluid ammonia | #35 |
| effects manganese | #35 |
| activation proinflammatory | #35 |
| neuropsychiatric abnormalities | #35 |
| dawley reverse | #35 |
| neurotransmitter amino | #35 |
| octadecaneuropeptide | #35 |
| overt encephalopathy | #35 |
| space glutamic | #35 |
| chapter 29 | #35 |
| uptake glutamate | #36 |
| arterial ammonia | #36 |
| thioacetamide treatment | #36 |
| muscarinic sites | #36 |
| astrocyte glutamate | #36 |
| electricalfield stimulation | #36 |
| numerous etiologies | #36 |
| cycle glucose | #36 |
| acid brain | #36 |
| cerebral cortical astrocytes | #36 |
| synthesis glutamate | #36 |
| detoxification product | #36 |
| aom treatment | #36 |
| astrocytic glutamine | #36 |
| brain regions studies | #36 |
| protein glutamate | #37 |
| increased blood glucose | #37 |
| perivenous hepatocytes | #37 |
| alf mice | #37 |
| increased voluntary | #37 |
| mice ammonia | #37 |
| acute receptors | #37 |
| blood manganese levels | #37 |
| 3beta5alpha | #37 |
| excitotoxic mechanism | #37 |
| mild hypothermia therapy | #37 |
| csf cisterna magna | #37 |
| increase glutamine | #38 |
| glutamatergic function | #38 |
| ammonium acetate | #38 |
| astrocytic marker | #38 |
| gfap immunohistochemistry | #38 |
| brain rats | #38 |
| corneal reflex | #38 |
| glutamate ammonia | #38 |
| brain amino acids | #38 |
| failure male | #38 |
| hypothermia attenuates | #38 |
| severe liver dysfunction | #39 |
| findings increased | #39 |
| chronic alcoholism | #39 |
| clive | #39 |
| pdhc | #39 |
| loss gene expression | #39 |
| benzodiazepine antagonist | #39 |
| hyperammonaemic | #39 |
| glutamine formation | #39 |
| posterior columns | #39 |
| concomitant decreases | #39 |
| pca surgery | #39 |
| brain regional distribution | #39 |
| thiamine administration | #39 |
| nmdamediated excitotoxicity | #40 |
| ammonia homeostasis | #40 |
| neurological alterations | #40 |
| increased density | #40 |
| quin levels | #40 |
| etiology severity | #40 |
| acetylcoa levels | #40 |
| concentration areas | #40 |
| nitroarginine rats rats | #40 |
| regiondependent manner | #40 |
| glutamine glycine | #40 |
| liver inasl | #40 |
| argininic acid | #40 |
| concentrations catecholamines | #40 |
| arginine uptake | #40 |
| seizures mental retardation | #40 |
| dheas | #40 |
| regionally selective | #40 |
| complications chronic | #41 |
| brain extracts | #41 |
| cellcell signalling | #41 |
| regulation caveolin1 | #41 |
| sgc activation | #41 |
| increased glutamate release | #41 |
| vulnerable area | #41 |
| regions concentrations | #41 |
| detoxification ammonia | #41 |
| activation nmda receptor | #41 |
| brain benzodiazepine receptors | #41 |
| acid neurotransmitter | #41 |
| deficiency disease | #41 |
| lateral vestibular nucleus | #41 |
| brain taurine | #41 |
| thiamine metabolism | #41 |
| trace amines | #42 |
| benzodiazepine sites | #42 |
| complex pdhc | #42 |
| thdoc | #42 |
| illness terminology topic | #42 |
| pk11195 binding | #42 |
| cerebral glutamine | #42 |
| cerebral alterations | #42 |
| transcarbamylase | #43 |
| nonalcoholic patients | #43 |
| acute ammonia intoxication | #43 |
| increased neuronal | #43 |
| gabaa tritium | #43 |
| liver assist | #43 |
| carbamoyltransferase deficiency | #43 |
| glutamine insulin | #43 |
| metabolism acute | #43 |
| sarcopenia cirrhosis | #44 |
| reduction brain | #44 |
| ohe mhe | #44 |
| aged portacaval | #44 |
| ataxia humans | #44 |
| severe hyperammonemia | #44 |
| treament | #44 |
| toxic liver | #44 |
| acid glutamine | #44 |
| mechanisms disorder | #44 |
| ammonia increases | #44 |
| behavioral excitation | #44 |
| cerebral levels | #44 |
| increased serotonin | #44 |
| western brain dna | #44 |
| cholinergic neuronal | #45 |
| small meals | #45 |
| glutamate transporter | #45 |
| isoquinolines kinetics | #45 |
| aspartate gaba | #45 |
| cortex dose | #45 |
| model congenital | #45 |
| welldefined areas | #45 |
| mild encephalopathy | #45 |
| ventral white matter | #45 |
| mice etanercept | #45 |
| thiamin deficiency | #45 |
| cortex glutamate | #46 |
| brain oxidative metabolism | #46 |
| fatigue controls | #46 |
| normoglycemic rats | #46 |
| 11cnmethylspiperone | #46 |
| treatment downregulation | #46 |
| brain gamma | #46 |
| exposed ammonia | #46 |
| brain amino | #47 |
| benzodiazepine receptors | #47 |
| alcoholic cirrhotics | #47 |
| distinctive pattern | #47 |
| glutamate removal | #47 |
| neurosteroid | #47 |
| human rat brain | #47 |
| metabolism astrocytes | #47 |
| glutamate aspartate | #47 |
| microsomes isolated | #47 |
| pathophysiologically | #47 |
| rtpcr experiments | #47 |
| anaplerotic flux | #47 |
| cerebellum medulla | #48 |
| sites nmda | #48 |
| 3hmuscimol | #48 |
| age injection | #48 |
| cerebral dysfunction | #48 |
| amino acid synthesis | #48 |
| central nervous function | #48 |
| thalamus pons | #48 |
| allopregnanolone concentrations | #48 |
| maob | #48 |
| hyperammonemia | #48 |
| tnf brain | #48 |
| neurotoxic agents | #48 |
| mitochondrial benzodiazepine | #48 |
| 113cglucose | #48 |
| concomitant increases | #48 |
| glycerol phenylbutyrate | #49 |
| brain tryptophan | #49 |
| central benzodiazepine | #49 |
| ammonia detoxification | #49 |
| nmda binding | #49 |
| pallidal | #49 |
| rcts low risk | #49 |
| neurotoxic actions | #49 |
| voluntary ethanol | #49 |
| cerebellum patients | #49 |
| hepatic congestion | #50 |
| rational explanation | #50 |
| effects body temperature | #50 |
| increased extracellular | #50 |
| expression glt1 | #50 |
| alcoholic dementia | #50 |
| brain banks | #50 |
| manganese middle | #50 |
| extracellular glycine | #50 |
| hepatic encephalopathy study | #50 |
| levels brain | #50 |
| tyrosine ammonia | #50 |
| electromyographic evaluation | #51 |
| acids measured | #51 |
| early microglial activation | #51 |
| false neurotransmitters | #51 |
| righting | #51 |
| glutamate receptors nmda | #51 |
| lcarnitine treatment | #51 |
| inflamed brain | #51 |
| management hepatic | #51 |
| alcoholic cirrhotic | #52 |
| brain concentrations | #52 |
| synthesis glutamine | #52 |
| pse | #52 |
| mice carnitine | #52 |
| early losses | #52 |
| severe stages | #52 |
| neurobehavioral disturbances | #52 |
| vivo microdialysis | #52 |
| cognitive motor dysfunction | #52 |
| nitroarginine rats | #52 |
| 12 rats | #52 |
| complex rats | #52 |
| friedreichs ataxia patients | #52 |
| altered permeability | #52 |
| rats portacaval shunt | #53 |
| 3hkainate | #53 |
| 3hmuscimol binding | #53 |
| treatment alf | #53 |
| neurosteroid pregnenolone | #53 |
| pathophysiologic | #53 |
| central histaminergic | #53 |
| neurosteroid synthesis | #53 |
| mildest form | #54 |
| ischemic liver | #54 |
| kidney testis | #54 |
| portacaval shunt pcs | #54 |
| subsequent alteration | #54 |
| cerebral inflammation | #54 |
| stroke penumbra | #54 |
| neuropsychiatric syndrome | #54 |
| activation guanylate cyclase | #54 |
| mechanisms proposed | #54 |
| gene expression liver | #54 |
| liver atrophy | #54 |
| portacaval shunts | #54 |
| substitutive therapy | #54 |
| concomitant reductions | #55 |
| messenger spraguedawley receptors | #55 |
| occludin levels | #55 |
| hyperglycemic | #55 |
| human disorder | #55 |
| glutathione plasma | #55 |
| activation glutamate receptors | #55 |
| neurotransmitter agents | #55 |
| heterogenity | #55 |
| encephalopathy hyperammonemia | #55 |
| deficiency decreased | #56 |
| ca2dependent release | #56 |
| oxidative nitrosative | #56 |
| awaits | #56 |
| severe cognitive dysfunction | #56 |
| regions rats | #56 |
| delays onset | #56 |
| levels allopregnanolone | #56 |
| increased intracellular ca2 | #57 |
| resonance signal | #57 |
| failure muscle | #57 |
| tetrahydroprogesterone | #57 |
| mechanisms implicated | #57 |
| ammonia exposure | #57 |
| brain glutamate levels | #57 |
| h1 receptors | #57 |
| rats ouabain | #57 |
| type mitochondrial | #57 |
| coma patients | #57 |
| current therapeutic options | #57 |
| astrocytes glutamate | #58 |
| levels ammonia | #58 |
| pdhc activity | #58 |
| probenecid treatment | #58 |
| swelling brain | #58 |
| levels amino acids | #58 |
| portacaval shunt | #58 |
| dansyl derivatives | #58 |
| nervous complications | #58 |
| activation glutamate | #58 |
| manganese copper | #58 |
| severity encephalopathy | #58 |
| lowering strategies | #58 |
| brain histamine | #58 |
| uptake arginine | #59 |
| gfap gfap mrna | #59 |
| 13c enrichments | #59 |
| acetaminophen toxicity | #59 |
| patients thiamine | #59 |
| neuropharmacological studies | #59 |
| saline treated controls | #59 |
| bilirubin metabolism | #59 |
| mechanism protective | #59 |
| hyperammonaemia | #59 |
| lazabemide | #60 |
| purposing | #60 |
| ammonia intoxication | #60 |
| brain production | #60 |
| alcoholic patients | #60 |
| ammonia toxicity | #60 |
| energy metabolites | #60 |
| alcoholics patients | #60 |
| spontaneous synaptic activity | #60 |
| required cofactor | #60 |
| cirrhosis middle | #60 |
| cirrhotic patients patients | #60 |
| opioid penicillamine | #61 |
| ataxia friedreich | #61 |
| 015 mmol | #61 |
| comparable magnitude | #61 |
| excitotoxic brain injury | #61 |
| bz receptors | #61 |
| maob maoa | #61 |
| sham operated | #61 |
| stem cerebral | #61 |
| threefold increase | #61 |
| acid distribution | #61 |
| subjects free | #61 |
| affinity gaba | #61 |
| concentrations glutamate | #61 |
| il1beta mrna expression | #61 |
| hypertension brain | #62 |
| brain1 | #62 |
| elevated uptake | #62 |
| increased expression mrna | #62 |
| ultimate test | #62 |
| βendorphin | #62 |
| suggested role | #62 |
| receptors pathogenesis | #62 |
| taurine synthesis | #62 |
| forebrain cholinergic neurons | #62 |
| heavy drinking day | #63 |
| gaba glutamic acid | #63 |
| role glutamate | #63 |
| rtpcr gene expression | #63 |
| manganese intoxication | #63 |
| metabolism glutamine | #63 |
| spectroscopy tomography | #63 |
| subclinical hepatic | #63 |
| manganese treatment | #63 |
| regions contrast | #63 |
| thiamine | #63 |
| failure evidence | #63 |
| focal increases | #63 |
| portocaval | #63 |
| disease activities | #64 |
| parietal lobe rats | #64 |
| neurotoxic substances | #64 |
| transketolase activity | #64 |
| sodium phenylacetate | #64 |
| attenuates oxidative | #64 |
| fatigue pbc | #64 |
| thalamus gamma | #64 |
| neurosteroid allopregnanolone | #64 |
| brain | #64 |
| hypokinesia | #65 |
| sodium benzoate | #65 |
| brain chemistry | #65 |
| frontal parietal cortex | #65 |
| kcl nacl | #65 |
| butyrylcholinesterases | #65 |
| glutamine ammonia | #65 |
| brain cell death | #65 |
| symptoms addition | #65 |
| methylhistamine | #65 |
| 2454 | #65 |
| female flumazenil | #65 |
| deficiency induced | #65 |
| manganese deposits | #65 |
| increases brain | #66 |
| isethionic | #66 |
| putative endogenous ligands | #66 |
| uptake cultured | #66 |
| mice sodium | #66 |
| 13cnmr | #66 |
| gaba animals | #66 |
| brain water | #66 |
| ataxia patients | #66 |
| erythrocyte transketolase | #67 |
| brain patients | #67 |
| brain 24 | #67 |
| cerebral energy metabolism | #67 |
| αmethylptyrosine | #67 |
| humans korsakoff | #67 |
| lactate increase | #67 |
| tyrosine content | #67 |
| ascorbate synthesis | #67 |
| selective reductions | #68 |
| benzodiazepine receptor ligands | #68 |
| decreased concentrations | #68 |
| glutamate transporter glast | #68 |
| reduction ammonia | #68 |
| serotonin transport | #68 |
| indian national | #68 |
| drug repositioning humans | #69 |
| decreased removal | #69 |
| rats sham operation | #69 |
| hepatoprotection | #69 |
| active removal | #69 |
| substance rats | #69 |
| osmotic effects | #69 |
| processing product | #69 |
| unleaded gasoline | #69 |
| attenuation effects | #69 |
| bergmann glial | #70 |
| electronic manual searches | #70 |
| m1 sites | #70 |
| glutamic acid hippocampus | #70 |
| cortex caudate | #70 |
| reduces brain | #70 |
| carbamoyltransferase | #71 |
| failure animals | #71 |
| medium concentrations | #71 |
| animals benzodiazepines | #71 |
| glutamates glutamic | #71 |
| alloxan diabetes | #71 |
| shunting | #71 |
| gabaa tomography | #72 |
| concentration norepinephrine | #72 |
| cortex increased | #72 |
| common inborn error | #72 |
| brain allopregnanolone | #72 |
| glutamine brain | #72 |
| organic aciduria | #72 |
| hyperammonemia male | #72 |
| agematched control subjects | #72 |
| pse patients | #73 |
| sites observed | #73 |
| onset neurological | #73 |
| alterations mitochondrial function | #73 |
| astrocyte swelling | #73 |
| thiamine treatment | #73 |
| hippocampal ca1 subfield | #73 |
| ro15 | #73 |
| cerebroprotective effects | #73 |
| homologous structures | #73 |
| glutamine glutamate | #73 |
| mechanisms involving | #74 |
| astrocytes brain | #74 |
| decrease brain | #74 |
| brain content | #74 |
| gaba steroids | #74 |
| glutamic | #74 |
| cortex chromatography | #74 |
| bath concentration | #74 |
| thiamine transport | #75 |
| superfused slices | #75 |
| acids hepatic | #75 |
| expression glial | #75 |
| fully elucidated | #75 |
| normal limits | #75 |
| severe neurological impairment | #75 |
| nature distribution | #75 |
| cerebral cortex patients | #75 |
| cirrhosis brain | #76 |
| direct toxic effects | #76 |
| gaba glutamine | #76 |
| glutamate binding | #76 |
| receptors gaba | #76 |
| transporter eaat3 | #76 |
| receptors studied | #76 |
| larginine uptake | #76 |
| muscle acute | #77 |
| millimolar range | #77 |
| glutamate concentration | #77 |
| metabolite acetaldehyde | #77 |
| brain skeletal muscle | #77 |
| alcoholic patients cirrhosis | #77 |
| glycine concentrations | #77 |
| interatomic bonds | #78 |
| muscle glutamine | #78 |
| brain glucose metabolism | #78 |
| function hepatic | #78 |
| benzodiazepines binding | #78 |
| lnitroarginine methyl ester | #78 |
| nnos protein | #78 |
| oxide liver | #78 |
| previous reports | #79 |
| cns function | #79 |
| taming | #79 |
| thiamine triphosphate | #79 |
| semiquantitative rtpcr | #79 |
| neuronally | #79 |
| methylcyclopentadienyl | #79 |
| excited ground states | #79 |
| hepatic energy | #79 |
| deep coma | #79 |
| l‐carnitine | #79 |
| metabolism brain | #79 |
| quantitative autoradiographic | #80 |
| gaba benzodiazepine | #80 |
| pathogenesis animals | #80 |
| emerging therapeutic target | #80 |
| encephalopathy treatment | #80 |
| cresyl violet staining | #80 |
| failure nitric | #80 |
| medullapons | #80 |
| neurosteroid biosynthesis | #80 |
| expression glutamate | #80 |
| maximal binding | #80 |
| study sections | #81 |
| muscle ammonia | #81 |
| molecular neurobiology | #81 |
| 85 mmol | #81 |
| controls increased | #81 |
| astrocyte morphology | #81 |
| glutamine astrocytes | #81 |
| agents receptors | #82 |
| brain extracellular | #82 |
| lcarnitine administration | #82 |
| receptor regions | #82 |
| chaired | #82 |
| shortchain acylcoa dehydrogenase | #82 |
| glutamate nitric | #82 |
| treatment thiamine | #83 |
| tca cycle flux | #83 |
| proposed explain | #83 |
| 3hro15 | #83 |
| ethanol preference | #83 |
| glutamate brain | #83 |
| cerebral cortex striatum | #84 |
| patients decreases | #84 |
| measured brain | #84 |
| water channel protein | #84 |
| pathophysiologic basis | #84 |
| elevated ammonia | #84 |
| pbgd | #84 |
| aom induced | #84 |
| devascularization | #84 |
| 3hflumazenil | #84 |
| concomitant decrease | #85 |
| decreased ca2 | #85 |
| arga | #85 |
| increase brain | #85 |
| 3hgammaaminobutyric acid | #85 |
| role glutamine | #85 |
| ammonia patients | #85 |
| maoa maob | #85 |
| urea cycle enzymes | #85 |
| 5ht turnover | #85 |
| central muscarinic | #86 |
| release synaptic | #86 |
| glutamate amino | #86 |
| wilsonian | #87 |
| spraguedawley statistics | #87 |
| rats sacrificed | #87 |
| complication cirrhosis | #88 |
| tissue brain | #88 |
| selective vulnerability | #88 |
| benzodiazepines brain | #88 |
| csf lactate | #88 |
| 52 mmol | #88 |
| concomitantly | #88 |
| brain binding | #88 |
| prior onset | #89 |
| brain regions rats | #89 |
| edema cerebral | #89 |
| sham operations | #89 |
| role human diseases | #89 |
| caudate nuclei | #89 |
| alpha ketoglutarate | #89 |
| undoubtedly | #89 |
| olivopontocerebellar atrophy opca | #89 |
| exposure ammonia | #89 |
| glutamatemediated excitotoxicity | #90 |
| patients alf | #90 |
| rats species | #90 |
| receptor ligand | #90 |
| lactate increased | #90 |
| encephalopathy ohe | #90 |
| reduced brain | #91 |
| bcaa concentrations | #91 |
| monoamine neurotransmitters | #91 |
| gaba modulators | #91 |
| bckdh | #92 |
| amino acids brain | #92 |
| leucine concentrations | #92 |
| altered protein expression | #92 |
| enzymopathies | #92 |
| neuroinflammatory response | #92 |
| congenital deficiencies | #93 |
| widespread damage | #93 |
| induced alf | #93 |
| acid liver | #93 |
| thiamin diphosphate | #94 |
| neuronal loss | #94 |
| manganese poisoning | #94 |
| mri intensity | #94 |
| brain compared | #94 |
| increases extracellular | #94 |
| brain kidney | #94 |
| inhibitory neurotransmission | #95 |
| ammonia accumulation | #95 |
| benzodiazepines treatment | #95 |
| glutamine synthetase expression | #95 |
| induced stereotyped | #95 |
| patients liver failure | #95 |
| acetate administration | #95 |
| discrete areas | #96 |
| skeletal muscle brain | #96 |
| βlipotropin | #96 |
| astrocytic function | #96 |
| ornithine phenylacetate | #96 |
| 16 mmol | #96 |
| brain cytokine | #97 |
| ammonia release | #97 |
| astrocytes neurons | #97 |
| molecules brain | #97 |
| brain vivo | #97 |
| covert hepatic encephalopathy | #97 |
| glycine transporters | #98 |
| glutamate glutamine | #98 |
| dorsal tegmental nucleus | #98 |
| hepatocerebral degeneration | #98 |
| thiamine diphosphate | #98 |
| dehydroascorbic acid | #98 |
| carbamoyltransferase ornithine | #98 |
| acrylamides animals | #98 |
| receptors increased | #98 |
| stress ammonia | #99 |
| examination role | #99 |
| 3045 | #99 |
| walking gait | #99 |
| symptomatic stage | #100 |
| fatigue impact scale | #100 |
| commonly encountered | #100 |
| aspartate levels | #100 |
| inhibitory amino acids | #101 |
| animal hypothermia | #101 |
| temporal cortex | #101 |
| increases levels | #101 |
| proinflammatory | #101 |
| pressure liver | #101 |
| cerebral cortex cerebellum | #102 |
| tk activity | #102 |
| levels dheas | #102 |
| brain barrier breakdown | #102 |
| treatment complications | #102 |
| neurological symptoms patients | #102 |
| microdialysis rats | #102 |
| lcarnitine | #102 |
| synergistic mechanisms | #102 |
| collisional deactivation | #103 |
| removal ammonia | #103 |
| benzodiazepine receptor | #103 |
| brain extracellular space | #103 |
| controls cirrhotic patients | #103 |
| brain levels | #103 |
| thiamine monophosphate | #104 |
| regional distribution | #104 |
| 90 loss | #104 |
| cerebral oxidative metabolism | #104 |
| methylspiperone | #104 |
| label incorporation | #104 |
| experimental animal models | #104 |
| transporter glt1 | #105 |
| olivopontocerebellar atrophy | #105 |
| neurological consequences | #105 |
| experimental models | #105 |
| fatigue severity | #105 |
| m3 exposure | #105 |
| loss cholinergic | #105 |
| receptors brain | #105 |
| complication liver | #106 |
| toxic liver injury | #106 |
| receptors rats | #107 |
| concentrations serotonin | #107 |
| 3h8ohdpat | #107 |
| sham operated controls | #108 |
| gaba content | #108 |
| dopaminergic dysfunction | #108 |
| characteristic alterations | #108 |
| current theories | #108 |
| monoamines | #108 |
| symptomatic animals | #109 |
| disease hepatic | #109 |
| ldeprenyl | #109 |
| glutamate plasma | #109 |
| t1weighted magnetic resonance | #109 |
| glutamates humans | #110 |
| rats hepatic | #110 |
| 3hnisoxetine | #110 |
| azoxymethane aom | #110 |
| deficiency humans | #110 |
| extrapyramidal symptoms | #110 |
| reye syndrome | #111 |
| glt1 glast | #111 |
| enzymes brain | #111 |
| evidence role | #112 |
| 3alpha5alpha | #112 |
| lymphocytes rats | #113 |
| hypertension liver | #113 |
| ligated rats | #113 |
| expression testis | #113 |
| metabolic block | #113 |
| brain preparations | #113 |
| midbrain striatum | #113 |
| activities | #113 |
| glutamate synaptic | #113 |
| fco | #114 |
| radioenzymatic assay | #114 |
| rat astrocytes | #114 |
| 57 reduction | #114 |
| nutritional management | #114 |
| nmda receptor expression | #115 |
| experimental animals | #115 |
| brain dogs | #115 |
| gabaa gabaergic | #116 |
| mammillary body | #116 |
| 3hmepyramine | #116 |
| decreased synthesis | #116 |
| pallidum putamen | #116 |
| friedreich ataxia patients | #117 |
| cholinergic deficit | #117 |
| cortex alzheimer | #117 |
| opioid brain | #117 |
| growing body | #117 |
| tips procedure | #117 |
| controls plasma levels | #117 |
| myelin synthesis | #118 |
| allopregnanolone | #118 |
| amine levels | #118 |
| brain dopamine | #118 |
| albumin dialysis | #118 |
| cirrhotic | #118 |
| arginine deficiency | #118 |
| mechanism ammonia | #118 |
| cerebral energy | #119 |
| pathologic manifestations | #119 |
| nervous dysfunction | #119 |
| apapinduced | #119 |
| site densities | #119 |
| opioid beta | #119 |
| hydroxylating | #119 |
| patients fatty liver | #119 |
| genes coding | #120 |
| glutamates | #120 |
| frontal cortex | #120 |
| ouabain induced | #120 |
| balb cbyj mice | #120 |
| pugh score | #121 |
| copper manganese | #121 |
| 3hketanserin | #121 |
| monoamine oxidaseb | #121 |
| mechanisms pathogenesis | #121 |
| unleaded | #122 |
| rat brain synaptosomes | #122 |
| brain enzyme | #122 |
| bergmann glia | #122 |
| brain evidence | #122 |
| nuclear signal | #122 |
| complex activities | #122 |
| selective damage | #123 |
| beneficial patients | #123 |
| normal human brains | #123 |
| implicated | #123 |
| newborn astrocytes cells | #124 |
| modulatory site | #124 |
| gene expression brain | #124 |
| asterixis | #124 |
| icp cbf | #125 |
| ammonia control | #125 |
| neurological signs | #125 |
| striatum cerebellum | #125 |
| brain male | #126 |
| ala2mephe4met0ol | #126 |
| glt1 | #126 |
| ol20 | #126 |
| ornithine aminotransferase | #126 |
| role ammonia | #126 |
| 11cpk11195 | #126 |
| synthase nitroarginine | #126 |
| high‐affinity | #127 |
| proteins nitric | #128 |
| taurine uptake | #128 |
| cytokines brain | #128 |
| neuronal cell | #128 |
| glutamate concentrations | #129 |
| neurochemical mechanisms | #129 |
| cox2 immunoreactivity | #129 |
| chronic alcoholic patients | #129 |
| patients friedreichs ataxia | #129 |
| unanesthetized dogs | #130 |
| agonist action | #130 |
| blood ethanol levels | #130 |
| cox2 levels | #130 |
| spontaneous activities | #130 |
| ammonia levels | #131 |
| primary deficit | #131 |
| observed brain | #131 |
| llactate dehydrogenase | #131 |
| taurine release | #132 |
| blood ammonia | #132 |
| continuous supply | #132 |
| hepatic abnormalities | #132 |
| carnitine administration | #132 |
| animals azoxymethane | #132 |
| nacetyl cysteine | #133 |
| ischemia rat | #133 |
| factor pathogenesis | #133 |
| manganese neurotoxicity | #133 |
| α ketoglutarate | #133 |
| friedreich | #133 |
| site human | #133 |
| lipoamide dehydrogenase | #133 |
| brain glial | #134 |
| lactate accumulation | #134 |
| concentrations gaba | #135 |
| exposure manganese | #135 |
| models acute | #135 |
| endogenous amino acids | #135 |
| kidney skeletal muscle | #135 |
| impact treatments | #136 |
| function addition | #137 |
| pregnenolone rats | #137 |
| acid ammonia | #137 |
| psychometric testing | #137 |
| increased intracranial pressure | #137 |
| release glutamate | #137 |
| 3hcitalopram | #137 |
| manganese toxicity | #137 |
| inherited ataxias | #138 |
| spinocerebellar degeneration | #138 |
| neuropsychiatric complications | #138 |
| lornithine | #139 |
| disorder animals | #139 |
| glutamine alanine | #139 |
| nanomolar affinity | #139 |
| cerebral herniation | #139 |
| tracer doses | #139 |
| −70°c | #139 |
| chatpositive neurons | #139 |
| cycle enzyme | #139 |
| patients friedreich | #140 |
| nutritional recommendations | #140 |
| aminobutyric acid | #141 |
| concentrations nacl | #141 |
| dehydrogenase pdh | #141 |
| nonbenzodiazepine | #141 |
| cortex male | #141 |
| alcoholic nonalcoholic | #142 |
| cerebellar ataxias | #142 |
| gaba synaptic | #142 |
| huntingtons chorea | #142 |
| development hepatic | #142 |
| humans isoquinolines | #142 |
| cbyj | #142 |
| brain glucose uptake | #143 |
| alternative site | #143 |
| lactate alanine | #143 |
| diminished activity | #143 |
| hypothermia induced | #143 |
| serotonin precursor | #143 |
| monoamine oxidasea | #143 |
| delayed myelination | #144 |
| brain gaba | #144 |
| allosteric agonists | #144 |
| selective brain | #144 |
| dopamine metabolism | #144 |
| ornithine carbamoyltransferase | #144 |
| insulin hypoglycaemia | #144 |
| taurine content | #144 |
| glutamateglutamine | #144 |
| hyperglycemic rats | #145 |
| cerebral microdialysis | #145 |
| inferior olivary nucleus | #145 |
| brain tissue | #145 |
| relation degree | #146 |
| receptormediated responses | #146 |
| glucose load | #146 |
| brain hypothermia | #146 |
| brain peripheral tissues | #146 |
| lateral vestibular | #147 |
| rapid filtration | #147 |
| comparable degree | #147 |
| increase presence | #147 |
| animals brain | #148 |
| lactate brain | #148 |
| energy failure | #148 |
| neurosteroids | #149 |
| glutamate neurons | #149 |
| western cells rats | #149 |
| coa acetyl | #149 |
| cirrhosis hepatic | #149 |
| diazepam binding inhibitor | #149 |
| acetyllcarnitine | #149 |
| ohe | #149 |
| probenecid rats | #150 |
| metabolic impairments | #150 |
| consumption ethanol | #150 |
| failure studies | #150 |
| protein tyrosine nitration | #151 |
| animals astrocytes | #151 |
| fatigue scores | #151 |
| patient tissue | #151 |
| zo2 | #151 |
| female friedreich | #151 |
| progesterone metabolites | #151 |
| selective neuronal death | #152 |
| beta actin | #152 |
| patients hepatic encephalopathy | #152 |
| inhibition binding | #153 |
| increased synthesis | #153 |
| concentrations amino | #153 |
| testis brain | #153 |
| transporter protein | #154 |
| alcoholism brain | #154 |
| impaired brain | #154 |
| tight junction proteins | #154 |
| 15 1788 | #155 |
| increased cerebral | #155 |
| ammonia ligase | #156 |
| experimental male rats | #156 |
| brain cerebrospinal | #156 |
| neuroactive | #157 |
| radioenzymatic | #157 |
| affinity uptake | #157 |
| protein acute | #157 |
| 1788 | #157 |
| ethanol day | #158 |
| dimethadione | #158 |
| korsakoff syndrome | #158 |
| gfap expression | #159 |
| increased 5 | #159 |
| water brain | #159 |
| prominent increase | #159 |
| glt1 expression | #159 |
| nitrosative | #159 |
| glutamate ampa | #160 |
| groups responses | #160 |
| astrocytosis | #160 |
| brain dysfunction | #160 |
| 3methoxytyramine | #160 |
| neuropathologically | #161 |
| expression hepatic | #161 |
| diphosphatase | #161 |
| gfap mrna | #161 |
| reaction ammonia | #161 |
| synaptosomal uptake | #162 |
| increased stimulation | #162 |
| homogenates | #162 |
| mercaptans | #162 |
| perivenous | #162 |
| affinity transport | #163 |
| rats nitric | #163 |
| neurological evaluation | #163 |
| vicious cycle | #163 |
| transketolase | #164 |
| mice acetaminophen | #164 |
| glutamine production | #164 |
| manganese concentrations | #164 |
| increased degradation | #164 |
| human alcoholics | #165 |
| victor | #165 |
| brain energy metabolism | #166 |
| glast | #166 |
| extracellular concentrations | #166 |
| regions levels | #166 |
| bergmann glial cells | #166 |
| male manganese | #167 |
| severe signs | #167 |
| increased csf | #167 |
| neurotransmitter | #167 |
| aids aidsrelated complex | #167 |
| increased cerebrospinal | #167 |
| dansyl chloride | #167 |
| benzodiazepine | #167 |
| neurotoxic compounds | #168 |
| deficiency liver | #168 |
| surgical models | #168 |
| malateaspartate shuttle | #169 |
| precise role | #169 |
| monophosphatase | #170 |
| strains spectrometry | #170 |
| acetaminophen acetylcysteine | #171 |
| increase pge2 | #171 |
| medial geniculate nucleus | #171 |
| complications liver | #171 |
| elevated activities | #171 |
| expression alpha1 | #172 |
| early increases | #172 |
| ketoglutarate | #172 |
| apap administration | #172 |
| terms relationship | #172 |
| transport brain | #172 |
| rats protective | #173 |
| complex pyruvate | #174 |
| protein gfap | #174 |
| binding calcium | #175 |
| dehydroascorbic | #175 |
| taurine concentrations | #175 |
| brain energy | #175 |
| stereotyped behavior | #175 |
| synergistic actions | #175 |
| chain amino | #175 |
| gfap immunoreactivity | #176 |
| guanidino compounds | #177 |
| neurological dysfunction | #178 |
| eaat4 | #178 |
| neurological complications | #178 |
| fine motor function | #179 |
| patients plasma levels | #179 |
| symptoms including | #180 |
| brain monoamine | #180 |
| serotonin 5hydroxytryptamine | #180 |
| rats csf | #180 |
| autoradiography binding | #181 |
| experimental hepatic | #181 |
| 3hflunitrazepam | #181 |
| brain concentration | #181 |
| dehydroepiandrosterone sulphate | #182 |
| accumulation brain | #182 |
| dheas dhea | #182 |
| biochemical consequences | #182 |
| competitive brain | #183 |
| patients mhe | #183 |
| neuropsychiatric | #183 |
| nutritional consequences | #184 |
| nnos mrna | #184 |
| animals antimetabolites | #184 |
| glast glt1 | #185 |
| neurological disorder | #185 |
| branchedchain amino acids | #185 |
| amphetamine apomorphine | #185 |
| fluorescence analysis | #185 |
| mm kcl | #186 |
| spraguedawley serotonin | #187 |
| expression occludin | #187 |
| sequellae | #187 |
| controls regions | #187 |
| stress pathogenesis | #187 |
| pcr ratio | #188 |
| alcar | #188 |
| cb154 | #188 |
| compared sham | #188 |
| dehydrogenase complex | #188 |
| dawley serotonin | #188 |
| otc | #188 |
| rat cerebellum | #189 |
| highaffinity uptake | #189 |
| vasogenic brain edema | #189 |
| agonist properties | #190 |
| aminobutyric | #190 |
| dopamine turnover | #191 |
| pregnanolone | #192 |
| specific ligand | #192 |
| aged ammonia | #192 |
| studies alterations | #193 |
| pavlov | #194 |
| gilles tourettes syndrome | #194 |
| patient material | #194 |
| righting reflex | #194 |
| limited therapeutic | #195 |
| gamma aminobutyric | #195 |
| patients immunohistochemistry | #195 |
| of3h | #195 |
| intracellular receptors | #196 |
| expression tight | #197 |
| mice acute | #197 |
| tissue patients | #197 |
| mrna protein expression | #198 |
| concomitant loss | #198 |
| guanidino | #198 |
| astrocyte function | #198 |
| unaltered | #198 |
| manganese compounds | #198 |
| thalamus hippocampus | #199 |
| glutamatergic synaptic | #200 |
| mitochondria neurons | #200 |
| substitutive | #200 |
| 35 degrees | #200 |
| noradrenaline transporter | #200 |
| experimental chronic | #200 |
| etiology patients | #200 |
| synthetase expression | #201 |
| csf concentrations | #201 |
| brainstem structures | #201 |
| highest density | #201 |
| cerebral glucose utilization | #202 |
| equal | #202 |
| translation clinic | #202 |
| activation brain | #202 |
| severity liver disease | #202 |
| activities increased | #203 |
| vitro receptor | #203 |
| therapeutic interventions | #203 |
| chronic alcohol abuse | #204 |
| benzodiazepine binding | #204 |
| cns dysfunction | #205 |
| ketone oxidoreductases | #205 |
| poor nutrition | #206 |
| grc | #206 |
| manganism | #206 |
| trials low risk | #206 |
| cuznsod | #206 |
| ldh5 | #207 |
| central noradrenergic | #207 |
| ldh1 | #207 |
| immunohistochemistry messenger receptors | #209 |
| laboratory rat | #209 |
| astrocytic response | #209 |
| neuropathological studies | #209 |
| overt hepatic | #210 |
| bergmann | #210 |
| uptake pattern | #210 |
| concomitant increase | #210 |
| ethanol increased | #210 |
| millimolar concentrations | #211 |
| histopathological studies | #212 |
| brain structures | #212 |
| laspartate | #212 |
| patients liver dysfunction | #212 |
| isoquinolines male | #212 |
| cns gaba | #212 |
| cerebellum striatum | #213 |
| address issue | #214 |
| patients died | #214 |
| plasma ammonia | #214 |
| gabaa receptor agonist | #214 |
| 3h8 | #215 |
| role pathogenesis | #215 |
| animals liver | #216 |
| nitrite nitrate levels | #216 |
| failure mice | #216 |
| glutamine cycle | #216 |
| key factor | #216 |
| noradrenergic function | #217 |
| bbb breakdown | #217 |
| glutamine synthetase activity | #217 |
| cultured rat astrocytes | #218 |
| 3hro | #219 |
| thiamine vitamin | #219 |
| taurine animals | #219 |
| inbred strains spectrometry | #220 |
| new therapeutic opportunities | #221 |
| excitatory neurotransmitters | #221 |
| glutamate exposure | #221 |
| agonal | #221 |
| level severity | #222 |
| 3 post | #222 |
| terry | #223 |
| death mechanisms | #224 |
| deficient animals | #224 |
| cyclase sgc | #225 |
| vulnerable period | #226 |
| 2 quality | #226 |
| gaba receptor | #227 |
| exposure inhalation | #228 |
| gaba cns | #228 |
| il1beta mrna | #228 |
| hepatic microcirculation | #228 |
| animals effects | #229 |
| cortical synaptosomes | #229 |
| acute chronic exposure | #229 |
| excitatory transmitter | #229 |
| shunt | #230 |
| muscarinic cholinergic | #230 |
| mk801 treatment | #230 |
| opca | #230 |
| cholestatic rats | #230 |
| hippocrates | #231 |
| glutamate excitotoxicity | #231 |
| previous report | #231 |
| receptor ligands | #231 |
| extracellular glutamate | #232 |
| rats weeks | #233 |
| spraguedawley reference values | #234 |
| increasing evidence | #234 |
| glutamate transport | #234 |
| increased intracranial | #234 |
| phosphate esters | #235 |
| cau | #235 |
| brain deposition | #235 |
| liver injury mice | #236 |
| pair fed | #236 |
| resonance study | #236 |
| serotonin tryptophan | #237 |
| 3hglutamate | #237 |
| glial proliferation | #238 |
| lc3 lipidation | #238 |
| pdh complex | #238 |
| animals rats | #239 |
| encephalopathy mhe | #239 |
| reduced glutathione levels | #240 |
| binding brain | #240 |
| concentrations elevated | #240 |
| levels glutamate | #240 |
| end‐stage liver disease | #240 |
| multiple systematic reviews | #240 |
| nacl kcl | #241 |
| minimal hepatic | #241 |
| caudate putamen | #241 |
| presynaptic neuron | #241 |
| psychoactive medications | #241 |
| 13cacetate | #242 |
| cycle disorders | #242 |
| brain samples | #242 |
| sgc | #243 |
| neurobehavioral | #243 |
| treatment central | #243 |
| glur2 | #243 |
| neuronal localization | #244 |
| cerebral cortex hippocampus | #244 |
| normal processes | #244 |
| neuronal membrane | #244 |
| alf patients | #244 |
| manganese concentration | #244 |
| hypothalamus hypothalamus | #245 |
| aged monoamine | #245 |
| acids animals | #246 |
| tritium animals | #246 |
| bloodbrain barrier breakdown | #246 |
| glutamine concentration | #246 |
| unchanged | #246 |
| neurologic assessment | #246 |
| plasma brain | #247 |
| soluble guanylate | #247 |
| synaptosomal preparations | #247 |
| nonpregnant rats | #247 |
| hippocampal sclerosis | #248 |
| minimal hepatic encephalopathy | #248 |
| neuroactive steroids | #248 |
| histaminergic | #248 |
| 5 hydroxyindoleacetic | #248 |
| betaep | #249 |
| allosteric coupling | #249 |
| deficient rats | #249 |
| increased expression | #250 |
| synaptic transmission | #250 |
| glutamate transporter glt1 | #250 |
| glutamate gaba | #251 |
| findings activation | #251 |
| reactive nitrogen intermediates | #251 |
| gaba uptake | #252 |
| fatigue chronic | #252 |
| symptoms brain | #253 |
| animals aspartic | #253 |
| reduced cerebral | #253 |
| focal loss | #254 |
| rats taurine | #255 |
| rat cerebellar | #256 |
| brain caudate | #256 |
| watersoluble vitamins | #256 |
| alterations expression | #257 |
| therapeutic measures | #257 |
| 4513 | #257 |
| soluble guanylate cyclase | #257 |
| norepinephrine turnover | #257 |
| brain disorder | #257 |
| mhe | #258 |
| pallidum | #258 |
| animals ataxia | #258 |
| ed1 | #259 |
| transporters amino | #259 |
| choline acetyltransferase | #259 |
| – brain | #259 |
| receptor autoradiography | #259 |
| rats time factors | #259 |
| precipitating factors | #260 |
| phenylalanine levels | #260 |
| glutamine synthetase | #260 |
| agents rats | #260 |
| liver liver failure | #261 |
| gene expression alterations | #261 |
| liver skeletal muscle | #262 |
| binding ligands | #262 |
| endogenous ligands | #262 |
| treatment neurological disorders | #262 |
| acetyl carnitine | #263 |
| neurological impairment | #263 |
| liver testis | #264 |
| alcoholic male | #264 |
| gamma tumor | #264 |
| muscle rigidity | #264 |
| concentrations brain | #264 |
| spf | #264 |
| rats compared | #265 |
| gabaergic neurotransmission | #265 |
| cisterna | #265 |
| calleja | #265 |
| cerebellar pathology | #266 |
| dopamine noradrenaline | #267 |
| dopamine spiperone | #267 |
| reactive gliosis | #267 |
| male c57bl6 mice | #267 |
| electrically stimulated | #268 |
| protein gene expression | #268 |
| isoquinolines | #268 |
| cell volume regulation | #268 |
| contributory | #269 |
| expression nitric | #270 |
| female hepatic | #271 |
| hepatic | #271 |
| sleep abnormalities | #271 |
| displaceable | #272 |
| pharmacological manipulation | #272 |
| hydroxyindoleacetic acid | #272 |
| octanoic acid | #272 |
| microdialysates | #272 |
| brain human | #272 |
| brains | #274 |
| neurotransmitter systems | #274 |
| greenwood | #276 |
| expression brain | #277 |
| normal conditions | #277 |
| quin | #277 |
| neuronal cell death | #278 |
| glutamate uptake | #279 |
| gamma liver | #280 |
| national association | #280 |
| neurotoxic action | #280 |
| tryptamine | #280 |
| microassay | #281 |
| striatum cerebral cortex | #281 |
| 14c2 | #281 |
| metal toxicity | #281 |
| guanylate cyclase | #282 |
| intracranial hypertension | #282 |
| gaba levels | #282 |
| glur3 | #283 |
| maoa | #283 |
| behavioural impairment | #284 |
| cortical astrocytes | #284 |
| 3mt | #284 |
| severe neurological | #284 |
| barrier breakdown | #285 |
| ht release | #285 |
| nitrated proteins | #285 |
| ucds | #285 |
| concentrations dopamine | #285 |
| glomerular filtrate | #287 |
| acute hepatic failure | #287 |
| deficiency disorders | #288 |
| excitatory amino acids | #289 |
| acid astrocytes | #289 |
| reduction oxidative stress | #290 |
| apap hepatotoxicity | #290 |
| adult values | #290 |
| azoxymethane | #291 |
| mice cerebral | #292 |
| patients fatigue | #292 |
| brain cerebellum | #292 |
| ligands male | #292 |
| human liver disease | #292 |
| autoradiographic studies | #293 |
| concentrations zinc | #293 |
| brain regional | #293 |
| glutamine | #293 |
| effects hypothermia | #293 |
| failure rats | #293 |
| reduced capacity | #293 |
| induced swelling | #294 |
| odn | #294 |
| blood – | #294 |
| altered expression | #294 |
| substantial increases | #295 |
| synthase expression | #296 |
| betaactin | #297 |
| rats increased | #297 |
| overt hepatic encephalopathy | #300 |
| rats western cells | #300 |
| groups sham | #304 |
| dawley receptors opioid | #304 |
| brain choline | #304 |
| actin mrna | #304 |
| rifamycins rifaximin | #305 |
| lnoarg | #306 |
| cytotoxic mechanism | #306 |
| severe alterations | #306 |
| gamma aminobutyric acid | #306 |
| damaged liver | #306 |
| 3hsch | #307 |
| glutamate | #307 |
| powerful antioxidant | #307 |
| selection model | #307 |
| cerebral function | #308 |
| bioaccumulation | #308 |
| dihydrolipoamide | #308 |
| molecular biological techniques | #310 |
| tight junction protein | #310 |
| serotonin metabolism | #311 |
| gaba taurine | #312 |
| agonists gaba | #312 |
| 4864 | #312 |
| brain genes | #312 |
| rats messenger | #313 |
| treatment rats | #313 |
| male osmolar | #314 |
| secondary biliary cirrhosis | #315 |
| receptors glutamate | #316 |
| brain serotonin | #316 |
| chloride animals | #316 |
| adjacent sections | #318 |
| mice mutant | #318 |
| nitrogen metabolism | #318 |
| basal ganglia patients | #319 |
| mitochondrial proliferation | #319 |
| humans manganese | #319 |
| quantitative autoradiography | #319 |
| cell death mechanisms | #320 |
| cultured hippocampal neurons | #320 |
| rats brain | #320 |
| dehydrogenase activity | #321 |
| tailpipe | #321 |
| 235triphenyltetrazolium chloride | #322 |
| eaat3 | #322 |
| isethionate | #323 |
| aqp4 expression | #324 |
| acid 5 | #325 |
| thalamus | #325 |
| complications outcome | #327 |
| nervous function | #327 |
| neurochemical studies | #327 |
| decreased brain | #327 |
| olivopontocerebellar | #328 |
| 5 hiaa | #328 |
| uptake increased | #329 |
| pathol | #329 |
| flumazenil | #330 |
| cerebellar astrocytes | #330 |
| β endorphin | #331 |
| sites human | #331 |
| proinflammatory cytokines | #333 |
| locomotor | #333 |
| aaas | #333 |
| uptake brain | #333 |
| experimental rat | #334 |
| increased binding | #335 |
| 13cglucose | #335 |
| neurotransmitter uptake | #335 |
| hydroxyindoleacetic | #335 |
| 8 rats | #336 |
| brain accumulation | #336 |
| nitrotyrosine | #337 |
| inhalation exposure | #338 |
| responsible | #339 |
| cortex brain | #339 |
| positive synergistic | #340 |
| transport defect | #340 |
| pdh activity | #341 |
| human hepatic | #341 |
| biological plausibility | #341 |
| mutant rats | #342 |
| cerebral cortical | #342 |
| reyes syndrome | #343 |
| brain 5 | #344 |
| altered mental status | #344 |
| benzodiazepine site | #344 |
| dehydrogenase humans | #345 |
| placebo improvement | #345 |
| activation nmda | #346 |
| dansyl | #346 |
| intraventricularly | #347 |
| control values | #347 |
| acid gaba | #347 |
| vulnerable | #347 |
| marked decreases | #349 |
| bdl rats | #349 |
| glutamate levels | #350 |
| increased immunoreactivity | #350 |
| pigs groups | #350 |
| nonalcoholics | #351 |
| patients dying | #351 |
| alanine amino | #351 |
| cortex cerebellum | #352 |
| consequent increase | #352 |
| manganese | #353 |
| apapinduced liver injury | #354 |
| consumption rats | #354 |
| proinflammatory cytokine release | #354 |
| series studies | #354 |
| western brain | #354 |
| expression increased | #355 |
| complex male | #356 |
| brain excitability | #356 |
| duct ligated | #356 |
| thiamine supplementation | #356 |
| receptor sites | #357 |
| deterioration | #357 |
| 5hiaa | #358 |
| wellestablished model | #358 |
| postmortem brain tissue | #358 |
| convulsions | #359 |
| onset brain | #359 |
| proposed role | #359 |
| increase extracellular | #361 |
| mammalian brain | #361 |
| glutamate homeostasis | #361 |
| autoradiography brain | #362 |
| metabolic events | #363 |
| neuroinflammatory | #363 |
| histamine h1 | #363 |
| reduced plasma | #363 |
| rats cns | #364 |
| 9998 | #365 |
| expression pglycoprotein | #365 |
| acids branched | #366 |
| white matter structures | #366 |
| posttranslational rats rats | #367 |
| neuroglia | #367 |
| folic acid antagonists | #368 |
| methoxytyramine | #369 |
| cerebral oedema | #370 |
| sulfate dheas | #370 |
| 56 mm | #370 |
| sites binding | #371 |
| nacetylcysteine nac | #371 |
| perineuronal | #372 |
| glutamate synthesis | #372 |
| metabolic impairment | #372 |
| acid rats | #373 |
| affinities | #373 |
| encountered | #373 |
| induction cox2 | #373 |
| chemical forms | #373 |
| astrocytes microglia | #375 |
| 3hmk801 | #375 |
| accompanied | #375 |
| anaplerotic | #376 |
| highaffinity | #376 |
| ca1 subfield | #376 |
| antioxidant nacetylcysteine | #377 |
| nh3 nh4 | #377 |
| acetyltransferase chat | #378 |
| cirrhosis alcoholic | #378 |
| ngnitro | #378 |
| novo synthesis | #379 |
| cell swelling | #380 |
| positive allosteric | #380 |
| basal ganglia thalamus | #380 |
| pons | #382 |
| acute chronic | #382 |
| epileptic patients | #382 |
| overwhelming evidence | #383 |
| pregnenolone | #383 |
| densities | #385 |
| transporter glut1 | #386 |
| exposure brain | #386 |
| dihydrolipoamide dehydrogenase | #386 |
| phenylalanine tyrosine | #388 |
| acetylcholine synthesis | #390 |
| hyperglycemic conditions | #390 |
| effects administration | #390 |
| pbz | #390 |
| cerebral edema | #390 |
| focal cerebral ischemia | #390 |
| pet assessment | #392 |
| mice enos | #393 |
| glycine transporter | #394 |
| phthalaldehyde | #394 |
| thioacetamide induced | #394 |
| scatchard plot | #395 |
| phenylacetate | #395 |
| failure induced | #396 |
| model acute | #396 |
| carnitine levels | #397 |
| positive allosteric modulator | #397 |
| omega 3 | #398 |
| methylhistamines | #399 |
| bbb permeability | #399 |
| pathophysiological mechanism | #399 |
| korsakoff | #400 |
| vestibular nucleus | #400 |
| acetyl coa | #400 |
| patients platelets | #400 |
| insulin metabolism | #401 |
| frontal | #401 |
| falls patients | #402 |
| inferior olive | #402 |
| radioligands | #403 |
| rats purpose | #405 |
| concerted effort | #407 |
| liver gut | #407 |
| marker enzymes | #408 |
| neuropathologic | #408 |
| methionine sulfoximine | #408 |
| releasable | #410 |
| adult activities | #412 |
| dopaminergic neurones | #414 |
| shunt surgery | #415 |
| forebrain cholinergic | #416 |
| patients ataxia | #416 |
| ketamine anesthesia | #417 |
| gabaa gammaaminobutyric acid | #418 |
| intellectual function | #419 |
| pk11195 | #419 |
| alcoholic liver | #421 |
| fibrillary | #421 |
| serotonin content | #422 |
| regions brain | #423 |
| rats animal | #423 |
| housekeeping gene | #423 |
| asparagine | #423 |
| sham operation | #423 |
| diazepam binding | #424 |
| hypothermia | #424 |
| tissues brain | #425 |
| salinetreated controls | #425 |
| direct evidence | #426 |
| binding parameters | #426 |
| aidsrelated complex | #426 |
| exsanguination | #427 |
| rats mutant | #428 |
| hepatocyte necrosis | #430 |
| protein utilization | #431 |
| glutamine levels | #431 |
| sacrificed | #432 |
| hippocampus frontal cortex | #434 |
| dawley tissue | #434 |
| onset severe | #434 |
| peripheral benzodiazepine | #434 |
| rats experimental | #435 |
| patients pbc | #437 |
| cytotoxic edema | #437 |
| 12 control subjects | #438 |
| benzoate | #438 |
| addition evidence | #439 |
| isoquinoline | #440 |
| ligand selectivity | #440 |
| attenuates | #441 |
| central process | #441 |
| neurological syndrome | #442 |
| acids brain | #442 |
| brain glucose | #443 |
| arginine transport | #443 |
| brain microglia | #443 |
| 13c enrichment | #443 |
| patients encephalopathy | #443 |
| cultured astrocytes | #444 |
| glyt1 | #444 |
| operated | #445 |
| cultured cerebellar | #445 |
| compounds rats | #446 |
| butterworth | #446 |
| brain water content | #447 |
| liver skeletal | #450 |
| pyruvate dehydrogenase | #450 |
| agematched controls | #450 |
| topographic distribution | #450 |
| acute mice mice | #451 |
| brain tissue patients | #451 |
| effects liver | #451 |
| t1weighted mri | #453 |
| severe liver | #454 |
| immunohistochemistry liver | #455 |
| aged amino | #455 |
| s100beta | #455 |
| central pontine myelinolysis | #455 |
| h1 receptor | #456 |
| parachlorophenylalanine | #456 |
| body evidence | #456 |
| brain swelling | #456 |
| vitro binding assay | #457 |
| impaired liver function | #457 |
| aspartic | #457 |
| brain monoamines | #458 |
| brain alterations | #460 |
| effects brain | #460 |
| neurobiology | #460 |
| increased release | #461 |
| neuropathology | #462 |
| equivocal | #463 |
| 5ht levels | #463 |
| substantial body | #463 |
| neurological | #465 |
| hepatic glutathione | #466 |
| dentate nuclei | #466 |
| neurobehavioural | #467 |
| studies reveal | #468 |
| glutamic acid | #469 |
| central cholinergic | #469 |
| reye | #470 |
| amino acid levels | #471 |
| monoamine metabolism | #471 |
| urea production | #472 |
| alcoholic liver disease | #473 |
| patients hippocampal | #473 |
| putamen patients | #474 |
| ox42 | #475 |
| glutamate transporters | #475 |
| liver dysfunction | #475 |
| gaba glycine | #475 |
| inherited defects | #476 |
| alcohol brain | #477 |
| thiamin | #477 |
| release proinflammatory cytokines | #479 |
| thiamine pyrophosphate | #479 |
| acid humans | #480 |
| amino acid transporters | #480 |
| parkinsons diseases | #481 |
| inferior colliculus | #482 |
| acute male | #482 |
| images brain | #482 |
| brain csf | #484 |
| chronic alcoholics | #484 |
| nitric oxide synthase | #487 |
| manganese levels | #488 |
| concentrations increased | #488 |
| triphosphate amino | #488 |
| acids rats | #490 |
| urea ammonia | #491 |
| multinuclear nmr spectroscopy | #491 |
| role brain | #492 |
| increased production | #492 |
| glial fibrillary | #492 |
| jadad | #492 |
| ischemic cortex | #493 |
| pet ligand | #494 |
| outer mitochondrial membrane | #495 |
| pyruvates | #495 |
| aspartate glutamate | #495 |
| ammonium ion | #495 |
| emitted radiation | #495 |
| hexanones | #496 |
| rat hippocampal | #496 |
| schaffer collaterals | #496 |
| neurons nitric | #499 |
| ataxic | #499 |
| brain diseases | #501 |
| beneficial | #502 |
| 3hd | #505 |
| brain synaptosomes | #505 |
| 5 hydroxytryptophan | #507 |
| ketoacid | #508 |
| acid metabolites | #509 |
| gene therapy treatment | #510 |
| fatal complication | #510 |
| histamine h1 receptors | #511 |
| discrete brain regions | #511 |
| increased icp | #511 |
| medulla oblongata | #511 |
| exposure rats | #515 |
| acids amino | #516 |
| major feature | #517 |
| abnormal metabolism | #517 |
| humans neurons | #518 |
| chain acyl | #518 |
| concentrations 5 | #521 |
| neurochemistry | #523 |
| ltrp | #523 |
| inflammation mediators | #525 |
| toxic agents | #526 |
| brain female | #530 |
| rat hippocampal slices | #530 |
| aom | #531 |
| dawley receptors | #533 |
| agents dopamine | #533 |
| receptor complex | #533 |
| focal cerebral | #534 |
| muscle loss | #534 |
| ligation bdl | #534 |
| neurotoxins | #534 |
| 100 µg | #534 |
| combined actions | #535 |
| cerebellum cerebral | #536 |
| bdz | #537 |
| divalent metals | #538 |
| carroll | #539 |
| selective | #539 |
| severe liver disease | #539 |
| alcoholic cirrhosis | #539 |
| tipss | #540 |
| hydroxymethylbilane | #541 |
| tyrosine nitration | #541 |
| brain astrocytes | #542 |
| moderate drinking | #542 |
| moderate increase | #543 |
| aspartate | #544 |
| pyruvate oxidation | #544 |
| portasystemic | #544 |
| liver enzyme | #545 |
| organic osmolytes | #545 |
| chronic liver | #545 |
| energy metabolism | #546 |
| model hepatic | #547 |
| unanesthetized rats | #548 |
| dissected | #548 |
| cumene | #548 |
| nitrosative stress | #548 |
| alpha1 alpha2 | #549 |
| unconjugated bilirubin | #549 |
| thalamic lesions | #550 |
| taurine levels | #551 |
| brain region | #551 |
| fatigue patients | #553 |
| genes brain | #553 |
| glutamatergic neurotransmission | #554 |
| brain cytokines | #554 |
| increased uptake | #555 |
| water ammonia | #555 |
| nmda receptor antagonist | #556 |
| disease liver | #557 |
| failure liver | #558 |
| rats bile | #558 |
| gabaergic gaba | #563 |
| levels hepatic | #563 |
| microdialysate | #563 |
| hydroxytryptophan | #564 |
| cortex female humans | #564 |
| microglial response | #566 |
| serum bilirubin levels | #567 |
| malnutrition patients | #567 |
| mhe patients | #567 |
| established role | #568 |
| ischemia liver | #568 |
| transient increase | #569 |
| autoradiographic | #569 |
| lhistidine | #569 |
| neurotransmitter glutamate | #571 |
| neurologic signs | #573 |
| pathway brain | #574 |
| gaba | #574 |
| decarboxylase gad | #576 |
| octopamine | #577 |
| outcome liver | #577 |
| expression mrnas | #578 |
| apap induced | #578 |
| il1beta expression | #578 |
| liver pathology | #580 |
| oxobutanoate | #580 |
| biogenic monoamines | #581 |
| increases blood | #582 |
| pyridinium compounds | #582 |
| octanoic | #582 |
| histological lesions | #583 |
| brain metabolism | #583 |
| 5hydroxytryptophan | #584 |
| neurobehavioral effects | #588 |
| monoamine oxidases | #589 |
| edema formation | #589 |
| bloodbrain barrier | #589 |
| human spinal | #590 |
| activity brain | #591 |
| 13c nuclear | #592 |
| toxic levels | #593 |
| accompanying | #593 |
| endogenous opioid | #594 |
| catalytic sites | #594 |
| pathophysiological mechanisms | #594 |
| t1weighted imaging | #597 |
| highenergy phosphates | #598 |
| aminobutyric acid gaba | #599 |
| extracellular fluid | #600 |
| neuronal nitric | #601 |
| leigh disease | #601 |
| include | #601 |
| neuroglial | #601 |
| taurine | #602 |
| 3hcholine | #602 |
| largest increases | #604 |
| male nitric | #606 |
| methyltyrosines | #606 |
| glutamine humans | #607 |
| vermis | #608 |
| extracellular compartment | #608 |
| acetyl | #609 |
| molecular studies | #609 |
| cirrhosis | #609 |
| cortical slices | #610 |
| male metabolism | #610 |
| ventricular enlargement | #612 |
| ammonia concentration | #612 |
| friedreich ataxia | #612 |
| animals autoradiography | #614 |
| neurovascular unit | #615 |
| spraguedawley receptors | #615 |
| microglial | #616 |
| selective accumulation | #616 |
| axonopathy | #616 |
| c57bl6 mice | #618 |
| artery ligation | #618 |
| tricarboxylic | #618 |
| normothermic | #619 |
| mammillary | #620 |
| increased expression genes | #620 |
| acidic protein | #621 |
| junction proteins | #624 |
| controls addition | #624 |
| hippocampal slices | #625 |
| oxidase mao | #625 |
| new approaches | #625 |
| amino acid concentrations | #626 |
| semi quantitative | #626 |
| edema brain | #627 |
| nimesulide | #628 |
| hepatic levels | #628 |
| experimental animal model | #628 |
| dbi | #629 |
| clf | #629 |
| free radical formation | #630 |
| blood borne | #631 |
| neurobehavior | #631 |
| dehydroepiandrosterone sulfate dheas | #633 |
| ataxia | #634 |
| contributory role | #635 |
| dopamine striatum | #635 |
| allosteric interactions | #635 |
| urea synthesis | #635 |
| encephalopathies | #636 |
| neurological damage | #637 |
| levels observed | #638 |
| neuroinflammation | #638 |
| astrocyte cultures | #638 |
| harper | #638 |
| cerebellum | #639 |
| deleterious effects | #640 |
| conduction velocities | #640 |
| rats glucose | #641 |
| acid hippocampus | #643 |
| receptor densities | #644 |
| neuronal excitability | #645 |
| excitatory inhibitory | #645 |
| early role | #646 |
| frontal temporal | #647 |
| nntetraacetic acid | #647 |
| chronic exposure | #647 |
| desoxycorticosterone | #652 |
| matsumoto | #652 |
| branched chain | #653 |
| excitatory amino | #653 |
| cytokines tnf | #654 |
| tricarbonyl | #655 |
| gabaa gaba | #656 |
| 1400w | #657 |
| mental state | #657 |
| enos gene | #659 |
| acid transporter | #659 |
| dawley sodium | #661 |
| potential toxic effects | #662 |
| cerebral cortex | #663 |
| uptake release | #664 |
| metabolic basis | #665 |
| 3hspiperone | #665 |
| fibrillary acidic | #666 |
| cycle enzymes | #668 |
| heterogeneous distribution | #669 |
| cogent | #670 |
| minocycline treatment | #673 |
| inhibitory properties | #673 |
| metabolism rats | #675 |
| potassium concentration | #675 |
| 7ni | #678 |
| 7nitroindazole | #679 |
| evoked release | #682 |
| neuropathological | #683 |
| reduction expression | #683 |
| excitatory | #684 |
| ornithine | #684 |
| millimolar | #684 |
| regional specificity | #684 |
| ammonia treatment | #684 |
| gammaaminobutyric acid | #685 |
| frontal cortex hippocampus | #686 |
| microg m3 | #688 |
| cerebral atrophy | #688 |
| spraguedawley | #688 |
| protein tspo | #691 |
| ca1 pyramidal cells | #695 |
| fulminant | #695 |
| hepatic damage | #695 |
| brain regions | #695 |
| acetylcysteine animals | #697 |
| daily administration | #697 |
| extrapyramidal | #698 |
| synthase nnos | #698 |
| enzyme complex | #699 |
| bcaas | #700 |
| brain disorders | #700 |
| immunolabeling | #701 |
| blood‐brain barrier | #701 |
| ammonia production | #703 |
| normoglycemic | #703 |
| autophagy markers | #704 |
| rats dawley receptors | #705 |
| quinolinic | #706 |
| ethanol ingestion | #706 |
| acetylcysteine nac | #709 |
| cornerstone | #711 |
| glut1 expression | #714 |
| cortex rats | #715 |
| reductions | #719 |
| phenylbutyrate | #723 |
| bmax values | #723 |
| surgical samples | #724 |
| 6 day | #724 |
| nutritional status patients | #725 |
| acute hepatic | #726 |
| ketoglutaric | #729 |
| contribute | #730 |
| serotoninergic | #730 |
| expression isoforms | #736 |
| intensive study | #737 |
| piribedil | #740 |
| fluorimetric detection | #741 |
| mm nacl | #742 |
| ligation liver | #744 |
| dopaminergic function | #745 |
| biochemical alterations | #746 |
| cerebellar granule | #746 |
| methylglucose | #747 |
| tight junction | #748 |
| male microdialysis | #749 |
| glucose oxidation | #749 |
| choline acetyltransferase chat | #752 |
| cytochrome oxidase activity | #753 |
| alterations | #754 |
| scatchard analysis | #754 |
| illness terminology | #756 |
| portasystemic shunt | #757 |
| glutamate glu | #757 |
| delta receptors opioid | #758 |
| alcoholism animals | #760 |
| ergic | #761 |
| varying degrees | #762 |
| ammonium chloride | #763 |
| substantial evidence | #763 |
| opioid delta receptors | #764 |
| tryptamines | #764 |
| neutron activation analysis | #765 |
| levels 5 | #768 |
| normal liver function | #769 |
| excitotoxic | #769 |
| gdh | #769 |
| barrier permeability | #770 |
| control genes | #773 |
| newborn astrocytes | #774 |
| peripheral organs | #775 |
| cellular energy metabolism | #776 |
| ethanol consumption | #777 |
| increased blood | #778 |
| brain gene | #780 |
| species reactive | #783 |
| hepatic dysfunction | #783 |
| receptor function | #784 |
| cortex thalamus | #785 |
| mnsod | #785 |
| methods principal findings | #785 |
| glut1 | #786 |
| messenger rats | #786 |
| nakatpase | #787 |
| globus pallidus | #787 |
| early alterations | #789 |
| brain function | #790 |
| spraguedawley receptors messenger | #791 |
| probenecid | #791 |
| major route | #791 |
| 2 fold | #792 |
| glyceraldehyde3 phosphate | #792 |
| specific ligands | #793 |
| hypothermia treatment | #793 |
| rat cerebral | #795 |
| selective effects | #796 |
| typical cases | #796 |
| plasma clearance | #797 |
| ethanol solution | #797 |
| neuronal integrity | #799 |
| severity liver | #799 |
| nitroarginine | #801 |
| pertinence | #805 |
| hiaa | #806 |
| neurotoxic effects | #807 |
| nh4cl | #807 |
| ultimately | #807 |
| pyruvate metabolism | #808 |
| mrna protein | #809 |
| chat | #811 |
| acute brain injury | #812 |
| predilection | #812 |
| role astrocytes | #812 |
| enos mice | #815 |
| update | #816 |
| coma | #816 |
| glycolytic activity | #819 |
| cerebellar granule cells | #820 |
| nmethyldaspartate | #822 |
| eaat1 | #823 |
| pbc patients | #823 |
| iii groups | #824 |
| pathogenesis treatment | #825 |
| complete disappearance | #825 |
| edema | #826 |
| age matched | #826 |
| alzheimer type | #828 |
| atomic absorption spectrometry | #828 |
| synthesis rates | #829 |
| nitrite nitrate | #829 |
| glial | #830 |
| neurons astrocytes | #831 |
| water homeostasis | #831 |
| diseases alcoholic | #832 |
| alcoholics | #832 |
| eaat2 | #833 |
| monoamine | #834 |
| decreases | #835 |
| manifested | #836 |
| pathophysiological | #837 |
| operated rats | #837 |
| explain | #838 |
| amino3 | #838 |
| oligonucleotide primers | #839 |
| animal cell | #839 |
| treatment improvement | #841 |
| metabolic disorder | #842 |
| expression ho1 | #843 |
| cell loss | #845 |
| hypothermia patients | #846 |
| isotopomer | #846 |
| cfos cjun | #848 |
| oblongata | #849 |
| pharmacokinetic analyses | #849 |
| chronic alcohol consumption | #851 |
| gaba receptors | #852 |
| receptor mediated | #853 |
| nmda receptor | #853 |
| matched age | #854 |
| daily injections | #854 |
| glutamatergic | #856 |
| consequence | #856 |
| compromised | #857 |
| bbb integrity | #858 |
| griess | #861 |
| aromatic amino acids | #861 |
| hepatic disease | #862 |
| alcoholic | #862 |
| order role | #862 |
| antioxidant action | #863 |
| continues | #863 |
| inflammatory mechanisms | #866 |
| thalamic nuclei | #866 |
| cerebellar ataxia | #867 |
| early induction | #867 |
| normalizes | #869 |
| manifest | #870 |
| chronic liver disease | #871 |
| oxide rats | #872 |
| fpc | #874 |
| succimer | #877 |
| low risk bias | #880 |
| nmda receptor antagonists | #881 |
| greater susceptibility | #882 |
| excitatory amino acid | #882 |
| barrier bbb | #882 |
| cisterna magna | #882 |
| stimulated release | #887 |
| comatose | #890 |
| dehydrogenase | #890 |
| western cells | #890 |
| multinuclear | #891 |
| shamoperated animals | #891 |
| cultured hippocampal | #892 |
| nutritional intervention | #893 |
| interfere | #893 |
| mutant mouse | #894 |
| lipoamide | #897 |
| neuropsychiatric symptoms | #898 |
| exp | #899 |
| acetaminophen apap | #900 |
| common death | #901 |
| sulfoximine | #901 |
| dizocilpine maleate | #901 |
| cirrhosis pbc | #902 |
| neurons rna | #904 |
| lowering | #904 |
| experimental animal | #905 |
| quinolinic acid | #905 |
| pcs | #907 |
| autopsy brain | #907 |
| brain activities | #908 |
| factor tumor | #912 |
| acid animals | #912 |
| pathophysiology | #913 |
| colliculus | #913 |
| selective ligands | #913 |
| publication acidosis | #919 |
| placebo intervention | #919 |
| cerebellar degeneration | #920 |
| microdialysis study | #920 |
| liver homogenates | #922 |
| rat cortical | #922 |
| delta receptors | #924 |
| survival mice | #926 |
| urea cycle | #929 |
| striatum hippocampus | #930 |
| pugh | #931 |
| nacetylcysteine | #931 |
| findings evidence | #932 |
| microglial activation | #932 |
| hydroxy2di | #933 |
| activities enzymes | #936 |
| tartrates | #942 |
| reaction water | #942 |
| hepatic diseases | #942 |
| developing rat brain | #942 |
| rats exposed | #943 |
| agents oxidative | #943 |
| injured liver | #943 |
| mammalian cns | #943 |
| study liver | #943 |
| marked | #945 |
| rapid removal | #945 |
| pca | #948 |
| maladies | #949 |
| cirrhosis magnetic | #950 |
| 25mm | #951 |
| concentrations observed | #954 |
| spontaneous release | #957 |
| altered | #962 |
| spraguedawley receptors rats | #963 |
| detailed review | #964 |
| assay rats | #967 |
| putamen | #967 |
| translocator protein | #969 |
| humans hypothermia | #969 |
| moderate hypothermia | #970 |
| increased glycolysis | #971 |
| intermediary metabolism | #971 |
| cerebral glucose | #971 |
| chronic liver diseases | #971 |
| acid transport | #971 |
| nm range | #973 |
| autoradiographic study | #974 |
| aspartic acid | #979 |
| kidney heart | #979 |
| post translational modifications | #980 |
| neurological disease | #983 |
| occludin | #984 |
| oxygenase1 ho1 | #988 |
| 9 mice mice | #990 |
| pdh | #990 |
| effective measures | #990 |
| cirrhosis experimental | #991 |
| aquaporin4 | #991 |
| rats ethanol | #992 |
| brain oedema | #992 |
| increased plasma | #993 |
| spared | #993 |
| propylaminotetralin | #998 |
| damage mechanisms | #999 |
| adaptive mechanisms | #1006 |
| role oxidative stress | #1006 |
| soluble guanylyl | #1008 |
| flunitrazepam | #1008 |
| uptake kinetics | #1008 |
| cerebro | #1009 |
| rifaximin | #1009 |
| metabolic consequences | #1010 |
| rat brain | #1012 |
| progressing | #1013 |
| neurotoxic | #1013 |
| presymptomatic | #1015 |
| modulatory | #1015 |
| electrified | #1016 |
| fulminant hepatic | #1016 |
| publication amino acids | #1017 |
| ligands receptors | #1019 |
| animal models | #1020 |
| unsuspected | #1020 |
| abundant evidence | #1020 |
| 1h | #1023 |
| acids bcaa | #1023 |
| pallidus humans | #1024 |
| antioxidant anti | #1029 |
| astrocyte | #1030 |
| metabolism inborn | #1031 |
| tele | #1032 |
| microsomes | #1032 |
| etanercept treatment | #1034 |
| 7 hours | #1036 |
| muscle expression | #1038 |
| catalepsy | #1039 |
| interleukin1beta | #1041 |
| nutritional assessment | #1043 |
| monoamine oxidase | #1045 |
| pharmacology | #1048 |
| acid decarboxylase | #1050 |
| gabaergic | #1050 |
| aqp4 | #1050 |
| major factor | #1053 |
| caudate nucleus | #1053 |
| endogenous | #1055 |
| aquaporin 4 | #1056 |
| specific antagonist | #1057 |
| hepatolenticular | #1057 |
| involved pathogenesis | #1058 |
| synthetase | #1058 |
| frontoparietal cortex | #1060 |
| adaptive mechanism | #1060 |
| oxygenase1 | #1064 |
| gabaa receptors | #1066 |
| progression liver | #1067 |
| 5ht neurons | #1067 |
| sodium acetate | #1072 |
| rat hepatocytes | #1075 |
| efficacy treatment | #1075 |
| reflex | #1077 |
| membrane preparations | #1077 |
| inflammation infection | #1078 |
| glucose blotting | #1080 |
| accompanies | #1081 |
| gilles | #1083 |
| enzyme activities | #1083 |
| 34dihydroxyphenylacetic acid | #1085 |
| nonneuronal | #1086 |
| content increased | #1090 |
| complex carbohydrates | #1092 |
| lactate concentrations | #1092 |
| major players | #1095 |
| muscle brain | #1097 |
| radioligand assay | #1098 |
| intense staining | #1099 |
| awaiting | #1099 |
| rat primary | #1101 |
| baptaam | #1102 |
| normal physiological conditions | #1106 |
| cell culture studies | #1107 |
| tpp | #1107 |
| junction protein | #1108 |
| medial septum | #1109 |
| hyperintensity | #1111 |
| 5 mm | #1111 |
| assay receptors | #1113 |
| human brain tissue | #1116 |
| patients alzheimers disease | #1117 |
| inflammation role | #1117 |
| cirrhotics | #1118 |
| atrophy brain | #1122 |
| severe malnutrition | #1122 |
| ischemic core | #1127 |
| sprague | #1128 |
| cirrhosis male | #1129 |
| findings role | #1129 |
| astrocytes | #1130 |
| transient elevation | #1131 |
| amino acids | #1134 |
| tetrabenazine | #1135 |
| weight brain | #1137 |
| age controls | #1138 |
| diagonal band | #1139 |
| haloperidol humans | #1142 |
| oxide synthase | #1143 |
| receptors histamine | #1145 |
| hepatobiliary | #1146 |
| pyruvate | #1148 |
| nonepileptic | #1153 |
| lactic acidosis | #1153 |
| worsens | #1153 |
| dehydroepiandrosterone sulfate | #1154 |
| control tissue | #1157 |
| altered brain | #1162 |
| biogenic amines | #1163 |
| cresyl | #1166 |
| portosystemic | #1167 |
| h1 | #1168 |
| benzilate | #1171 |
| combustion products | #1172 |
| emax | #1173 |
| enzymologic | #1174 |
| lactate | #1177 |
| etanercept | #1179 |
| rats subjected | #1180 |
| parkinsonian symptoms | #1181 |
| peripheral tissues | #1182 |
| glutamate dehydrogenase | #1182 |
| nerve conduction | #1183 |
| nnos | #1185 |
| rats receptors | #1185 |
| urine levels | #1186 |
| principally | #1189 |
| mechanisms involved | #1191 |
| cardinal features | #1192 |
| synaptic cleft | #1192 |
| hyperintensities | #1193 |
| delta opioid | #1196 |
| causal factor | #1197 |
| rapid onset | #1198 |
| gabaa receptor | #1199 |
| transcriptase polymerase | #1201 |
| venous blood | #1204 |
| dawley | #1205 |
| dopamine uptake | #1205 |
| acetyl cysteine | #1207 |
| death cells | #1207 |
| hepatolenticular degeneration | #1209 |
| development brain | #1211 |
| increasing body | #1214 |
| direct effects | #1216 |
| stereotypy | #1218 |
| radiometric | #1220 |
| brains mice | #1220 |
| binding inhibitor | #1220 |
| pig model | #1221 |
| 5htp | #1222 |
| nmethyld | #1223 |
| fold increase | #1224 |
| neuropsychological impairment | #1226 |
| skeletal rats rats | #1226 |
| mitochondrial swelling | #1228 |
| transjugular | #1229 |
| deprenyl | #1229 |
| wilson disease | #1229 |
| 100 iu | #1232 |
| cultured rat | #1234 |
| severity assessment | #1234 |
| circadian rhythmicity | #1234 |
| hippocampus vitro | #1236 |
| nakatpase activity | #1239 |
| spraguedawley receptors opioid | #1239 |
| hyperexcitability | #1239 |
| congenitally | #1241 |
| glyceraldehyde3 | #1242 |
| hypermetabolism | #1242 |
| brain axis | #1246 |
| partial recovery | #1251 |
| elucidation | #1252 |
| kinetics male | #1253 |
| receptors neurotransmitter | #1254 |
| sprague dawley | #1255 |
| convincing evidence | #1258 |
| methyl aspartate | #1259 |
| gabaa | #1260 |
| 5hydroxyindoleacetic acid | #1261 |
| albumen | #1261 |
| clinical entities | #1262 |
| acetylcysteine | #1262 |
| hippocampus striatum | #1262 |
| myoinositol | #1264 |
| overactivation | #1270 |
| astroglial | #1271 |
| 1h 13c | #1271 |
| olfactory bulbs | #1273 |
| maleate | #1276 |
| rats expression | #1276 |
| congenital | #1281 |
| vicious | #1281 |
| apoenzyme | #1281 |
| milligram | #1281 |
| variable degree | #1282 |
| glutamate decarboxylase | #1287 |
| loss expression | #1288 |
| patients tle | #1288 |
| induced inhibition | #1289 |
| brain inflammation | #1290 |
| acid male | #1291 |
| metabolite | #1291 |
| acid cycle | #1291 |
| cortex kidney | #1292 |
| quisqualate | #1294 |
| ischemia cerebral | #1295 |
| rifamycins | #1296 |
| radioreceptor | #1296 |
| dawley animals | #1297 |
| protective | #1297 |
| deficient | #1297 |
| zinc concentrations | #1300 |
| permeability blood | #1301 |
| synaptosomes | #1302 |
| potential therapeutic approach | #1305 |
| frontoparietal | #1306 |
| opioid delta | #1308 |
| 7 males | #1308 |
| neuronal dysfunction | #1310 |
| caveolin1 | #1310 |
| 5mm | #1314 |
| liver | #1314 |
| heme oxygenase1 | #1316 |
| greater magnitude | #1317 |
| adrenals | #1318 |
| 35°c | #1319 |
| threefold | #1320 |
| receptors methyl | #1321 |
| invariably | #1324 |
| neurotransmission | #1325 |
| dopamine serotonin | #1328 |
| nanomolar | #1328 |
| guanylyl | #1329 |
| appearance | #1329 |
| major complication | #1334 |
| animal electrophoresis | #1334 |
| signaling mechanisms | #1335 |
| acetyltransferase | #1337 |
| phosphate dehydrogenase | #1344 |
| cerebellum hippocampus | #1344 |
| astrocytes cells | #1346 |
| cgmp pathway | #1349 |
| heavy drinkers | #1350 |
| transporter proteins | #1352 |
| brain effects | #1358 |
| dopamine female | #1361 |
| neuronal | #1361 |
| female globus | #1364 |
| interleukin1 receptors | #1364 |
| shunt tips | #1368 |
| male rats rats | #1369 |
| hypoglycaemic | #1375 |
| small decrease | #1378 |
| fur | #1380 |
| electrolyte balance | #1381 |
| aromatic amino | #1383 |
| bile duct ligation | #1386 |
| chelation therapy | #1387 |
| synergism | #1387 |
| nitrated | #1388 |
| gaba agonists | #1389 |
| ca2independent | #1392 |
| preliminary studies | #1394 |
| neurological sequelae | #1395 |
| transamination | #1396 |
| occipital cortex | #1401 |
| intrauterine growth | #1402 |
| immediateearly genes | #1403 |
| guanylate | #1409 |
| pallidus | #1409 |
| larginine | #1412 |
| selectively | #1416 |
| cerebral | #1417 |
| patients findings | #1425 |
| paper details | #1426 |
| normo | #1427 |
| mutant strains | #1429 |
| acute brain | #1433 |
| motor nerve | #1441 |
| paralleled | #1444 |
| shamoperated | #1445 |
| common approaches | #1450 |
| childpugh score | #1450 |
| mitochondrial membranes | #1451 |
| risk falls | #1451 |
| peripheral | #1452 |
| longer wavelength | #1453 |
| hypoglycaemia | #1455 |
| effective prevention | #1456 |
| intraventricular injections | #1456 |
| benzodiazepinones | #1459 |
| clonazepam | #1460 |
| modulatory effects | #1462 |
| hydroxydopamines | #1465 |
| studies brain | #1471 |
| quinuclidinyl | #1472 |
| swelling | #1477 |
| brain tissues | #1479 |
| patients liver disease | #1481 |
| saturable | #1482 |
| 23390 | #1485 |
| 13c | #1485 |
| deficiency | #1486 |
| excitatory neurotransmission | #1488 |
| characteristic | #1488 |
| gfap | #1491 |
| dopamine agents | #1499 |
| messenger rats rats | #1504 |
| neuroprotective role | #1505 |
| bilirubin levels | #1509 |
| histological studies | #1509 |
| primary concern | #1509 |
| increases | #1512 |
| volume regulation | #1512 |
| cortex striatum | #1513 |
| primary biliary cirrhosis | #1514 |
| receptor subunits | #1515 |
| herniation | #1516 |
| liver disease | #1519 |
| rat cerebral cortex | #1519 |
| 1h magnetic | #1523 |
| glutamic acid decarboxylase | #1525 |
| integrity | #1525 |
| tyrosine residues | #1527 |
| branched | #1530 |
| tk | #1532 |
| temporal profile | #1539 |
| increased capacity | #1541 |
| transport animals | #1546 |
| brain homogenates | #1547 |
| apomorphine | #1548 |
| acetylcarnitine | #1548 |
| cholinergic | #1549 |
| vitamins minerals | #1550 |
| tricarboxylic acid | #1551 |
| wistar receptors rats | #1552 |
| lactulose | #1554 |
| regional differences | #1557 |
| pathological hallmark | #1557 |
| neurochemical | #1559 |
| lactate levels | #1561 |
| cirrhosis liver | #1564 |
| reflexes | #1566 |
| pathological mechanisms | #1567 |
| extracellular | #1568 |
| neurotransmitters | #1572 |
| poor diet | #1575 |
| major forms | #1579 |
| brain cerebral | #1580 |
| scad | #1584 |
| light energy | #1584 |
| biliary cirrhosis | #1584 |
| tryptophan | #1585 |
| epilepsy tle | #1585 |
| brain cell | #1586 |
| patients review | #1589 |
| ependymal cells | #1591 |
| ngnitrolarginine methyl ester | #1592 |
| new findings | #1594 |
| lesser extent | #1595 |
| pyruvate carboxylase | #1596 |
| aspartate nmda | #1598 |
| llysine | #1600 |
| pbc | #1601 |
| rat hippocampus | #1602 |
| mri signal | #1605 |
| specific therapies | #1606 |
| brain slices | #1606 |
| ouabain | #1615 |
| tdp | #1615 |
| travelled | #1618 |
| unanesthetized | #1623 |
| anastomosis | #1626 |
| acute mice | #1627 |
| neuroglia neurons | #1629 |
| deficient diet | #1631 |
| failure mechanisms | #1633 |
| receptor human | #1635 |
| prevents | #1637 |
| zinc copper | #1640 |
| cerebellar | #1641 |
| tritium | #1642 |
| dorsal raphe nucleus | #1646 |
| regulation animals | #1647 |
| male membrane glycoproteins | #1648 |
| died | #1650 |
| experimental treatment | #1651 |
| animals cerebral | #1651 |
| brain endothelial | #1652 |
| synthase nitric | #1653 |
| neuromodulatory | #1653 |
| amino acid transport | #1654 |
| distribution animals | #1657 |
| glutamate receptors | #1657 |
| fourfold | #1658 |
| extracellular space | #1660 |
| excitotoxicity | #1661 |
| bbb disruption | #1664 |
| rapid accumulation | #1664 |
| gapdh | #1667 |
| striking similarities | #1667 |
| supporting cells | #1669 |
| autoradiography | #1673 |
| previous findings | #1674 |
| synthetase activity | #1675 |
| messenger | #1677 |
| veratrum | #1688 |
| brain area | #1691 |
| dehydrogenase deficiency | #1694 |
| diseases metabolic | #1696 |
| glycogen metabolism | #1701 |
| brainstem | #1704 |
| midbrain | #1708 |
| postulated | #1708 |
| thp | #1710 |
| accumulate | #1716 |
| fulminant hepatic failure | #1723 |
| ibotenic | #1723 |
| dizocilpine | #1724 |
| inborn | #1724 |
| polyclonal antibody | #1725 |
| benzodiazepines | #1726 |
| phenomenon | #1726 |
| il1beta | #1733 |
| alternative mechanism | #1734 |
| carnitine | #1735 |
| animals arginine | #1735 |
| cumene hydroperoxide | #1737 |
| noninvasive techniques | #1737 |
| disorders nervous | #1739 |
| decarboxylase | #1750 |
| normalization | #1756 |
| alternative hypothesis | #1757 |
| liver disease patients | #1757 |
| magna | #1759 |
| consequent | #1760 |
| tricarboxylic acid cycle | #1761 |
| c57bl6 | #1762 |
| shunts | #1762 |
| spiperone | #1763 |
| metabolism glucose | #1769 |
| intrahepatic portosystemic | #1770 |
| allosteric | #1770 |
| critical appraisal | #1773 |
| betaamyloid | #1781 |
| granule neurons | #1785 |
| acetaminophen induced | #1788 |
| muscarinic | #1789 |
| cell damage | #1790 |
| rats spraguedawley receptors | #1791 |
| brain damage | #1791 |
| body temperature | #1794 |
| adult rat brain | #1794 |
| normothermia | #1794 |
| glucose utilization | #1797 |
| common complication | #1799 |
| nmr study | #1802 |
| ampa receptors | #1806 |
| superfusion | #1810 |
| preliminary investigation | #1812 |
| primary metabolism | #1813 |
| coa dehydrogenase | #1815 |
| nutritional supplements | #1815 |
| major organs | #1815 |
| endorphin | #1817 |
| oxazepam | #1822 |
| pyruvic | #1822 |
| rat | #1829 |
| hypertension intracranial | #1832 |
| dorsal raphe | #1833 |
| hippocampal ca1 | #1834 |
| hepatic failure | #1835 |
| vmax values | #1836 |
| major roles | #1837 |
| bdl | #1839 |
| mild | #1840 |
| reuptake | #1843 |
| neurological deterioration | #1844 |
| compared controls | #1845 |
| granule cells | #1846 |
| metalloproteinase9 | #1847 |
| γaminobutyric acid | #1849 |
| toxins | #1850 |
| regulatory processes | #1854 |
| capillary gas chromatography | #1856 |
| ammonium compounds | #1857 |
| chronic alcohol | #1857 |
| monoaminergic | #1862 |
| cirrhotic rats | #1863 |
| body water | #1865 |
| liver transplantation patients | #1865 |
| caudate | #1868 |
| cholinergic neurons | #1872 |
| stroke outcome | #1876 |
| immunoreactivities | #1877 |
| lactate production | #1877 |
| platelets patients | #1882 |
| disorder treatment | #1886 |
| neurotoxicity syndromes | #1886 |
| glutamate release | #1886 |
| beta endorphin | #1892 |
| acute | #1900 |
| locomotor activity | #1902 |
| hepatoprotective | #1903 |
| common feature | #1904 |
| induced liver | #1906 |
| atp adp | #1913 |
| induced rats | #1917 |
| cirrhosis biliary | #1919 |
| stereotyped | #1920 |
| penicillamine | #1920 |
| colorimetric assay | #1921 |
| patients cirrhosis | #1923 |
| rodent models | #1923 |
| grossly | #1925 |
| dipeptides | #1930 |
| behavioral abnormalities | #1932 |
| precipitated | #1934 |
| tspo | #1935 |
| nitration | #1937 |
| areas brain | #1941 |
| patients aids | #1944 |
| neurocognitive impairment | #1945 |
| major metabolite | #1952 |
| major site | #1957 |
| synthase | #1958 |
| dpat | #1961 |
| concomitant | #1962 |
| cerebral metabolism | #1965 |
| normal dogs | #1965 |
| acid transporters | #1966 |
| acid synthesis | #1966 |
| spectroscopy male | #1968 |
| manganese superoxide dismutase | #1970 |
| druginduced liver injury | #1977 |
| globus | #1977 |
| 5hydroxytryptamine | #1977 |
| nmethyldaspartate receptors | #1977 |
| mice compared | #1981 |
| 28 weeks | #1981 |
| degeneration humans | #1986 |
| potassium exchanging | #1987 |
| erk1 | #1990 |
| cognitive dysfunction | #1991 |
| duct ligation | #1991 |
| neurologic symptoms | #1991 |
| idazoxan | #1993 |
| oxotremorine | #1994 |
| ideal model | #1994 |
| 5 ht | #1996 |
| recirculating | #1997 |
| primary biliary | #2000 |
| radioligand | #2001 |
| 2fold increase | #2006 |
| mk801 | #2007 |
| ampa receptor | #2015 |
| heterogeneously | #2017 |
| cerebellar cortex | #2019 |
| overactivity | #2020 |
| injury mice | #2022 |
| arterio | #2023 |
| pet imaging | #2028 |
| glucose brain | #2034 |
| neurologic complications | #2036 |
| microdialysis | #2036 |
| aminoacids | #2036 |
| sham rats | #2036 |
| sham | #2040 |
| osmolytes | #2041 |
| peroneal nerve | #2041 |
| resonance nmr | #2043 |
| exchanging atpase | #2043 |
| cyclase | #2046 |
| cerebri | #2046 |
| pathogenetic mechanisms | #2047 |
| passive diffusion | #2050 |
| suggested | #2053 |
| groups iii | #2063 |
| decreased activity | #2064 |
| tracings | #2064 |
| 10 12 | #2068 |
| dawley rats | #2069 |
| convulsants | #2071 |
| stage liver | #2072 |
| vivo brain | #2074 |
| elucidated | #2077 |
| tumor necrosis factoralpha | #2079 |
| penumbra | #2080 |
| biochemical parameters | #2082 |
| deficit | #2084 |
| acetates | #2087 |
| transjugular intrahepatic | #2089 |
| trace amounts | #2090 |
| international society | #2094 |
| autopsy | #2098 |
| ensuing | #2103 |
| zo1 | #2106 |
| solely | #2108 |
| atrophies | #2109 |
| p0018 | #2111 |
| nitric oxide synthesis | #2117 |
| portal pressure | #2117 |
| chp | #2121 |
| parallel | #2121 |
| synthase type | #2125 |
| neurological manifestations | #2141 |
| ligase | #2142 |
| synergistically | #2143 |
| exception | #2143 |
| brain barrier | #2148 |
| subsequent degradation | #2149 |
| indicative | #2150 |
| rats spraguedawley | #2158 |
| bmax | #2158 |
| time onset | #2158 |
| intracranial pressure | #2167 |
| amnestic | #2169 |
| male rat | #2170 |
| muscimol | #2173 |
| acute effects | #2178 |
| human patients | #2179 |
| neural inhibition | #2180 |
| gaa | #2180 |
| reactive nitrogen | #2187 |
| subchronic | #2189 |
| blood csf | #2194 |
| apap | #2194 |
| increasing recognition | #2200 |
| cox2 | #2203 |
| overt | #2205 |
| parkinsonism | #2209 |
| methysergide | #2212 |
| homovanillic acid | #2217 |
| pressure icp | #2217 |
| vitamin supplements | #2220 |
| hypothermic | #2223 |
| nitroarginine methyl | #2223 |
| brain cells | #2225 |
| function brain | #2230 |
| antiparkinson | #2232 |
| liver enzymes | #2238 |
| minocycline | #2242 |
| pss | #2244 |
| chelators | #2245 |
| neurological disorders | #2248 |
| humans liver | #2249 |
| diminution | #2262 |
| blood brain | #2265 |
| symporters | #2265 |
| liver circulation | #2265 |
| doubt | #2267 |
| nutritional deficiencies | #2268 |
| messenger systems | #2271 |
| gliosis | #2279 |
| behavior rats | #2280 |
| additional factors | #2297 |
| synaptic vesicles | #2297 |
| rats liver | #2299 |
| phosphate | #2300 |
| eeg activity | #2302 |
| acrylamides | #2303 |
| patients minimal | #2304 |
| isoxazolepropionic | #2307 |
| immunoreactive neurons | #2308 |
| superoxide dismutase | #2314 |
| tle | #2315 |
| memantine | #2320 |
| multiorgan failure | #2322 |
| cortex hippocampus | #2325 |
| brain expression | #2326 |
| cultured cerebral | #2327 |
| systemic inflammatory response | #2328 |
| primary cultures | #2328 |
| male nerve | #2330 |
| blindly | #2333 |
| hrqol patients | #2334 |
| housekeeping | #2336 |
| acidosis | #2338 |
| relative increase | #2338 |
| convincing | #2340 |
| scatchard | #2349 |
| lactates | #2359 |
| binding assays | #2360 |
| ligands | #2360 |
| olivary | #2362 |
| benzoic | #2364 |
| inbred strains | #2366 |
| patients increased | #2373 |
| endstage liver disease | #2376 |
| synaptic dysfunction | #2377 |
| voluntary | #2377 |
| competitive inhibitor | #2380 |
| clinical condition | #2391 |
| mental fatigue | #2392 |
| deficiencies | #2392 |
| potential adverse effects | #2393 |
| exchanging | #2401 |
| brains patients | #2401 |
| neurotoxin | #2406 |
| homovanillic | #2416 |
| lnmma | #2430 |
| induced brain | #2432 |
| protein mrna | #2433 |
| transporter 2 | #2443 |
| calcium binding | #2449 |
| cerebral metabolic | #2467 |
| extracellular levels | #2471 |
| 01 mm | #2473 |
| histamine receptor | #2483 |
| fluorescence detection | #2489 |
| peripheral inflammation | #2490 |
| adult male rats | #2491 |
| bbb | #2498 |
| receptors ampa | #2502 |
| synaptic function | #2508 |
| pathogenic role | #2509 |
| count cell | #2510 |
| effects alcohol | #2511 |
| pyridinium | #2513 |
| animal model | #2513 |
| activation microglia | #2514 |
| noxious stimuli | #2518 |
| hypotonia | #2524 |
| vmax | #2529 |
| 5ht | #2530 |
| physical conditioning | #2532 |
| nuclear magnetic | #2534 |
| dopac | #2534 |
| metabolic acidosis | #2541 |
| expression endothelial | #2563 |
| alcohol induced | #2566 |
| male matrix | #2571 |
| fmol | #2572 |
| humans ligands | #2573 |
| understanding pathophysiology | #2573 |
| ataxias | #2577 |
| alpha1 | #2577 |
| receptor density | #2577 |
| vessel walls | #2581 |
| postmortem brain | #2588 |
| microglia neurons | #2591 |
| mao | #2594 |
| multiple mechanisms | #2597 |
| acetylcholinesterase | #2598 |
| cerebrospinal | #2601 |
| groups subjects | #2608 |
| il1β il6 | #2619 |
| possibility | #2621 |
| 10 microm | #2621 |
| cognitive motor | #2623 |
| 15–30 | #2625 |
| greater extent | #2626 |
| methylaspartate | #2630 |
| normalisation | #2632 |
| nitrosation | #2635 |
| biochemical evidence | #2639 |
| circulating concentrations | #2640 |
| deteriorating | #2640 |
| day treatment | #2647 |
| activity rats | #2661 |
| thalamic | #2663 |
| transcriptase | #2663 |
| katpase | #2665 |
| nitric | #2665 |
| chc | #2665 |
| binding competitive | #2668 |
| olfactory bulb | #2669 |
| glutathione levels | #2669 |
| osmolar | #2683 |
| patients alcoholic | #2684 |
| guanylyl cyclase | #2685 |
| glial cell | #2686 |
| serotonin 5 | #2689 |
| effects ethanol | #2695 |
| indwelling | #2704 |
| nerve terminals | #2705 |
| rats control | #2705 |
| laboratory findings | #2710 |
| groups animals | #2715 |
| lactic | #2723 |
| situ nickend | #2733 |
| publication animals behavior | #2737 |
| frontal lobe | #2742 |
| hemodiafiltration | #2755 |
| suggests | #2760 |
| glutaminase | #2764 |
| functional integrity | #2767 |
| regions | #2769 |
| 6hydroxydopamine | #2771 |
| neurons animals | #2774 |
| kindred | #2775 |
| leucine | #2779 |
| turnover rate | #2779 |
| 24h | #2786 |
| systemic circulation | #2789 |
| glutamate receptor | #2789 |
| animal rats | #2790 |
| rhythmicity | #2798 |
| amino acid | #2798 |
| severity patients | #2806 |
| osmolar concentration | #2813 |
| inbred strains mice | #2814 |
| pontine | #2817 |
| exposed | #2821 |
| mechanisms | #2824 |
| hydroxy5 | #2826 |
| microglial cells | #2827 |
| p38mapk | #2831 |
| gastrointestinal agents | #2833 |
| neurological deficit | #2834 |
| regulation enzymologic | #2834 |
| minneapolis | #2835 |
| blood brain barrier | #2841 |
| brain calcium | #2847 |
| marked decrease | #2867 |
| bilirubin | #2876 |
| twofold increase | #2877 |
| amino | #2882 |
| alcoholic fatty | #2882 |
| nerve cells | #2883 |
| alanine | #2885 |
| synaptic | #2888 |
| diabetic animals | #2890 |
| ca2dependent | #2893 |
| pet study | #2897 |
| mmt | #2898 |
| trafficking | #2901 |
| kainate | #2903 |
| slices | #2905 |
| rigidity | #2905 |
| standpoint | #2906 |
| ameliorating | #2910 |
| confirming | #2918 |
| clinical syndrome | #2931 |
| cell volume | #2936 |
| dying | #2938 |
| normal control | #2938 |
| normal animals | #2939 |
| subfield | #2943 |
| translocator | #2943 |
| 12 weeks treatment | #2944 |
| receptors opioid | #2962 |
| impaired | #2964 |
| 11c | #2965 |
| assist devices | #2970 |
| astrocytes cell | #2971 |
| brain uptake | #2974 |
| inflammation liver | #2982 |
| unaffected | #2982 |
| excitatory synapses | #3000 |
| pyruvic acid | #3000 |
| intermediary | #3008 |
| normal values | #3015 |
| aquaporin | #3036 |
| uptake | #3039 |
| kainic | #3043 |
| barrier brain | #3047 |
| cox2 expression | #3051 |
| incubation medium | #3051 |
| ca1 pyramidal | #3053 |
| biliary obstruction | #3054 |
| weighted magnetic | #3069 |
| concert | #3073 |
| tmp | #3076 |
| portosystemic shunt | #3078 |
| metabolite concentrations | #3078 |
| harmful effects | #3082 |
| attenuation | #3083 |
| selegiline | #3086 |
| activated microglia | #3088 |
| reserpine | #3093 |
| liver injury | #3095 |
| cd1 | #3099 |
| catecholaminergic | #3109 |
| atp levels | #3111 |
| adult rats | #3113 |
| renal vein | #3115 |
| valine | #3133 |
| short halflife | #3136 |
| toxic effects | #3137 |
| relative roles | #3149 |
| decreased | #3156 |
| myo inositol | #3161 |
| higher doses | #3168 |
| animals binding | #3169 |
| dhea | #3171 |
| nmda | #3172 |
| loss | #3180 |
| carboxamide | #3189 |
| failure | #3192 |
| endorphins | #3192 |
| relation | #3194 |
| abruptly | #3195 |
| radical scavengers | #3198 |
| inhalation | #3199 |
| bcaa | #3199 |
| mental retardation | #3201 |
| enzymologic genes | #3209 |
| clinical presentations | #3210 |
| ketanserin | #3214 |
| liver function | #3214 |
| heavy drinking | #3218 |
| coenzymes | #3220 |
| noradrenaline | #3224 |
| imidodiphosphate | #3226 |
| active transport | #3232 |
| portal | #3235 |
| gad | #3238 |
| shortchain fatty acids | #3238 |
| acidic | #3243 |
| synaptic membranes | #3244 |
| pyrophosphate | #3248 |
| induced hepatic | #3252 |
| treated rats | #3256 |
| nitrogen species | #3267 |
| systemic | #3276 |
| oxidative metabolism | #3281 |
| respects | #3285 |
| induced seizures | #3287 |
| synaptosomal | #3291 |
| drug repositioning | #3296 |
| behavioral symptoms | #3300 |
| water electrolyte | #3306 |
| kcl | #3307 |
| cell death | #3311 |
| metabolic alterations | #3324 |
| anterolateral | #3326 |
| reverse | #3327 |
| metabolized | #3331 |
| nanomolar concentrations | #3335 |
| sedatives | #3342 |
| general circulation | #3344 |
| nac | #3347 |
| dab | #3352 |
| rats received | #3359 |
| regionally | #3359 |
| benzoates | #3360 |
| membrane transport | #3361 |
| dosedependent fashion | #3364 |
| aspartate receptors | #3366 |
| rats inbred | #3368 |
| subsequent studies | #3371 |
| phenylalanine | #3384 |
| opioid | #3388 |
| cerebral ischemia | #3388 |
| inbred strains receptors | #3389 |
| cortex | #3391 |
| robust evidence | #3394 |
| hydroxytryptamine | #3402 |
| tyrphostins | #3403 |
| galactosamine | #3404 |
| brain disease | #3407 |
| brain lesions | #3412 |
| disturbances | #3421 |
| falls | #3421 |
| progressive increase | #3423 |
| histamine | #3423 |
| ldopa | #3426 |
| quaternary ammonium | #3427 |
| morphologic | #3428 |
| transaminases | #3432 |
| gln | #3436 |
| decreased levels | #3437 |
| modulation | #3439 |
| levels liver | #3443 |
| indole3 | #3446 |
| superior colliculus | #3451 |
| epilepsy temporal | #3453 |
| toxic | #3455 |
| strains mice | #3456 |
| biogenic | #3458 |
| accumulates | #3462 |
| timecourse | #3467 |
| phosphocreatine | #3473 |
| rats rats | #3474 |
| indomethacin | #3480 |
| striatum | #3482 |
| developing rat | #3485 |
| upregulation | #3491 |
| glycine | #3492 |
| brain stem | #3495 |
| liver male | #3497 |
| subcortical structures | #3497 |
| new evidence | #3499 |
| electrochemical detection | #3499 |
| basal ganglia | #3500 |
| rat models | #3503 |
| lobe epilepsy | #3503 |
| previous observations | #3507 |
| aids patients | #3511 |
| huntington | #3515 |
| dehydroepiandrosterone | #3537 |
| aging brain | #3542 |
| neurons oxidative | #3545 |
| rats treatment | #3545 |
| kidney liver | #3555 |
| tyramine | #3558 |
| fold | #3563 |
| cytokines disease | #3576 |
| nerve degeneration | #3584 |
| inferior vena cava | #3600 |
| portal vein | #3600 |
| tissue distribution | #3600 |
| brain structure | #3613 |
| truncated 250 | #3627 |
| antioxidant properties | #3627 |
| pathology | #3635 |
| prolonged exposure | #3636 |
| cofactor | #3636 |
| hypertonic saline | #3638 |
| disease states | #3648 |
| implication | #3650 |
| increased activity | #3655 |
| hydroxydopamine | #3657 |
| precipitating | #3664 |
| ache | #3664 |
| fatty liver | #3666 |
| investigator | #3675 |
| circadian rhythms | #3680 |
| scavengers | #3682 |
| lobe | #3694 |
| splanchnic | #3699 |
| regional variation | #3700 |
| arginine | #3718 |
| proinflammatory cytokine | #3722 |
| new model | #3723 |
| medial | #3735 |
| thioacetamide | #3741 |
| cassette transporters | #3742 |
| treated animals | #3746 |
| induced neurotoxicity | #3751 |
| stress rats | #3755 |
| normal mice | #3758 |
| consensus statement | #3765 |
| dopamine d1 | #3773 |
| 4 wk | #3786 |
| 1968 | #3791 |
| parietal lobe | #3793 |
| acetylcholinesterase ache | #3799 |
| dietary protein | #3801 |
| mitochondrion | #3807 |
| finding | #3814 |
| major | #3815 |
| neural cell | #3825 |
| diazepam | #3825 |
| control animals | #3825 |
| resemble | #3833 |
| western blot analyses | #3838 |
| systemically | #3846 |
| inborn errors | #3846 |
| prefrontal | #3857 |
| effects chronic | #3872 |
| nmr spectroscopy | #3879 |
| malabsorption | #3896 |
| type nitric | #3897 |
| dopamine d1 receptors | #3899 |
| dopa | #3907 |
| enhanced production | #3909 |
| metabolic pathway | #3911 |
| elucidate | #3914 |
| levels measured | #3915 |
| new therapeutic approaches | #3919 |
| nitric oxide production | #3919 |
| tone | #3924 |
| pindolol | #3929 |
| peripheral neuropathy | #3937 |
| ascorbate | #3942 |
| medulla | #3949 |
| csf | #3949 |
| reabsorption | #3949 |
| wet weight | #3951 |
| tourette | #3975 |
| neuropsychiatric disorders | #3978 |
| purkinje cells | #3983 |
| antiinflammatory | #3987 |
| complication | #3992 |
| fatigue | #3992 |
| tca cycle | #4003 |
| pseudotumor | #4006 |
| brain activation | #4009 |
| day 5 | #4011 |
| treatment prevention | #4021 |
| transporter | #4026 |
| elevated blood | #4053 |
| nmda receptors | #4053 |
| bz | #4054 |
| strains receptors | #4069 |
| neurotoxicity | #4070 |
| fischer | #4082 |
| cultured neurons | #4097 |
| remove | #4101 |
| gastrointestinal bleeding | #4103 |
| involve | #4104 |
| nonalcoholic | #4111 |
| intracranial | #4134 |
| coa | #4138 |
| visible spectrum | #4140 |
| induced mitochondrial | #4149 |
| exacerbate | #4165 |
| lower affinity | #4172 |
| motor activity | #4178 |
| future clinical trials | #4178 |
| reverse transcriptase | #4185 |
| nitroso | #4190 |
| nuclear magnetic resonance | #4193 |
| oxide production | #4198 |
| ampa | #4204 |
| endothelial nitric | #4205 |
| liver cirrhosis | #4232 |
| steadystate levels | #4244 |
| knockout receptors | #4249 |
| enkephalins | #4276 |
| tips | #4318 |
| isoenzymes | #4321 |
| pathogenetic | #4326 |
| contention | #4326 |
| 3h | #4342 |
| oxidase inhibitors | #4346 |
| female frontal | #4355 |
| alcohol abuse | #4357 |
| matched | #4358 |
| chelator | #4359 |
| vitro model | #4364 |
| groups rats | #4365 |
| acids | #4373 |
| chorea | #4373 |
| geniculate | #4374 |
| prevention | #4375 |
| ratelimiting enzyme | #4382 |
| neocortical | #4398 |
| rtpcr | #4402 |
| mrna expression | #4418 |
| hepatic artery | #4425 |
| enos | #4425 |
| immunohistochemical analysis | #4428 |
| peripherally | #4430 |
| postnatally | #4433 |
| 10 micrograms | #4438 |
| specific activities | #4449 |
| carbon isotopes | #4449 |
| acid amino | #4455 |
| inos | #4460 |
| tetrahydrobiopterin | #4480 |
| diencephalon | #4481 |
| citric | #4487 |
| agents steroidal | #4499 |
| isoleucine | #4507 |
| chemical drug | #4509 |
| incompletely | #4517 |
| hippocampal neurons | #4518 |
| endogenously | #4521 |
| potent inhibitor | #4528 |
| pglycoprotein | #4535 |
| tissue concentrations | #4552 |
| model chronic | #4561 |
| animal studies | #4562 |
| gssg | #4562 |
| mitochondrial dysfunction | #4575 |
| substantia nigra | #4577 |
| neurological function | #4585 |
| explanation | #4600 |
| acetaminophen | #4606 |
| transaminase | #4608 |
| 250 | #4627 |
| small increase | #4629 |
| liver diseases | #4637 |
| mrna | #4639 |
| narcotic | #4643 |
| models neurological | #4666 |
| enzymes | #4671 |
| myo | #4677 |
| dopamine | #4679 |
| choline | #4683 |
| nitrites | #4684 |
| worsening | #4685 |
| tremor | #4694 |
| relate | #4701 |
| ho1 | #4704 |
| diphosphate | #4705 |
| neuronal survival | #4712 |
| develops | #4714 |
| realtime quantitative pcr | #4719 |
| techniques male | #4729 |
| key enzymes | #4730 |
| debilitating | #4732 |
| skeletal muscle | #4736 |
| amines | #4737 |
| receptors tumor | #4740 |
| motor coordination | #4745 |
| patients liver cirrhosis | #4749 |
| neurovascular | #4749 |
| triphosphate | #4752 |
| receptors | #4761 |
| apoptotic cell death | #4774 |
| patients liver | #4775 |
| neuroprotective agents | #4778 |
| mn2 | #4792 |
| male rats | #4793 |
| ulnar | #4795 |
| opioid peptides | #4821 |
| ganglia | #4828 |
| failing | #4835 |
| membrane cells | #4837 |
| liver regeneration | #4853 |
| constellation | #4875 |
| regional cerebral | #4875 |
| nonselective | #4891 |
| opioid receptors | #4901 |
| modulator | #4905 |
| transporters | #4906 |
| tyrosine | #4906 |
| 001 | #4915 |
| animals antioxidants | #4919 |
| injections intraperitoneal | #4921 |
| neurons rats | #4927 |
| glucose humans | #4936 |
| epilepsy humans | #4940 |
| degree | #4943 |
| kainic acid | #4963 |
| evident | #4988 |
| rapid progression | #4996 |
| viral hepatitis | #4998 |
| indazoles | #5000 |
| methyl2 | #5002 |
| clinical conditions | #5004 |
| 25 mm | #5009 |
| ammonium | #5017 |
| acid metabolism | #5018 |
| neurological diseases | #5024 |
| raphe | #5043 |
| consequences | #5048 |
| immunostaining | #5051 |
| weighted mri | #5053 |
| offspring | #5054 |
| tight | #5055 |
| alcoholism | #5063 |
| cyclooxygenase2 | #5066 |
| malnutrition | #5080 |
| metabolism | #5084 |
| suggesting | #5106 |
| endoperoxide | #5129 |
| clinical criteria | #5130 |
| acid | #5133 |
| nitric oxide | #5140 |
| disorder | #5143 |
| sarcopenia | #5163 |
| anticonvulsant | #5164 |
| glial cells | #5213 |
| temporal lobe | #5226 |
| leads | #5232 |
| animals | #5236 |
| portal hypertension | #5238 |
| child pugh | #5266 |
| severe | #5277 |
| sustained | #5277 |
| normal rats | #5278 |
| cerebrum | #5280 |
| organ dysfunction | #5288 |
| cerebrospinal fluid | #5299 |
| animal brain | #5308 |
| restores | #5312 |
| reversal | #5325 |
| methylarginine | #5330 |
| intoxication | #5344 |
| major impact | #5349 |
| 4 groups | #5350 |
| animal humans | #5364 |
| biomarkers brain | #5401 |
| gastroenterology | #5403 |
| experimental model | #5414 |
| superoxide production | #5416 |
| publication animals | #5417 |
| presynaptic | #5426 |
| induced acute | #5434 |
| regional brain | #5435 |
| gastrointestinal diseases | #5444 |
| intracellular levels | #5450 |
| postsynaptic | #5452 |
| concentrations | #5459 |
| food deprivation | #5463 |
| focal | #5466 |
| blotting western | #5466 |
| thioredoxins | #5505 |
| halflife | #5506 |
| aquaporins | #5515 |
| involving | #5517 |
| cns | #5517 |
| effects exposure | #5523 |
| nash | #5525 |
| controls | #5541 |
| catecholamines | #5549 |
| isolated rat | #5552 |
| affinity | #5553 |
| tca | #5564 |
| glucose metabolism | #5569 |
| lack | #5572 |
| higher density | #5575 |
| sleep disturbances | #5580 |
| hyperbilirubinemia | #5586 |
| glucose transport | #5607 |
| n11 | #5608 |
| summarizes | #5611 |
| platelets | #5615 |
| endotoxemia | #5639 |
| major complications | #5645 |
| free radicals | #5647 |
| postnatal development | #5651 |
| magnetic resonance images | #5652 |
| cachexia | #5666 |
| acute ischemic | #5672 |
| drinkers | #5693 |
| antimetabolites | #5699 |
| tnf | #5709 |
| 73 patients | #5711 |
| transport systems | #5712 |
| receptor binding | #5730 |
| 24 hours | #5741 |
| icp | #5768 |
| evidence base | #5790 |
| precipitate | #5790 |
| dehydrogenases | #5796 |
| nonalcoholic steatohepatitis | #5796 |
| p005 | #5800 |
| brain animals | #5810 |
| depolarization | #5812 |
| aspartate receptor | #5824 |
| serotonin | #5840 |
| substances | #5848 |
| prefrontal cortex | #5859 |
| extravasation | #5862 |
| steroidal | #5865 |
| neuroprotective | #5883 |
| levels elevated | #5885 |
| ketone | #5892 |
| western blot analysis | #5897 |
| appropriately | #5900 |
| mounting evidence | #5926 |
| enkephalin | #5928 |
| potentiate | #5945 |
| detoxification | #5949 |
| acrylamide | #5950 |
| disaccharides | #5950 |
| acid antagonists | #5952 |
| 100 microm | #5954 |
| background objectives | #5954 |
| bulb | #5976 |
| metabolites | #5993 |
| muscle mass | #5993 |
| coenzyme | #5994 |
| etiologies | #5997 |
| anterior cingulate cortex | #6016 |
| antagonist | #6019 |
| butyric | #6023 |
| reversible | #6029 |
| aged rats | #6030 |
| sodium potassium | #6068 |
| additional evidence | #6080 |
| transporter 1 | #6103 |
| methyl4 | #6109 |
| zona | #6114 |
| chemistry | #6120 |
| occurs | #6122 |
| barrier | #6138 |
| trh | #6148 |
| cirrhosis patients | #6152 |
| postmortem | #6152 |
| cortical regions | #6162 |
| hippocampus | #6166 |
| hydroperoxide | #6169 |
| deoxyglucose | #6171 |
| risk bias | #6188 |
| inbred | #6199 |
| esters | #6202 |
| proteins rats | #6221 |
| reduction oxidative | #6231 |
| nervous cns | #6235 |
| disruptions | #6250 |
| vascular endothelium | #6265 |
| anti inflammatory | #6284 |
| mitochondrial function | #6287 |
| hematoxylin | #6290 |
| lactate dehydrogenase | #6298 |
| chain | #6315 |
| carboxylase | #6322 |
| alpha2 | #6323 |
| protein expression | #6343 |
| induced increases | #6360 |
| 20 cases | #6371 |
| rna messenger | #6388 |
| dha | #6392 |
| cbf | #6404 |
| gamma | #6412 |
| remained | #6413 |
| chelating agents | #6422 |
| olfactory | #6441 |
| prosencephalon | #6456 |
| snap | #6464 |
| rats animals | #6469 |
| roi | #6470 |
| antagonists | #6475 |
| peripheral nerve | #6478 |
| histidine | #6482 |
| acyltransferases | #6490 |
| patients chronic | #6498 |
| mesencephalon | #6508 |
| notion | #6511 |
| disease brain | #6514 |
| bromocriptine | #6531 |
| ingestion | #6548 |
| ligation | #6552 |
| dopaminergic | #6553 |
| humans kinetics | #6566 |
| control mice | #6572 |
| longterm treatment | #6575 |
| nomenclature | #6576 |
| disease aged | #6579 |
| physiological function | #6586 |
| humans mitochondria | #6594 |
| oxidase | #6596 |
| microg | #6596 |
| led | #6597 |
| accumulation | #6599 |
| fluid csf | #6600 |
| mmol | #6609 |
| animal dose | #6610 |
| glycolytic | #6625 |
| publication analysis | #6642 |
| inducible nitric | #6643 |
| resonance spectroscopy | #6660 |
| glu | #6665 |
| lowers | #6665 |
| animals bile | #6671 |
| slowing | #6682 |
| p001 | #6684 |
| patients placebo | #6688 |
| proceedings | #6700 |
| interferongamma | #6742 |
| differential effects | #6755 |
| poisoning | #6767 |
| granule | #6768 |
| dystonia | #6769 |
| psychometric | #6774 |
| lad | #6783 |
| rats wistar receptors | #6791 |
| biological transport | #6801 |
| specific regions | #6806 |
| transport proteins | #6806 |
| cortices | #6825 |
| nitrates | #6833 |
| inflammatory processes | #6849 |
| n5 | #6849 |
| protects | #6857 |
| receptors dopamine | #6859 |
| tomography emission | #6887 |
| acetaldehyde | #6894 |
| enter | #6908 |
| patients brain | #6909 |
| sleep disorders | #6915 |
| mitochondrial membrane | #6916 |
| nutritional | #6921 |
| hypothalamus | #6930 |
| humans intracranial | #6937 |
| nutrition | #6972 |
| rendered | #6975 |
| cerebral blood flow | #6981 |
| low affinity | #6986 |
| acid levels | #7005 |
| eosin | #7011 |
| vitamins | #7012 |
| ascites | #7020 |
| adenosine triphosphate | #7030 |
| patients alzheimer | #7040 |
| compensatory | #7089 |
| free radical | #7092 |
| rois | #7098 |
| common form | #7109 |
| general agreement | #7117 |
| expression | #7125 |
| prothrombin | #7133 |
| mice treated | #7139 |
| synthases | #7140 |
| 13c nmr | #7146 |
| methyl | #7151 |
| hippocampus male | #7165 |
| methyl ester | #7177 |
| tartrate | #7178 |
| levels blood | #7198 |
| central nervous cns | #7202 |
| protective agents | #7214 |
| catecholamine | #7216 |
| undertaken | #7226 |
| probiotics | #7244 |
| humans inflammation | #7253 |
| systemic inflammation | #7280 |
| antiinflammatory agents | #7284 |
| neurodegeneration | #7290 |
| male sprague | #7307 |
| bile duct | #7311 |
| additional studies | #7322 |
| animal doseresponse relationship | #7334 |
| nh4 | #7336 |
| glucose transporter | #7337 |
| cyclooxygenase 2 | #7344 |
| life hrqol | #7350 |
| administration | #7353 |
| preliminary evidence | #7358 |
| symptomatic | #7371 |
| neuroprotection | #7374 |
| histamine release | #7378 |
| regional | #7382 |
| urea | #7386 |
| hippocampal | #7389 |
| insult | #7392 |
| pyridines | #7404 |
| intravenous infusion | #7420 |
| competitive | #7424 |
| animal | #7433 |
| excitability | #7442 |
| molecular mechanisms | #7448 |
| restored | #7464 |
| spectrophotometric | #7474 |
| osmotic | #7475 |
| biochemical studies | #7481 |
| ht | #7485 |
| excreted | #7507 |
| urease | #7536 |
| organ specificity | #7540 |
| lipid peroxidation | #7550 |
| pathological conditions | #7553 |
| dismutase | #7553 |
| brain ischemia | #7557 |
| implicating | #7564 |
| onset | #7570 |
| cytoprotection | #7580 |
| neuropathic pain | #7583 |
| imaging magnetic | #7585 |
| chromatography mass | #7603 |
| microglia | #7605 |
| matrix metalloproteinase | #7621 |
| mental status | #7630 |
| blood platelets | #7640 |
| characterized | #7659 |
| neuroprotective effects | #7659 |
| deleterious | #7665 |
| neurologic examination | #7672 |
| cortical neurons | #7687 |
| diminished | #7696 |
| specific binding | #7700 |
| guanidines | #7737 |
| perturbations | #7769 |
| alpha tnf | #7777 |
| oxide | #7779 |
| immunoreactivity | #7801 |
| oedema | #7810 |
| il6 levels | #7833 |
| tissue proteins | #7854 |
| tnf α | #7864 |
| animals blotting | #7882 |
| albumins | #7888 |
| m3 | #7897 |
| ca1 | #7899 |
| parietal cortex | #7915 |
| brain development | #7915 |
| cells brain | #7932 |
| freely | #7932 |
| lname | #7950 |
| aspartate aminotransferases | #7961 |
| assayed | #7986 |
| metabolic | #7989 |
| aetiology | #8016 |
| mouse brain | #8023 |
| alzheimer | #8025 |
| liver transplantation | #8033 |
| ka | #8038 |
| constitutes | #8040 |
| computerized | #8040 |
| organometallic compounds | #8052 |
| established | #8056 |
| brain humans | #8073 |
| cerebrovascular circulation | #8079 |
| chelation | #8081 |
| inferior | #8097 |
| reproduces | #8103 |
| modulate | #8143 |
| confirm | #8153 |
| produces | #8156 |
| large variety | #8164 |
| intraperitoneally | #8167 |
| immunohistochemistry male | #8184 |
| maintained | #8185 |
| benzazepines | #8192 |
| organs | #8193 |
| fluorescence intensity | #8201 |
| reduced | #8207 |
| neurologic | #8214 |
| dopamine receptor | #8253 |
| abnormally | #8260 |
| norepinephrine | #8288 |
| inflammatory agents | #8301 |
| neuronal damage | #8302 |
| antioxidant | #8310 |
| condition | #8326 |
| dependent | #8332 |
| therapeutic implications | #8336 |
| epileptic | #8359 |
| chromatography pressure | #8383 |
| turn | #8404 |
| gray matter | #8407 |
| reflect | #8410 |
| and or | #8413 |
| wistar receptors | #8433 |
| receptor expression | #8442 |
| chain reaction | #8446 |
| hyponatremia | #8454 |
| plasma levels | #8470 |
| citalopram | #8472 |
| hyperglycemia | #8472 |
| stereotaxic | #8495 |
| systemic inflammatory | #8499 |
| polymerase chain | #8501 |
| purkinje | #8517 |
| immunocytochemical | #8519 |
| brain imaging | #8538 |
| chloride | #8546 |
| copper | #8549 |
| intracellular ca2 | #8583 |
| restoration | #8595 |
| hepatotoxicity | #8598 |
| ischemia | #8616 |
| activates | #8631 |
| hippocampus humans | #8641 |
| oxide nitric | #8664 |
| levodopa | #8665 |
| n10 | #8672 |
| inflammatory cytokines | #8690 |
| male middle aged | #8715 |
| organometallic | #8716 |
| pyramidal cells | #8724 |
| retardation | #8736 |
| gsh | #8742 |
| oxidative | #8742 |
| 37°c | #8758 |
| emission computed | #8767 |
| parietal | #8790 |
| potassium chloride | #8814 |
| hplc | #8824 |
| nmr | #8871 |
| superoxide | #8875 |
| tonic | #8879 |
| sulfates | #8892 |
| devoid | #8898 |
| egf receptor | #8905 |
| lactic acid | #8906 |
| minimal | #8910 |
| caveolin | #8912 |
| oxo | #8932 |
| biochemical | #8935 |
| consciousness | #8985 |
| reflected | #9011 |
| intravenous injection | #9019 |
| alanine transaminase | #9038 |
| encephalitis | #9077 |
| emission tomography | #9083 |
| methylmercury | #9099 |
| aminotransferases | #9108 |
| acetate | #9111 |
| syndromes | #9112 |
| brain cognition | #9130 |
| aimed | #9163 |
| awake | #9175 |
| 62 patients | #9176 |
| likewise | #9181 |
| treated mice | #9194 |
| normal | #9207 |
| dysfunction | #9218 |
| corpus striatum | #9247 |
| key factors | #9254 |
| elevated | #9263 |
| deprived | #9285 |
| neuropathy | #9344 |
| cerebrospinal fluid csf | #9364 |
| cerebral blood | #9391 |
| pressure liquid | #9396 |
| deoxy | #9420 |
| immunoblotting | #9445 |
| complications patients | #9489 |
| citric acid | #9505 |
| intrahepatic | #9572 |
| oxidative stress | #9585 |
| irreversible | #9607 |
| naloxone | #9609 |
| synthase inos | #9615 |
| absence | #9615 |
| occipital | #9621 |
| neurons | #9627 |
| seizures | #9631 |
| terminals | #9647 |
| nerve tissue | #9655 |
| postoperative day | #9682 |
| compensate | #9687 |
| micromol | #9692 |
| imaging studies | #9718 |
| ameliorated | #9722 |
| bw | #9727 |
| protective effects | #9749 |
| 2 mm | #9756 |
| 064 | #9783 |
| neuro | #9788 |
| tumor necrosis | #9791 |
| middle cerebral | #9809 |
| chelating | #9823 |
| dependently | #9825 |
| patch clamp | #9830 |
| succinate | #9834 |
| diseases liver | #9842 |
| prevented | #9863 |
| severely | #9864 |
| contributes | #9880 |
| receptor agonist | #9912 |
| microm | #9930 |
| necrosis factor | #9933 |
| quantitative | #9943 |
| tight junctions | #9963 |
| liver cells | #9987 |
| neurobiological | #10000 |
| binding cassette | #10002 |
| central nervous | #10003 |
| conflicting | #10023 |
| kinetic parameters | #10033 |
| cycle | #10052 |
| mediated | #10072 |
| cortical | #10128 |
| cava | #10136 |
| dopamine receptors | #10169 |
| liver damage | #10178 |
| negative impact | #10202 |
| minerals | #10211 |
| stores | #10215 |
| ros production | #10235 |
| attenuated | #10240 |
| expression activity | #10242 |
| cgmp | #10262 |
| glutathione gsh | #10266 |
| transport complex | #10286 |
| plasma concentrations | #10292 |
| plasma patients | #10296 |
| urinary excretion | #10301 |
| adversely | #10328 |
| vitamin deficiency | #10328 |
| forebrain | #10337 |
| cassette | #10370 |
| permeable | #10373 |
| specific activity | #10384 |
| electroencephalogram | #10395 |
| steatohepatitis | #10395 |
| areas | #10419 |
| subacute | #10435 |
| biliary | #10436 |
| protein levels | #10453 |
| liver transplant | #10455 |
| hrqol | #10455 |
| nigra | #10479 |
| cerebral artery | #10481 |
| positron emission tomography | #10525 |
| biosynthesis | #10531 |
| substantia | #10550 |
| nervous | #10616 |
| transmitter | #10626 |
| twofold | #10627 |
| management patients | #10657 |
| lipopolysaccharide | #10674 |
| alzheimers disease | #10694 |
| dose dependent | #10699 |
| normal range | #10730 |
| protein level | #10752 |
| nutritional status | #10752 |
| quaternary | #10765 |
| glutathione | #10772 |
| glucose | #10806 |
| water content | #10826 |
| monophosphate | #10827 |
| liver mice | #10852 |
| vena | #10853 |
| nervous diseases | #10861 |
| microgram | #10880 |
| performance liquid | #10883 |
| entity | #10889 |
| eventually | #10941 |
| intraventricular | #10958 |
| occur | #10968 |
| saline | #10968 |
| dietary proteins | #10978 |
| breakdown | #10983 |
| earlier studies | #10997 |
| etiology | #10998 |
| doses | #11003 |
| accumbens | #11004 |
| impair | #11006 |
| rats inbred strains | #11023 |
| radioimmunoassay | #11026 |
| behavior animal | #11026 |
| atrophy | #11041 |
| tnfalpha | #11044 |
| atp binding | #11055 |
| tests male | #11061 |
| western | #11061 |
| peroxidation | #11077 |
| riboflavin | #11140 |
| positron emission | #11153 |
| potentiated | #11172 |
| preparations | #11184 |
| precursor | #11188 |
| adult male | #11195 |
| broad spectrum | #11196 |
| superoxides | #11202 |
| nick | #11227 |
| steroids | #11232 |
| animals anti | #11234 |
| acyl | #11314 |
| enzyme activity | #11342 |
| drug induced | #11347 |
| early identification | #11376 |
| neuropathic | #11380 |
| necrotic | #11392 |
| neurodegenerative disease | #11395 |
| centrally | #11415 |
| depletion | #11434 |
| major component | #11447 |
| clinical signs | #11463 |
| 3 weeks | #11495 |
| receptor antagonist | #11502 |
| animals disease | #11503 |
| complications | #11504 |
| alteration | #11581 |
| il1β | #11649 |
| trp | #11651 |
| prostaglandins | #11656 |
| survival cells | #11657 |
| kd | #11671 |
| dogs | #11676 |
| gut | #11676 |
| alcohol | #11740 |
| wilson | #11741 |
| dentate | #11769 |
| disappearance | #11773 |
| receptor antagonists | #11774 |
| ibuprofen | #11820 |
| neuron | #11824 |
| radiopharmaceuticals | #11825 |
| appears | #11872 |
| pigs | #11917 |
| inherited | #11924 |
| organ size | #11944 |
| mild cognitive impairment | #11954 |
| pyramidal | #12051 |
| corpus callosum | #12054 |
| gasoline | #12095 |
| aged alzheimer | #12101 |
| circulating levels | #12111 |
| carrier proteins | #12112 |
| reactive | #12134 |
| severity | #12227 |
| receptor activation | #12230 |
| blotting | #12274 |
| huntington disease | #12346 |
| infusions | #12347 |
| electrophysiological | #12375 |
| elevation | #12412 |
| aphasia | #12425 |
| emerging evidence | #12434 |
| atpase | #12447 |
| subclinical | #12476 |
| nh3 | #12499 |
| aminotransferase | #12509 |
| peripheral nervous | #12515 |
| absorbed | #12546 |
| cyclooxygenase | #12569 |
| exerts | #12573 |
| scavenger | #12589 |
| bile ducts | #12634 |
| c57bl 6 | #12683 |
| publisher | #12687 |
| chlorides | #12701 |
| reversed | #12782 |
| subcellular fractions | #12790 |
| inositol | #12832 |
| neuronal death | #12840 |
| measured | #12864 |
| intraperitoneal | #12878 |
| disorders | #12899 |
| cultured cells | #12900 |
| tnf alpha | #12912 |
| mediate | #12984 |
| mars | #13100 |
| slowly | #13118 |
| vesicular | #13121 |
| lesser | #13134 |
| pretreatment | #13141 |
| cerebral infarction | #13141 |
| therapeutic strategies | #13143 |
| basal | #13155 |
| 005 | #13194 |
| positron | #13197 |
| tomography pet | #13207 |
| circadian | #13222 |
| md | #13224 |
| caused | #13226 |
| hypotheses | #13238 |
| infused | #13242 |
| ischemic | #13289 |
| subjected | #13291 |
| methionine | #13299 |
| disrupted | #13336 |
| animals biomarkers | #13337 |
| normal controls | #13360 |
| anticonvulsants | #13440 |
| downregulation | #13444 |
| neurodegenerative | #13467 |
| reduction | #13499 |
| 23 patients | #13506 |
| chronic | #13511 |
| histocytochemistry | #13552 |
| psychomotor | #13555 |
| tissue | #13620 |
| sodium | #13631 |
| interleukin1 | #13734 |
| alpha | #13754 |
| cerebrovascular | #13767 |
| agonist | #13768 |
| partially | #13885 |
| oxidant | #13907 |
| postural | #13923 |
| mainstay | #13926 |
| sulfate | #13971 |
| nerve | #14045 |
| necrosis | #14050 |
| improvement | #14081 |
| gray | #14104 |
| hypothesize | #14117 |
| μmol | #14145 |
| skeletal | #14152 |
| exposure | #14214 |
| alcohol drinking | #14214 |
| electroencephalography | #14223 |
| sulfhydryl | #14242 |
| glia | #14250 |
| deficient mice | #14274 |
| blot analysis | #14352 |
| cytokine production | #14379 |
| multifactorial | #14398 |
| p002 | #14416 |
| damage | #14417 |
| enzyme inhibitors | #14422 |
| normalized | #14430 |
| dinoprostone | #14442 |
| permanent | #14471 |
| limbic | #14474 |
| cingulate | #14502 |
| healthrelated quality | #14573 |
| release | #14673 |
| 11 patients | #14695 |
| pge2 | #14705 |
| male | #14712 |
| ethanol | #14751 |
| chronic disease | #14773 |
| alzheimer disease | #14778 |
| cell count | #14785 |
| learning memory | #14831 |
| triphosphate animals | #14839 |
| vivo studies | #14851 |
| understood | #14879 |
| uric | #14905 |
| nmol | #14931 |
| agonists | #14948 |
| subcortical | #14957 |
| imbalance | #14958 |
| weighted | #15064 |
| manifestations | #15066 |
| lactation | #15115 |
| psychiatric | #15192 |
| creatine | #15221 |
| fluid | #15257 |
| cytokines | #15272 |
| triphosphatases | #15273 |
| intake | #15351 |
| protein tyrosine | #15367 |
| tissues | #15409 |
| localized | #15466 |
| ester | #15533 |
| synapses | #15538 |
| intellectual | #15568 |
| 042 | #15583 |
| evoked potentials | #15595 |
| prophylaxis | #15602 |
| clamp | #15646 |
| drinking | #15676 |
| sclerosis | #15727 |
| cholestasis | #15758 |
| nafld | #15783 |
| adenosine | #15804 |
| signs | #15804 |
| hypothesis | #15809 |
| trace | #15853 |
| chromatography | #15875 |
| exert | #15905 |
| appeared | #15927 |
| degeneration | #15939 |
| subcutaneously | #15941 |
| vivo vitro | #16006 |
| magnetic resonance | #16007 |
| reflects | #16036 |
| killed | #16092 |
| released | #16133 |
| parkinsons disease | #16161 |
| plays | #16220 |
| randomized controlled | #16247 |
| therapeutic | #16276 |
| 0001 | #16290 |
| hepatectomy | #16303 |
| muscle skeletal | #16331 |
| 1 week | #16336 |
| dorsal | #16343 |
| symptoms | #16440 |
| cytosolic | #16446 |
| aspect | #16495 |
| hepatitis chronic | #16549 |
| 5 | #16588 |
| transport | #16615 |
| abnormalities | #16625 |
| nucleus accumbens | #16636 |
| induction | #16656 |
| inadequate | #16667 |
| involves | #16686 |
| hepatocyte | #16740 |
| psychometrics | #16793 |
| decreasing | #16803 |
| cd40 | #16918 |
| random allocation | #16959 |
| pet | #17001 |
| mechanism | #17020 |
| spontaneous | #17046 |
| folic | #17100 |
| 10 patients | #17114 |
| organ | #17129 |
| 05 | #17137 |
| administered | #17168 |
| impairment | #17220 |
| transported | #17290 |
| reduces | #17300 |
| prominent | #17312 |
| publication aged aged | #17315 |
| tnfα | #17356 |
| diagnose | #17452 |
| humans | #17580 |
| parkinson | #17599 |
| mitochondrial | #17645 |
| incubation | #17654 |
| evoked | #17725 |
| modulates | #17799 |
| stimulatory | #17860 |
| commonly | #17870 |
| spectroscopy | #18016 |
| alter | #18029 |
| removed | #18045 |
| pharmacological | #18082 |
| 21 patients | #18092 |
| enzyme | #18126 |
| cognition disorders | #18188 |
| adult brain | #18254 |
| hepatocytes | #18338 |
| prevent | #18353 |
| blood samples | #18374 |
| moderately | #18395 |
| putative | #18427 |
| partly | #18450 |
| suffer | #18502 |
| stimulate | #18563 |
| animals biological | #18741 |
| neurodegenerative diseases | #18774 |
| depressed | #18788 |
| metalloproteinase | #18921 |
| vein | #19240 |
| ascorbic | #19380 |
| plasma | #19440 |
| 7 | #19485 |
| blot | #19526 |
| correlated | #19582 |
| membrane potentials | #19625 |
| serves | #19635 |
| depleted | #19648 |
| neuropsychological tests | #19672 |
| traumatic brain injury | #19727 |
| mm | #19825 |
| animals calcium | #19827 |
| soluble | #20005 |
| acetic | #20054 |
| frequently | #20106 |
| tumor necrosis factor | #20133 |
| serine | #20180 |
| dosedependent manner | #20198 |
| vitro techniques | #20371 |
| controversial | #20390 |
| motor | #20407 |
| radical | #20464 |
| ventral | #20527 |
| micrograms | #20674 |
| circulation | #20783 |
| raised | #20843 |
| inducible | #20861 |
| hypothalamic | #20873 |
| oxidation reduction | #20882 |
| counts | #20909 |
| brain mapping | #21000 |
| reactive oxygen | #21049 |
| 16 patients | #21061 |
| underlying mechanisms | #21109 |
| weeks | #21219 |
| labeled | #21292 |
| rodent | #21335 |
| method female | #21700 |
| maximal | #21940 |
| species ros | #22112 |
| vivo | #22128 |
| blood | #22216 |
| response relationship | #22303 |
| inflammation | #22526 |
| 073 | #22553 |
| induced cell | #22589 |
| 13 patients | #22656 |
| activation | #23016 |
| sufficient | #23212 |
| male membrane | #23275 |
| imaging mri | #23302 |
| gastrointestinal | #23302 |
| inflammatory | #23317 |
| intravenously | #23392 |
| infusions intravenous | #23567 |
| releasing | #23665 |
| magnetic resonance imaging | #23801 |
| intracellular | #24009 |
| cellular | #24252 |
| reducing | #24301 |
| c57bl | #24413 |
| correlate | #24434 |
| displayed | #24599 |
| unable | #24707 |
| 096 | #24715 |
| assess | #24780 |
| 12 patients | #24814 |
| activity | #25360 |
| body | #25376 |
| acquired | #25673 |
| modify | #25866 |
| limiting | #25928 |
| inhibit | #26079 |
| inbred c57bl | #26079 |
| modulated | #26122 |
| remain | #26178 |
| immunohistochemical | #26211 |
| cognitive | #26948 |
| represents | #26971 |
| management | #27196 |
| reflecting | #27352 |
| mental | #27490 |
| improves | #27652 |
| preventing | #27673 |
| behavioral | #27813 |
| hydrogen ion | #28292 |
| concluded | #28335 |
| proven | #28570 |
| aims | #28575 |
| evaluate | #28931 |
| proteins mice | #28975 |
| ion concentration | #29194 |
| magnetic | #29339 |
| mechanisms underlying | #29900 |
| subcellular | #29913 |
| mice inbred | #30075 |
| stained | #30210 |
| quantitatively | #30454 |
| arterial | #30516 |
| abnormal | #30579 |
| corrected | #30667 |
| humans hydrogen | #30710 |
| demonstrated | #30993 |
| sensitive | #31344 |
| resonance | #31346 |
| induces | #31608 |
| cultured | #31958 |
| enzyme activation | #32060 |
| markedly | #32813 |
| animals apoptosis | #33677 |
| remains | #34554 |
| unclear | #34875 |
| subsequent | #35401 |
| hypothesized | #36243 |
| treated | #36316 |
| inhibited | #36986 |
| linked | #37013 |
| inbred c57bl mice | #39261 |
| induce | #39552 |
| aged | #56385 |
Rapport d'exécution | |
Prominent publications by Roger F Butterworth∗
Region selective alterations of soluble guanylate cyclase content and modulation in brain of cirrhotic patients
[ PUBLICATION ]
Modulation of soluble guanylate cyclase (sGC) by nitric oxide (NO) is altered in brain from experimental animals with hyperammonemia with or without liver failure. The aim of this work was to assess the content and modulation of sGC in brain in chronic liver failure in humans. Expression of the alpha-1, alpha-2, and beta-1 subunits of sGC was measured by immunoblotting in autopsied frontal cortex and cerebellum from cirrhotic patients and controls. The contents of alpha-1 and alpha-2 ...
| Connu pour Guanylate Cyclase | Cirrhotic Patients | Modulation Sgc | Nitric Oxide Brain | Cerebellum Activation |
Hypothermia attenuates oxidative/nitrosative stress, encephalopathy and brain edema in acute (ischemic) liver failure
[ PUBLICATION ]
Encephalopathy and brain edema are serious complications of acute liver failure (ALF). The precise pathophysiologic mechanisms responsible have not been fully elucidated but it has been suggested that oxidative/nitrosative stress is involved. In the present study we evaluated the role of oxidative/nitrosative stress in the pathogenesis of hepatic encephalopathy and brain edema in rats with ALF resulting from hepatic devascularization. We also studied the effect of hypothermia, a ...
| Connu pour Brain Edema | Alf Rats | Nitrosative Stress | Liver Failure | Coma Stages |
KOL-Index: 13463
Acute liver failure (ALF) results in alterations of energy metabolites and of glucose-derived amino acid neurotransmitters in brain. However, the dynamics of changes in glucose metabolism remain unclear. The present study was undertaken using (1)H and (13)C nuclear magnetic resonance (NMR) spectroscopy to determine the rates of incorporation of glucose into amino acids and lactate via cell-specific pathways in relation to the severity of encephalopathy and brain edema in rats with ALF ...
| Connu pour Brain Lactate | Acute Liver | Magnetic Resonance | Coma Stages | Amino Acids |
Effects of hypothermia on brain glucose metabolism in acute liver failure: a 1H/13C-nuclear magnetic resonance study
[ PUBLICATION ]
BACKGROUND & AIMS: Mild hypothermia has a protective effect on brain edema and encephalopathy in both experimental and human acute liver failure. The goals of the present study were to examine the effects of mild hypothermia (35 degrees C) on brain metabolic pathways using combined (1)H and (13)C-Nuclear Magnetic Resonance (NMR) spectroscopy, a technique which allows the study not only of metabolite concentrations but also their de novo synthesis via cell-specific pathways in the ...
| Connu pour Acute Liver | Mild Hypothermia | Brain Glucose Metabolism | Magnetic Resonance | Frontal Cortex |
Neuroactive amino acids and glutamate (NMDA) receptors in frontal cortex of rats with experimental acute liver failure
[ PUBLICATION ]
It has been proposed that alterations of excitatory and inhibitory amino acids play a role in the pathogenesis of hepatic encephalopathy in acute liver failure. To evaluate this possibility, in vivo cerebral microdialysis was used to sample extracellular concentrations of amino acids in the frontal cortex of unanesthetized rats at various times during the progression of encephalopathy resulting from acute liver failure. Liver failure was induced by portacaval anastomosis followed 24 ...
| Connu pour Amino Acids | Frontal Cortex | Acute Liver Failure | Extracellular Concentrations | Hepatic Encephalopathy |
KOL-Index: 12801
Mild hypothermia is effective in the prevention of brain edema associated with cerebral ischemia and traumatic brain injury. Brain edema is also a serious complication of acute liver failure (ALF). To assess the effectiveness of hypothermia in ALF, groups of rats were subjected to hepatic devascularization (portacaval anastomosis, followed 48 hours later by hepatic artery ligation), and body temperatures were maintained at either 35 degrees C (hypothermic) or 37 degrees C (normothermic). ...
| Connu pour Mild Hypothermia | Brain Edema | Acute Liver | Rats Alf | Hepatic Encephalopathy |
Ammonia‐induced brain edema and intracranial hypertension in rats after portacaval anastomosis
[ PUBLICATION ]
Brain edema, leading to intracranial hypertension and brain herniation, is a major cause of death in fulminant liver failure. Astrocyte swelling is a prominent neuropathological feature in experimental fulminant liver failure. It has been postulated that the osmotic effects of glutamine, generated in astrocytes from ammonia and glutamate in a reaction catalyzed by glutamine synthetase, could mediate brain swelling. Normal rats and rats that received a portacaval anastomosis were infused ...
| Connu pour Intracranial Hypertension | Brain Edema | Portacaval Anastomosis | Ammonium Acetate | Osmotic Effects |
Effect of Portacaval Anastomosis on Glutamine Synthetase Protein and Gene Expression in Brain, Liver and Skeletal Muscle
[ PUBLICATION ]
The effects of chronic liver insufficiency resulting from end-to-side portacaval anastomosis (PCA) on glutamine synthetase (GS) activities, protein and gene expression were studied in brain, liver and skeletal muscle of male adult rats. Four weeks following PCA, activities of GS in cerebral cortex and cerebellum were reduced by 32% and 37% (p<0.05) respectively whereas GS activities in muscle were increased by 52% (p<0.05). GS activities in liver were decreased by up to 90% (p<0.01), a ...
| Connu pour Skeletal Muscle | Portacaval Anastomosis | Gene Expression | Surgical Rna | Pca Rats |
Cerebral inflammation contributes to encephalopathy and brain edema in acute liver failure: protective effect of minocycline
[ PUBLICATION ]
Encephalopathy and brain edema are serious complications of acute liver failure (ALF). The precise pathophysiologic mechanisms responsible have not been fully elucidated but it has been recently proposed that microglia-derived proinflammatory cytokines are involved. In the present study we evaluated the role of microglial activation and the protective effect of the anti-inflammatory drug minocycline in the pathogenesis of hepatic encephalopathy and brain edema in rats with ALF resulting ...
| Connu pour Brain Edema | Liver Failure | Rats Alf | Microglial Activation | Pathogenesis Hepatic Encephalopathy |
KOL-Index: 11822
There is evidence to suggest that, in acute liver failure (ALF), brain ammonia and proinflammatory cytokines may act synergistically to cause brain edema and its complications (intracranial hypertension, brain herniation). However, the molecular mechanisms involved remain to be established. In order to address this issue, semi-quantitative RT-PCR was used to measure the expression of genes coding for astrocytic proteins with an established role in cell volume regulation in cerebral ...
| Connu pour Brain Edema | Liver Failure | Proinflammatory Cytokines | Astrocytic Proteins | Cultured Astrocytes |
KOL-Index: 11726
Although earlier studies on thiamine deficiency have reported increases in extracellular glutamate concentration in the thalamus, a vulnerable region of the brain in this disorder, the mechanism by which this occurs has remained unresolved. Treatment with pyrithiamine, a central thiamine antagonist, resulted in a 71 and 55% decrease in protein levels of the astrocyte glutamate transporters GLT-1 and GLAST, respectively, by immunoblotting in the medial thalamus of day 14 symptomatic rats ...
| Connu pour Medial Thalamus | Glutamate Transporter | Glt1 Glast | Spraguedawley Statistics | Protein Levels |
KOL-Index: 11620
N-acetylcysteine (NAC) is an effective antidote to treat acetaminophen (APAP)-induced acute liver failure (ALF). NAC is hepatoprotective and prevents the neurological complications of ALF, namely hepatic encephalopathy and brain edema. The protective effect of NAC and its mechanisms of action in ALF due to other toxins, however, are still controversial. In the present study, we investigated the effects of NAC in relation to liver pathology, hepatic and cerebral glutathione, plasma ...
| Connu pour Liver Failure | Nac Alf | Induced Acute | Aom Mice | Brain Edema |
Ammonia and related amino acids in the pathogenesis of brain edema in acute ischemic liver failure in rats
[ PUBLICATION ]
The pathogenesis of brain edema in acute liver failure is poorly understood. We have previously shown that rats with ischemic acute liver failure (portacaval anastomosis followed by hepatic artery ligation) exhibit brain edema and intracranial hypertension, with swelling of cortical astrocytes as the most prominent neuropathological abnormality. Because ammonia has been shown to induce swelling of astrocytes in vivo and in vitro, we examined the relationship between brain ammonia, amino ...
| Connu pour Amino Acids | Brain Edema | Portacaval Anastomosis | Liver Failure | Glutamine Alanine |
Ammonia induces MK‐801‐sensitive nitration and phosphorylation of protein tyrosine residues in rat astrocytes
[ PUBLICATION ]
Astrocytes play a key role in the pathogenesis of ammonia-induced neurotoxicity and hepatic encephalopathy. As shown here, ammonia induces protein tyrosine nitration in cultured rat astrocytes, which is sensitive to the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801. A similar pattern of nitrated proteins is produced by NMDA. Ammonia-induced tyrosine nitration depends on a rise in [Ca2+]i, IkB degradation, and NO synthase (iNOS) induction, which are prevented by MK-801 and the ...
| Connu pour Rat Astrocytes | Glutamine Synthetase | Protein Tyrosine | Ammonia Induces | Oxide Nitric |
Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure: Role of glutamine redefined
[ PUBLICATION ]
Acute liver failure (ALF) is characterized neuropathologically by cytotoxic brain edema and biochemically by increased brain ammonia and its detoxification product, glutamine. The osmotic actions of increased glutamine synthesis in astrocytes are considered to be causally related to brain edema and its complications (intracranial hypertension, brain herniation) in ALF. However studies using multinuclear (1)H- and (13)C-NMR spectroscopy demonstrate that neither brain glutamine ...
| Connu pour Brain Edema | Acute Liver Failure | Hepatic Encephalopathy | Intracranial Hypertension | Glutamine Synthesis |
Des personnes clés pour Hepatic Encephalopathy
Top Kols dans le monde
Sélectionnez une phrase de recherche hepatic encephalopathy , hepatic encephalopathy patients , hepatic encephalopathy humans , hepatic encephalopathy 95 , hepatic encephalopathy rats
Roger F Butterworth∗:Impact expert
Concepts pour lesquelsRoger F Butterworth∗a une influence directe:Hepatic encephalopathy, Acute liver failure, Liver failure, Thiamine deficiency, Cirrhotic patients, Brain edema, Portacaval anastomosis, Mild hypothermia.
Roger F Butterworth∗:Impact de Kol
Concepts liés au travail d'autres auteurs pour lesquelsfor which Roger F Butterworth∗ a une influence:Hepatic encephalopathy, Acute liver failure, Thiamine deficiency, Liver cirrhosis, Oxidative stress, Brain edema, Cirrhotic patients.
Tools
Est-ce votre profil? Réclamez votre profil Copier le lien ENCHED LIEN À VOTRE PROFIL |